{
    "Introduction": [
        {
            "undefined": "Introduction to formulary"
        },
        {
            "undefined": "What is a Formulary?"
        },
        {
            "undefined": "Formulary is a continually updated list of medications and related information, representing the clinical judgment of physicians, pharmacists, and other experts in the diagnosis, prophylaxis, or treatment of diseases and promotion of health. "
        },
        {
            "undefined": "What is CCHI Formulary?"
        },
        {
            "undefined": "CCHI Formulary is an evidence-based disease focused open Formulary which provides an essential drug list, either prescription or over the counter (OTC), that is necessary to treat a certain disease. CCHI Formulary Governance Committee (FGC) with the Pharmacy and Therapeutic committee (PTC) govern, maintain and continually update the Formulary to make sure that all SFDA drugs are available based on the most recent clinical national and  international guidelines and the provided drugs are safe and effective for the community of Saudi Arabia."
        },
        {
            "undefined": "What is the Objective of CCHI Formulary?"
        },
        {
            "undefined": "The Objective of this Formulary is to provide impartial and objective information to insurance companies in the Kingdom of Saudi Arabia, as well as to service providers and patients to promote safe, effective and rational use of medicines, which is based on evidence and global best practices. Other objectives include:                                                                                                                                                                                                Rationalize use of medicine (therapeutically accurate and cost effective)                                                                                                                \r\nProvide a comprehensive resource to insurance companies and HCPs\r\nStandardize the prescribing practices in KSA by using the best selected evidence-based guidelines\r\nPromote affordable and equitable access to healthcare\r\nImprove governance on the private health care insurance sector\r\nDecrease healthcare expenditure through the use of therapeutically equivalent but more affordable treatment options"
        }
    ],
    "Development_of_the_formulary": [
        {
            "undefined": "Overall approach for building the drug formulary"
        }
    ],
    "How to use the formulary": [
        {
            "undefined": "How to use the Formulary"
        },
        {
            "undefined": "What information does the CCHI Formulary provide?"
        },
        {
            "undefined": "CCHI Formulary provides the following information:\r\n- Indication\r\n- Drug_Class\r\n- ICD_Code\r\n- Drug_Sub_Class\r\n- Trade_Name \r\n- Registration_Number \r\n- Active_ingredient\r\n- ATC_Code\r\n- Dosage_Form \r\n- ROA (Route of Administration)\r\n- Strength\r\n- G_or_B (Generic or Brand)\r\n- Prescribing_edits\r\n- Quantity_Limit_Adults \r\n- Quantity_Limit_Pediatrics\r\n- Notes\r\n"
        },
        {
            "undefined": "What is an ICD_Code?"
        },
        {
            "undefined": "International Classification of Diseases (ICD) code, based on WHO definition, is “the international standard for defining and reporting diseases and health conditions. It allows the world to compare and share health information using a common language.  The ICD defines the universe of diseases, disorders, injuries and other related health conditions. These entities are listed in a comprehensive way as a list of codes with their corresponding descriptions.”\r\n\r\nExample: "
        },
        {
            "undefined": "What is an ATC_Code?"
        },
        {
            "undefined": "“The Anatomical Therapeutic Chemical (ATC) Classification is an internationally accepted classification system for medicines that is maintained by the World Health Organization (WHO). The WHO assigns ATC_Codes to all active substances contained in medicines based on the therapeutic indication for the medicine.”\r\nExample:\r\nB01AC06 acetylsalicylic acid\r\nB01AC07 dipyridamole\r\nB01AC30 combinations (e.g. acetylsalicylic acid and dipyridamole)"
        },
        {
            "undefined": "What is SFDA Drug Code?"
        },
        {
            "undefined": "Saudi Food and Drug Administration (SFDA) drug code is a unique numerical SFDA generated code for each drug product specific to the drug Trade_Name including its strength, route of administration and Dosage_Form. "
        },
        {
            "undefined": "What are Prescribing_edits?"
        },
        {
            "undefined": "Some covered drugs may have additional requirements, rules or limits on coverage. These requirements and limits may include:"
        },
        {
            "undefined": "Description "
        },
        {
            "undefined": "Coverage may depend on patient age"
        },
        {
            "undefined": "Coverage may depend upon concurrent use of another drug"
        },
        {
            "undefined": "Coverage may depend on patient gender"
        },
        {
            "undefined": "Coverage may depend on prescribing physician’s specialty or board certification"
        },
        {
            "undefined": "Requires specific physician request process"
        },
        {
            "undefined": "Coverage may be limited to specific quantities per prescription and/or time period"
        },
        {
            "undefined": "Coverage may depend on previous use of another Drug"
        },
        {
            "undefined": "This drug status on Formulary is only for Emergency use."
        },
        {
            "undefined": "Use of drug is dependent on protocol combination, doses and sequence of therapy"
        },
        {
            "undefined": "Examples:\r\nAge edit: Desmopressin in Nocturnal Enuresis should not be prescribed for children < 5 years.  \r\nConcurrent Use Edit: Flavoxate in Nocturnal Enuresis should be used as add on to desmopressin after desmopressin failure and cannot be used alone.\r\nGender Edit: Exemestane in Endometriosis should be used only by Females.\r\nPhysician Specialty Edit: Fentanyl in Endometriosis should be prescribed by a gynecologist or pain management specialist."
        },
        {
            "undefined": "Prior Authorization: Desmopressin in Nocturnal Enuresis: The prescriber must check the following before prescribing:\r\n• Failure of combination of behavioral and alarm therapy.\r\n• Serum Na at the start of therapy, every 3-7 days and if stable every month then every 3 months thereafter.\r\n\r\nQuantity Limit: Idarubicin in Acute Leukemia: Cumulative dose should not exceed 150 mg/m2. Please note that this Quantity Limit is different than the one based on maximum daily dose as this is not necessary based on Maximum Daily Dose.\r\n\r\nStep Therapy: Aripiprazole in Social Anxiety: should be used as third line after:\r\n\r\nFirst-line: Escitalopram, fluvoxamine, fluvoxamine CR, paroxetine, paroxetine CR, pregabalin, sertraline, venlafaxine XR\r\n\r\nSecond-line: Alprazolam, bromazepam, citalopram, clonazepam, gabapentin\r\n\r\nEmergency use only: Furosemide IV form in Hypertension is used only in emergency setting.\r\n\r\nProtocol edit: Bendamustine Hydrochloride, Cyclophosphamide, Ifosfamide, Dacarbazine should be used in Lymphoma as per the following protocol"
        },
        {
            "undefined": "What is a Brand?"
        },
        {
            "undefined": "Also known as an originator drug, a brand-name is one marketed by a manufacturer under a brand name ( rather than its generic name). Brand-name drugs are often single-source drugs following their initial SFDA approval because of patent protection and SFDA-granted regulatory exclusivity. Later, generic versions of some brand-name drugs enter the market  and compete with the brand-name drug on price. "
        },
        {
            "undefined": "What is a Generic?"
        },
        {
            "undefined": "• This is a drug approved by the SFDA by referencing an originator brand-name drug's initial application. Generic drugs can enter the market after the reference product's regulatory exclusivity has expired and after its patents have either expired or been successfully challenged in court.  "
        },
        {
            "undefined": "What is a Quantity Limit?"
        },
        {
            "undefined": "This is either the adult or pediatric maximum amount of a drug that can be administered per day based on a maximum daily dose."
        },
        {
            "undefined": "What information are available in the notes?"
        },
        {
            "undefined": "“Notes” section provides details of the Prescribing_edits, extra important drug information and special warning and precautions."
        },
        {
            "undefined": "How to  navigate the Formulary?"
        },
        {
            "undefined": "The CCHI Formulary is provided on an excel sheet platform that users can filter by disease, ICD_Code, Drug_Classes, Trade_Name, SFDA Registration_Numbers, Active_ingredient, ATC_Code, and whether the drug is a  Brand or  Generic.\r\n\r\nThe Formulary provides Appendices with various tables and protocols that users should refer to whenever mentioned in the notes. Hyperlinked Appendices are provided on a separate column for each disease or indication."
        }
    ],
    "Indications": [
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Drug_Sub_Class": "Synthetic anticholinergics, esters with tertiary amino group",
            "Trade_Name": "BEVACOL 135MG TABLET",
            "Registration_Number": "42-171-04",
            "Active_ingredient": "MEBEVERINE HYDROCHLORIDE",
            "ATC_Code": "A03AA04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "135mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "405 mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Drug_Sub_Class": "Synthetic anticholinergics, esters with tertiary amino group",
            "Trade_Name": "DUSPAMEN 135MG TAB",
            "Registration_Number": "81-334-03",
            "Active_ingredient": "MEBEVERINE HYDROCHLORIDE",
            "ATC_Code": "A03AA04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "135mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "405 mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Drug_Sub_Class": "Synthetic anticholinergics, esters with tertiary amino group",
            "Trade_Name": "DUSPATALIN 135MGTAB",
            "Registration_Number": "6-370-03",
            "Active_ingredient": "MEBEVERINE HYDROCHLORIDE",
            "ATC_Code": "A03AA04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "135mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "405 mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Drug_Sub_Class": "Synthetic anticholinergics, esters with tertiary amino group",
            "Trade_Name": "DUSPATALIN 200MG PROLONGED RELEASE CAPS",
            "Registration_Number": "21-137-00",
            "Active_ingredient": "MEBEVERINE HYDROCHLORIDE",
            "ATC_Code": "A03AA04",
            "Dosage_Form": "CAPSULE, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "405 mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Drug_Sub_Class": "Synthetic anticholinergics, esters with tertiary amino group",
            "Trade_Name": "MEBAGEN",
            "Registration_Number": "67-325-02",
            "Active_ingredient": "MEBEVERINE HYDROCHLORIDE",
            "ATC_Code": "A03AA04",
            "Dosage_Form": "TABLET, COATED",
            "ROA": "ORAL",
            "Strength": "135mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "405 mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Drug_Sub_Class": "Synthetic anticholinergics, esters with tertiary amino group",
            "Trade_Name": "MEBAGEN SR 200MG CAPSULE",
            "Registration_Number": "297-325-19",
            "Active_ingredient": "MEBEVERINE HYDROCHLORIDE",
            "ATC_Code": "A03AA04 ",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "405 mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Drug_Sub_Class": "Synthetic anticholinergics, esters with tertiary amino group",
            "Trade_Name": "MEVA 135MG F.C.TABLET",
            "Registration_Number": "69-368-04",
            "Active_ingredient": "MEBEVERINE HYDROCHLORIDE",
            "ATC_Code": "A03AA04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "135mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "405 mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Drug_Sub_Class": "Synthetic anticholinergics, esters with tertiary amino group",
            "Trade_Name": "SPASMOTALIN 100MG TAB",
            "Registration_Number": "5-216-95",
            "Active_ingredient": "MEBEVERINE HYDROCHLORIDE",
            "ATC_Code": "A03AA04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "405 mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Drug_Sub_Class": "Synthetic anticholinergics, esters with tertiary amino group",
            "Trade_Name": "VERINE 135MG TAB",
            "Registration_Number": "176-212-02",
            "Active_ingredient": "MEBEVERINE HYDROCHLORIDE",
            "ATC_Code": "A03AA04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "135mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "405 mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Drug_Sub_Class": "Synthetic anticholinergics, esters with tertiary amino group",
            "Trade_Name": "VERINE SR 200MG SUSTAINED RELEASED CAP",
            "Registration_Number": "220-212-07",
            "Active_ingredient": "MEBEVERINE HYDROCHLORIDE",
            "ATC_Code": "A03AA04",
            "Dosage_Form": "CAPSULE, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "405 mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Drug_Sub_Class": "Other drugs for functional gastrointestinal disorders",
            "Trade_Name": "DICETEL TAB 50MG",
            "Registration_Number": "5-33-86",
            "Active_ingredient": "PINAVERIUM BROMIDE",
            "ATC_Code": "A03AX04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "50mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "300 mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "ANTIEMETICS AND ANTINAUSEANTS",
            "Drug_Sub_Class": "Other antiemetics",
            "Trade_Name": "BUSCOPAN TABLETS 10MG",
            "Registration_Number": "62-23-18",
            "Active_ingredient": "HYOSCINE (SCOPOLAMINE) BUTYLBROMIDE",
            "ATC_Code": "A04AD01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "10mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "60mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "ANTIEMETICS AND ANTINAUSEANTS",
            "Drug_Sub_Class": "Other antiemetics",
            "Trade_Name": "DEFOPAN 5MG-5ML SYRUP",
            "Registration_Number": "5-539-08",
            "Active_ingredient": "HYOSCINE (SCOPOLAMINE) BUTYLBROMIDE",
            "ATC_Code": "A04AD01",
            "Dosage_Form": "SYRUP",
            "ROA": "ORAL",
            "Strength": "1mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "60mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "ANTIEMETICS AND ANTINAUSEANTS",
            "Drug_Sub_Class": "Other antiemetics",
            "Trade_Name": "HYOPAN SYRUP 5 MG-5 ML",
            "Registration_Number": "36-352-04",
            "Active_ingredient": "HYOSCINE (SCOPOLAMINE) BUTYLBROMIDE",
            "ATC_Code": "A04AD01",
            "Dosage_Form": "SYRUP",
            "ROA": "ORAL",
            "Strength": "1mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "60mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "ANTIEMETICS AND ANTINAUSEANTS",
            "Drug_Sub_Class": "Other antiemetics",
            "Trade_Name": "NOSPASM 10 MG TAB",
            "Registration_Number": "107-212-99",
            "Active_ingredient": "HYOSCINE (SCOPOLAMINE) BUTYLBROMIDE",
            "ATC_Code": "A04AD01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "60mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "ANTIEMETICS AND ANTINAUSEANTS",
            "Drug_Sub_Class": "Other antiemetics",
            "Trade_Name": "SCOPINAL 20MG AMPOULE",
            "Registration_Number": "113-186-00",
            "Active_ingredient": "HYOSCINE (SCOPOLAMINE) BUTYLBROMIDE",
            "ATC_Code": "A04AD01",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "20mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "60mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "ANTIEMETICS AND ANTINAUSEANTS",
            "Drug_Sub_Class": "Other antiemetics",
            "Trade_Name": "SCOPINAL 5MG-5ML SYRUP",
            "Registration_Number": "73-186-98",
            "Active_ingredient": "HYOSCINE (SCOPOLAMINE) BUTYLBROMIDE",
            "ATC_Code": "A04AD01",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "1mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "60mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "ANTIEMETICS AND ANTINAUSEANTS",
            "Drug_Sub_Class": "Other antiemetics",
            "Trade_Name": "SCOPINAL TAB 10MG",
            "Registration_Number": "36-186-89",
            "Active_ingredient": "HYOSCINE (SCOPOLAMINE) BUTYLBROMIDE",
            "ATC_Code": "A04AD01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "10mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "60mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "ANTIEMETICS AND ANTINAUSEANTS",
            "Drug_Sub_Class": "Other antiemetics",
            "Trade_Name": "SPASMOPAN 10MG TAB.",
            "Registration_Number": "65-119-90",
            "Active_ingredient": "HYOSCINE (SCOPOLAMINE) BUTYLBROMIDE",
            "ATC_Code": "A04AD01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "60mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "ANTIEMETICS AND ANTINAUSEANTS",
            "Drug_Sub_Class": "Other antiemetics",
            "Trade_Name": "SPASMOPAN 20MG AMP.",
            "Registration_Number": "66-119-90",
            "Active_ingredient": "HYOSCINE (SCOPOLAMINE) BUTYLBROMIDE",
            "ATC_Code": "A04AD01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "20mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "60mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "BELLADONNA AND DERIVATIVES, PLAIN",
            "Drug_Sub_Class": "Belladonna alkaloids, tertiary amines",
            "Trade_Name": "LEVSIN TAB 0.125MG",
            "Registration_Number": "3-133-83",
            "Active_ingredient": "HYOSCYAMINE",
            "ATC_Code": "A03BA03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "0.125mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "60mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Drug_Sub_Class": "Synthetic anticholinergics, esters with tertiary amino group",
            "Trade_Name": "DEBRIDAT 1.2 GM-250ML SUSPENSION",
            "Registration_Number": "1-257-01",
            "Active_ingredient": "TRIMEBUTINE",
            "ATC_Code": "A03AA05",
            "Dosage_Form": "SUSPENSION",
            "ROA": "ORAL",
            "Strength": "4.8mg/ml",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "600 mg/day",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Abdominal Spasm",
            "ICD_Code": "R25.2",
            "Drug_Class": "DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS",
            "Trade_Name": "COLPERMIN 187MG CAPS",
            "Registration_Number": "2-366-02",
            "Active_ingredient": "PEPPERMINT OIL",
            "ATC_Code": "0000000",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "187mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "0.6ml/day ",
            "Notes_1": "Antispasmodics are used only for IBS if there is an Abdominal Spasm"
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "VALOPRA 200 MG-ML SOLUTION",
            "Registration_Number": "137-334-10",
            "Active_ingredient": "Valproate Sodium",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Oral solution",
            "ROA": "Oral",
            "Strength": "200 mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "Age, G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "first line monotherapy except if pregnant women and women of childbearing potential. AGE: Not used for children less than 2 years old. G: Valproate shouldn’t be used in pregnant woman and in females of child bearing period."
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "VALOPRA 57.64 MG-ML SYRUP",
            "Registration_Number": "136-334-10",
            "Active_ingredient": "Valproate Sodium",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "57.64 mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "Age, G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "first line monotherapy except if pregnant women and women of childbearing potential. AGE: Not used for children less than 2 years old. G: Valproate shouldn’t be used in pregnant woman and in females of child bearing period."
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "DEPAKINE 57.64MG-ML SYRUP",
            "Registration_Number": "11-883-16",
            "Active_ingredient": "Valproate Sodium",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40 mg/ml",
            "G_or_B": "B",
            "Prescribing_edits": "Age, G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "first line monotherapy except if pregnant women and women of childbearing potential. AGE: Not used for children less than 2 years old. G: Valproate shouldn’t be used in pregnant woman and in females of child bearing period."
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "EPIVAL 200MG\\5ML SYRUP",
            "Registration_Number": "27-271-17",
            "Active_ingredient": "Valproate Sodium",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40 mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "Age, G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "first line monotherapy except if pregnant women and women of childbearing potential. AGE: Not used for children less than 2 years old. G: Valproate shouldn’t be used in pregnant woman and in females of child bearing period."
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "DEPAKINE 200MG TABS",
            "Registration_Number": "18-883-18",
            "Active_ingredient": "Valproate Sodium",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200 mg",
            "G_or_B": "B",
            "Prescribing_edits": "Age, G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "first line monotherapy except if pregnant women and women of childbearing potential. AGE: Not used for children less than 2 years old. G: Valproate shouldn’t be used in pregnant woman and in females of child bearing period."
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "DEPAKINE 500MG TABS",
            "Registration_Number": "21-883-18",
            "Active_ingredient": "Valproate Sodium",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "B",
            "Prescribing_edits": "Age, G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "first line monotherapy except if pregnant women and women of childbearing potential. AGE: Not used for children less than 2 years old. G: Valproate shouldn’t be used in pregnant woman and in females of child bearing period."
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "DEPAKINE 200MG-ML SOLU.",
            "Registration_Number": "22-883-18",
            "Active_ingredient": "Valproate Sodium",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Oral solution",
            "ROA": "Oral",
            "Strength": "200 mg/ml",
            "G_or_B": "B",
            "Prescribing_edits": "Age, G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "first line monotherapy except if pregnant women and women of childbearing potential. AGE: Not used for children less than 2 years old. G: Valproate shouldn’t be used in pregnant woman and in females of child bearing period."
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "DEPAKINE CHRONO 500MG TABS",
            "Registration_Number": "26-883-19",
            "Active_ingredient": "Valproate Sodium",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "B",
            "Prescribing_edits": "Age, G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "first line monotherapy except if pregnant women and women of childbearing potential. AGE: Not used for children less than 2 years old. G: Valproate shouldn’t be used in pregnant woman and in females of child bearing period."
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "VALOPIN 200 MG E-C TABLETS",
            "Registration_Number": "250-186-08",
            "Active_ingredient": "VALPROATE SODIUM",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Gastro-resistant tablet",
            "ROA": "Oral",
            "Strength": "200mg",
            "G_or_B": "G",
            "Prescribing_edits": "Age, G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "first line monotherapy except if pregnant women and women of childbearing potential. AGE: Not used for children less than 2 years old. G: Valproate shouldn’t be used in pregnant woman and in females of child bearing period."
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "67-276-02",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Chewable tablet",
            "ROA": "Oral",
            "Strength": "100 mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 2, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 5, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 7",
            "Quantity_Limit_Pediatrics": "With valproic acid: 2, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 3, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 4",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "65-276-02",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100 mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 2, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 5, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 7",
            "Quantity_Limit_Pediatrics": "With valproic acid: 2, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 3, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 4",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMOTRIX 100MG TABLET",
            "Registration_Number": "3-718-13",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100 mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 2, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 5, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 7",
            "Quantity_Limit_Pediatrics": "With valproic acid: 2, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 3, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 4",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LOXOL 100MG TABLET",
            "Registration_Number": "148-334-11",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100 mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 2, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 5, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 7",
            "Quantity_Limit_Pediatrics": "With valproic acid: 2, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 3, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 4",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMIRA 100 mg TABLET",
            "Registration_Number": "357-212-17",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100 mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 2, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 5, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 7",
            "Quantity_Limit_Pediatrics": "With valproic acid: 2, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 3, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 4",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "SEIZET 100 mg Chewable/Dispersible Tablet",
            "Registration_Number": "10-5286-19",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Chewable tablet",
            "ROA": "Oral",
            "Strength": "100 mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 2, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 5, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 7",
            "Quantity_Limit_Pediatrics": "With valproic acid: 2, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 3, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 4",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LOXOL 200MG TABLET",
            "Registration_Number": "149-334-11",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200 mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 1, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 2.5, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 3.5",
            "Quantity_Limit_Pediatrics": "With valproic acid: 1, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 1.5 , With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 2",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "62-276-02",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Chewable tablet",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 20, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 28",
            "Quantity_Limit_Pediatrics": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 12, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 16",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "70-276-02",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Chewable tablet",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 20, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 28",
            "Quantity_Limit_Pediatrics": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 12, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 16",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "63-276-02",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 20, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 28",
            "Quantity_Limit_Pediatrics": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 12, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 16",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMOTRIX 25MG TABLET",
            "Registration_Number": "1-718-13",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 20, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 28",
            "Quantity_Limit_Pediatrics": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 12, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 16",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LOXOL 25MG TABLET",
            "Registration_Number": "146-334-11",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 20, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 28",
            "Quantity_Limit_Pediatrics": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 12, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 16",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMIRA 25 mg TABLET",
            "Registration_Number": "355-212-17",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 20, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 28",
            "Quantity_Limit_Pediatrics": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 12, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 16",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "SEIZET 25 mg Chewable/Dispersible Tablet",
            "Registration_Number": "9-5286-19",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Chewable tablet",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 20, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 28",
            "Quantity_Limit_Pediatrics": "With valproic acid: 8, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 12, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 16",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "64-276-02",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Chewable tablet",
            "ROA": "Oral",
            "Strength": "5 mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 40, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 100 ,With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 140",
            "Quantity_Limit_Pediatrics": "With valproic acid: 40, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 60 ,With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 80",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "66-276-02",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "50 mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 4, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 10, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 14",
            "Quantity_Limit_Pediatrics": "With valproic acid: 4, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 6 , With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 8",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMOTRIX 50MG TABLET",
            "Registration_Number": "2-718-13",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "50 mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 4, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 10, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 14",
            "Quantity_Limit_Pediatrics": "With valproic acid: 4, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 6 , With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 8",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LOXOL 50MG TABLET",
            "Registration_Number": "147-334-11",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "50 mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 4, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 10, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 14",
            "Quantity_Limit_Pediatrics": "With valproic acid: 4, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 6 , With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 8",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMIRA 50 mg TABLET",
            "Registration_Number": "356-212-17",
            "Active_ingredient": "Lamotrigine ",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "50 mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "With valproic acid: 4, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 10, With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 14",
            "Quantity_Limit_Pediatrics": "With valproic acid: 4, Without carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid: 6 , With carbamazepine, phenytoin, phenobarbital, or primidone and not with valproic acid: 8",
            "Notes_1": "ST: second line monotherapy or as add on therapy after trying valporic acid or if CI or intolerable "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "VALES 100 mg/ml oral solutin",
            "Registration_Number": "320-277-16",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Oral solution",
            "ROA": "Oral",
            "Strength": "100 mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "30 ml",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "EPITAM 100 mg/ml syrup",
            "Registration_Number": "233-334-16",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "100 mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "30 ml",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAVIE ORAL SOLUTION 150 ML",
            "Registration_Number": "144-368-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "100 mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "30 ml",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "KEPPRA 100MG-ML ORAL SOLUTION",
            "Registration_Number": "136-276-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Oral solution",
            "ROA": "Oral",
            "Strength": "100 mg/ml",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "30 ml",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LEVETAM 100 mg/ml Oral Solution",
            "Registration_Number": "371-212-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "100 mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "30 ml",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LEVETAM 100 mg/ml Oral Solution",
            "Registration_Number": "370-212-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "100 mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "30 ml",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "EPIXX 100MG/ML SYRUP",
            "Registration_Number": "1-5250-19",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Oral solution ",
            "ROA": "Oral",
            "Strength": "100 mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "30 ml",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "VALES 1000 mg film-coated tablet",
            "Registration_Number": "316-277-16",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "1000 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "3 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LEVETAM 1000 mg film-coated tablet",
            "Registration_Number": "342-212-16",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "1000 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "3 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "KEPPRA 1000MG F.C.TAB",
            "Registration_Number": "134-276-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "1000 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "3 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "KEPPRA 1000MG F.C.TAB",
            "Registration_Number": "135-276-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "1000 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "3 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAVIE 1000 mg Film-Coated Tablets",
            "Registration_Number": "147-368-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "1000 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "3 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LETIREM 1000 MG FILM COATED TABLET",
            "Registration_Number": "3-5128-19",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "1000 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "3 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "VALES 250 mg film-coated tablet",
            "Registration_Number": "317-277-16",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "12 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "EPITAM 250 mg film-coated tablet",
            "Registration_Number": "225-334-16",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "12 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "KEPPRA 250MG F.C.TAB",
            "Registration_Number": "130-276-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "12 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "KEPPRA 250MG F.C.TAB",
            "Registration_Number": "131-276-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "12 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LEVETAM 250 mg film-coated tablet",
            "Registration_Number": "363-212-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "12 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "ARPEK 250 mg film-coated tablet",
            "Registration_Number": "69-249-18",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "12 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LETIREM 250 MG FILM COATED TABLET",
            "Registration_Number": "5-5128-19",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "250 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "12 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "VALES 500 mg film-coated tablet",
            "Registration_Number": "318-277-16",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "VALES 500 mg film-coated tablet",
            "Registration_Number": "319-277-16",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "EPITAM 500 mg film-coated tablet",
            "Registration_Number": "226-334-16",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "EFRAM XR 500 mg TABLET",
            "Registration_Number": "22-968-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Prolonged-release tablet",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LEVETAM XR 500 mg TABLET",
            "Registration_Number": "358-212-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Prolonged-release tablet",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "KEPPRA 500MG F.C.TAB",
            "Registration_Number": "132-276-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "KEPPRA 500MG F.C.TAB",
            "Registration_Number": "133-276-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAVIE 500 mg Film-Coated Tablets",
            "Registration_Number": "146-368-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LEVETAM 500 mg film-coated tablet",
            "Registration_Number": "364-212-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "ARPEK 500 mg film-coated tablet",
            "Registration_Number": "70-249-18",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "EPITAM 500MG PROLONGED RELEASE TABLET",
            "Registration_Number": "268-334-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Prolonged-release tablet ",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "KEPCITAM 500 MG FILM COATED TABLET",
            "Registration_Number": "119-116-18",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LETIREM 500 MG FILM COATED TABLET",
            "Registration_Number": "4-5128-19",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "6 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LEVETAM 750 mg film-coated tablet",
            "Registration_Number": "343-212-16",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "4 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "EPITAM 750 mg film-coated tablet",
            "Registration_Number": "227-334-16",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "4 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "EFRAM XR 750 mg TABLET",
            "Registration_Number": "23-968-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Prolonged-release tablet",
            "ROA": "Oral",
            "Strength": "750 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "4 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LEVETAM XR 750 mg TABLET",
            "Registration_Number": "359-212-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Prolonged-release tablet",
            "ROA": "Oral",
            "Strength": "750 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "4 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "EPITAM 750MG PROLONGED RELEASE TABLET",
            "Registration_Number": "269-334-17",
            "Active_ingredient": "Levetiracetam ",
            "ATC_Code": "N03AX14",
            "Dosage_Form": "Prolonged-release tablet",
            "ROA": "Oral",
            "Strength": "750 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "4 tablets",
            "Quantity_Limit_Pediatrics": "Infants 1 to <6 months: 3\r\nInfants ≥6 months and Children <16 years: 6",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANXIOLYTICS",
            "Drug_Sub_Class": "Benzodiazepine derivatives",
            "Trade_Name": "TAPCLOB 5MG/5ML ORAL SUSPENSION",
            "Registration_Number": "13-468-17",
            "Active_ingredient": "Clobazam ",
            "ATC_Code": "N05BA09  ",
            "Dosage_Form": "suspension ",
            "ROA": "ORAL",
            "Strength": "1mg / ml",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "adult :80 ml        geriatric: 60 ml",
            "Quantity_Limit_Pediatrics": "Infants and Children <2 years:  10 ml\r\nChildren 2 to 16 years: 60 ml",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANXIOLYTICS",
            "Drug_Sub_Class": "Benzodiazepine derivatives",
            "Trade_Name": "TAPCLOB 10MG/5ML ORAL SUSPENSION",
            "Registration_Number": "14-468-17",
            "Active_ingredient": "Clobazam ",
            "ATC_Code": "N05BA09  ",
            "Dosage_Form": "suspension ",
            "ROA": "ORAL",
            "Strength": "2 mg / ml",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "adult :40 ml        geriatric: 30 ml",
            "Quantity_Limit_Pediatrics": "Infants and Children <2 years:  5 ml\r\nChildren 2 to 16 years: 30ml",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "IPRAMAX 100 MG FILM COATED TABLET",
            "Registration_Number": "220-277-11",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "100 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "10 tablets",
            "Quantity_Limit_Pediatrics": "6 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "TOPAMAX 100MG F.C.TAB.",
            "Registration_Number": "36-51-99",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "100 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "10 tablets",
            "Quantity_Limit_Pediatrics": "6 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "TALOPAM 100 mg film-coated tablet",
            "Registration_Number": "15-140-14",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "100 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "10 tablets",
            "Quantity_Limit_Pediatrics": "6 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "ALEVIO 100MG F.C.TABLET",
            "Registration_Number": "208-368-19",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "100 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "10 tablets",
            "Quantity_Limit_Pediatrics": "6 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "ALEVIO 100MG F.C.TABLET",
            "Registration_Number": "200-368-19",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "100 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "10 tablets",
            "Quantity_Limit_Pediatrics": "6 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "TOPAMAX 15MG SPRINKLE CAPSULES",
            "Registration_Number": "48-51-08",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "15 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "66 tablets",
            "Quantity_Limit_Pediatrics": "40 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "TOPAMAX 200MG F.C.TAB.",
            "Registration_Number": "37-51-99",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "200 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "5 tablets",
            "Quantity_Limit_Pediatrics": "3 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "IPRAMAX 25 MG FILM COATED TABLET",
            "Registration_Number": "218-277-11",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "40 tablets",
            "Quantity_Limit_Pediatrics": "24 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "TOPAMAX 25MG SPRINKLE CAPSULES",
            "Registration_Number": "49-51-08",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "40 tablets",
            "Quantity_Limit_Pediatrics": "24 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "TOPAMAX 25MG-TAB. F.C.TAB.",
            "Registration_Number": "38-51-99",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "40 tablets",
            "Quantity_Limit_Pediatrics": "24 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "TALOPAM 25 mg film-coated tablet",
            "Registration_Number": "14-140-14",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "40 tablets",
            "Quantity_Limit_Pediatrics": "24 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "ALEVIO 25MG F.C.TABLET",
            "Registration_Number": "207-368-19",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "40 tablets",
            "Quantity_Limit_Pediatrics": "24 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "ALEVIO 25 MG F.C.TABLET",
            "Registration_Number": "201-368-19",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "25 mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "40 tablets",
            "Quantity_Limit_Pediatrics": "24 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "TOPAMAX 50MG SPRINKLE CAPSULES",
            "Registration_Number": "50-51-08",
            "Active_ingredient": "Topiramate ",
            "ATC_Code": "N03AX11",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "50 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "20 tablets",
            "Quantity_Limit_Pediatrics": "12 tablets",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Benzodiazepine derivatives",
            "Trade_Name": "RIVOTRIL 2.5MG-ML ORAL SOLUTION",
            "Registration_Number": "263-24-07",
            "Active_ingredient": "Clonzepam ",
            "ATC_Code": "N03AE01",
            "Dosage_Form": "Oral drops, solution",
            "ROA": "Oral",
            "Strength": "2.5 mg/ml",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "20MG/day",
            "Quantity_Limit_Pediatrics": "Infants and Children <10 years or ≤30 kg:: 0.2 mg/kg/day Children ≥10 years or >30 kg and Adolescents: 20 mg/day",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Benzodiazepine derivatives",
            "Trade_Name": "RIVOTRIL TAB 2 MG",
            "Registration_Number": "136-24-80",
            "Active_ingredient": "Clonzepam ",
            "ATC_Code": "N03AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "0.5 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "10 tablets",
            "Quantity_Limit_Pediatrics": "Infants and Children <10 years or ≤30 kg:: 0.2 mg/kg/day Children ≥10 years or >30 kg and Adolescents: 20 mg/day",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Absence Seizures and Idiopathic Generalized Epilepsy",
            "ICD_Code": "G40",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Benzodiazepine derivatives",
            "Trade_Name": "RIVOTRIL TAB 0.5MG",
            "Registration_Number": "134-24-80",
            "Active_ingredient": "Clonzepam ",
            "ATC_Code": "N03AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "2 mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "40 tablets",
            "Quantity_Limit_Pediatrics": "Infants and Children <10 years or ≤30 kg:: 0.2 mg/kg/day Children ≥10 years or >30 kg and Adolescents: 20 mg/day",
            "Notes_1": "CU: USED only as an adjunctive therapy with valporic acid,lamotrigine "
        },
        {
            "Indication": "Active Enthesitis Juvenile Arthritis",
            "ICD_Code": "M77.9",
            "Drug_Class": "IMMUNOSUPPRESSANTS",
            "Drug_Sub_Class": "Tumor necrosis factor alpha (TNF-α) inhibitors",
            "Trade_Name": "HUMIRA",
            "Registration_Number": "1-921-15",
            "Active_ingredient": "ADALIMUMAB",
            "ATC_Code": "L04AB04",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "SUBCUTANEOUS",
            "Strength": "100mg/ml",
            "G_or_B": "B",
            "Prescribing_edits": "PA, MD, QL",
            "Quantity_Limit_Pediatrics": "10 kg to < 30 kg: 20 mg every other week\r\n≥ 30 kg: 40 mg every other week",
            "Notes_1": "QL: Adalimumab: maximum 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not responding within this time period.\r\nPA, MD:should be prescribed by rheumatology specialists experienced in the treatment of JIA. \r\nFor patient with active enthesitis: used in the following sequence:\r\n1.\tNSAIDs \r\n2.\tTNFIs (Adalimumab, etanercept, infliximab)\r\n3.\tMethotrexate or Sulfasalazine",
            "Notes_2": "Pediatrics (label approved ≥4 y)\r\nWeight 15–30 kg: 20 mg SubQ every 14 days\r\nWeight >30 kg:  40 mg  SubQ every 14 days"
        },
        {
            "Indication": "Active Enthesitis Juvenile Arthritis",
            "ICD_Code": "M77.9",
            "Drug_Class": "IMMUNOSUPPRESSANTS",
            "Drug_Sub_Class": "Tumor necrosis factor alpha (TNF-α) inhibitors",
            "Trade_Name": "Amgevita",
            "Registration_Number": "1603200042",
            "Active_ingredient": "Adalimumab",
            "ATC_Code": "L04AB04  ",
            "Dosage_Form": "Solution for injection in pre-filled pen",
            "ROA": "Subcutaneous use",
            "Strength": "40mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, MD, QL",
            "Quantity_Limit_Pediatrics": "10 kg to < 30 kg: 20 mg every other week\r\n≥ 30 kg: 40 mg every other week",
            "Notes_1": "QL: Adalimumab: maximum 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not responding within this time period.\r\nPA, MD:should be prescribed by rheumatology specialists experienced in the treatment of JIA. \r\nFor patient with active enthesitis: used in the following sequence:\r\n1.\tNSAIDs \r\n2.\tTNFIs (Adalimumab, etanercept, infliximab)\r\n3.\tMethotrexate or Sulfasalazine",
            "Notes_2": "Pediatrics (label approved ≥4 y)\r\nWeight 15–30 kg: 20 mg SubQ every 14 days\r\nWeight >30 kg:  40 mg  SubQ every 14 days"
        },
        {
            "Indication": "Active Enthesitis Juvenile Arthritis",
            "ICD_Code": "M77.9",
            "Drug_Class": "IMMUNOSUPPRESSANTS",
            "Drug_Sub_Class": "Tumor necrosis factor alpha (TNF-α) inhibitors",
            "Trade_Name": "Amgevita",
            "Registration_Number": "1603200041",
            "Active_ingredient": "Adalimumab",
            "ATC_Code": "L04AB04  ",
            "Dosage_Form": "Solution for injection in pre-filled syringe",
            "ROA": "Subcutaneous use",
            "Strength": "40mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, MD, QL",
            "Quantity_Limit_Pediatrics": "10 kg to < 30 kg: 20 mg every other week\r\n≥ 30 kg: 40 mg every other week",
            "Notes_1": "QL: Adalimumab: maximum 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not responding within this time period.\r\nPA, MD:should be prescribed by rheumatology specialists experienced in the treatment of JIA. \r\nFor patient with active enthesitis: used in the following sequence:\r\n1.\tNSAIDs \r\n2.\tTNFIs (Adalimumab, etanercept, infliximab)\r\n3.\tMethotrexate or Sulfasalazine",
            "Notes_2": "Pediatrics (label approved ≥4 y)\r\nWeight 15–30 kg: 20 mg SubQ every 14 days\r\nWeight >30 kg:  40 mg  SubQ every 14 days"
        },
        {
            "Indication": "Active Enthesitis Juvenile Arthritis",
            "ICD_Code": "M77.9",
            "Drug_Class": "IMMUNOSUPPRESSANTS",
            "Drug_Sub_Class": "Tumor necrosis factor alpha (TNF-α) inhibitors",
            "Trade_Name": "ENBREL 50MG PRE-FILLED PEN",
            "Registration_Number": "69-892-19",
            "Active_ingredient": "ETANERCEPT",
            "ATC_Code": "L04AB01",
            "Dosage_Form": "Injection*",
            "ROA": "Subcutaneous",
            "Strength": "50 MG",
            "G_or_B": "B",
            "Prescribing_edits": "PA, MD, QL, AGE ",
            "Quantity_Limit_Pediatrics": "50 mg/ week",
            "Notes_1": "QL: Etanercept: maximum 4 month then it will be of no value with continued disease activity \r\nAGE: Etanercept: not to be used for age < 2 years\r\nPA, MD:should be prescribed by rheumatology specialists experienced in the treatment of JIA. \r\nused in the following sequence:\r\n1.\tNSAIDs \r\n2.\tTNFIs (Adalimumab, etanercept, infliximab)\r\n3.\tMethotrexate or Sulfasalazine",
            "Notes_2": "0.8 mg/kg (max 50 mg) subQ once weekly \r\nOR\r\n0.4 mg/kg (max 25 mg) subQ twice weekly"
        },
        {
            "Indication": "Active Enthesitis Juvenile Arthritis",
            "ICD_Code": "M77.9",
            "Drug_Class": "IMMUNOSUPPRESSANTS",
            "Drug_Sub_Class": "Tumor necrosis factor alpha (TNF-α) inhibitors",
            "Trade_Name": "REMICADE 100MG VIAL FOR INJ",
            "Registration_Number": "1-842-13",
            "Active_ingredient": "INFLIXIMAB",
            "ATC_Code": "L04AB02",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "100mg",
            "G_or_B": "B",
            "Prescribing_edits": "PA, MD, AGE",
            "Quantity_Limit_Pediatrics": "Initial: 3 mg/kg at 0, 2, and 6 weeks; then 3 to 6 mg/kg/dose every 8 weeks thereafter",
            "Notes_1": "AGE: Infliximab: not to be used for age < 4 years\r\nPA, MD:should be prescribed by rheumatology specialists experienced in the treatment of JIA. \r\nused in the following sequence:\r\n1.\tNSAIDs \r\n2.\tTNFIs (Adalimumab, etanercept, infliximab)\r\n3.\tMethotrexate or Sulfasalazine",
            "Notes_2": "5–10 mg/kg IV every 2–8 weeks\r\nHigher doses of 10–20 mg/kg have been documented as safe \r\n(not FDA label approved for JIA)"
        },
        {
            "Indication": "Active Enthesitis Juvenile Arthritis",
            "ICD_Code": "M77.9",
            "Drug_Class": "IMMUNOSUPPRESSANTS",
            "Drug_Sub_Class": "Tumor necrosis factor alpha (TNF-α) inhibitors",
            "Trade_Name": "REMSIMA 100 mg powder for solution for infusion",
            "Registration_Number": "198-334-15",
            "Active_ingredient": "INFLIXIMAB",
            "ATC_Code": "L04AB02",
            "Dosage_Form": "POWDER, FOR SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, MD, AGE",
            "Quantity_Limit_Pediatrics": "Initial: 3 mg/kg at 0, 2, and 6 weeks; then 3 to 6 mg/kg/dose every 8 weeks thereafter",
            "Notes_1": "AGE: Infliximab: not to be used for age < 4 years\r\nPA, MD:should be prescribed by rheumatology specialists experienced in the treatment of JIA. \r\nused in the following sequence:\r\n1.\tNSAIDs \r\n2.\tTNFIs (Adalimumab, etanercept, infliximab)\r\n3.\tMethotrexate or Sulfasalazine",
            "Notes_2": "5–10 mg/kg IV every 2–8 weeks\r\nHigher doses of 10–20 mg/kg have been documented as safe \r\n(not FDA label approved for JIA)"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "BACTALL 250MG TABLET",
            "Registration_Number": "43-171-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "BACTALL 500MG TABLET",
            "Registration_Number": "44-171-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIFLOX 200MG-100ML I.V. INFUSION",
            "Registration_Number": "115-334-09",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Parenteral",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "MAXIMAL800MG PER DAY for 14 days then review",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIFLOX 200MG-100ML I.V. INFUSION",
            "Registration_Number": "100-334-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Parenteral",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "MAXIMAL800MG PER DAY for 14 days then review",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIFLOX 250MG TABLET",
            "Registration_Number": "37-352-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIFLOX 500MG TABLET",
            "Registration_Number": "38-352-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROBAY 200 mg solution for infusion",
            "Registration_Number": "26-4-91",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "200",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "MAXIMAL800MG PER DAY for 14 days then review",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROBAY 250MG TAB",
            "Registration_Number": "22-4-91",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROBAY 500MG TAB",
            "Registration_Number": "23-4-91",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROBAY 750MG TAB",
            "Registration_Number": "24-4-91",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROCIN 250MG TAB",
            "Registration_Number": "25-201-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROCIN 500MG TAB",
            "Registration_Number": "26-201-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPRODAR 500",
            "Registration_Number": "63-124-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLACIN 250 MG FILM COATED TABLETS",
            "Registration_Number": "16-295-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLACIN 500 MG FILM COATED TABLETS",
            "Registration_Number": "17-295-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLACIN 750 MG FILM COATED TABLETS",
            "Registration_Number": "18-295-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLOX 250MG TAB",
            "Registration_Number": "104-119-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLOX 500MG TAB",
            "Registration_Number": "105-119-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLOX 750MG TAB",
            "Registration_Number": "106-119-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLOXACIN 0.2% IN 0.9% SODIUM CHLORIDE INJECTION",
            "Registration_Number": "76-803-12",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "MAXIMAL800MG PER DAY for 14 days then review",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROGEN",
            "Registration_Number": "98-325-03",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROHEXAL 250MG F.C. TABLETS",
            "Registration_Number": "17-349-10",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROHEXAL 500MG F.C. TABLETS",
            "Registration_Number": "18-349-10",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROLET 250MG F.C. TABLETS",
            "Registration_Number": "2-453-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROLET 500MG F.C. TABLETS",
            "Registration_Number": "1-453-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROLON 200 VIAL 100ML",
            "Registration_Number": "128-172-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "MAXIMAL800MG PER DAY for 14 days then review",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROLON 500MG F.C. TABLETS",
            "Registration_Number": "157-172-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROLON 750MG F.C. TABLETS",
            "Registration_Number": "156-172-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROMAX 250 MG TABLET",
            "Registration_Number": "121-212-00",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROMAX 500 MG TABLET",
            "Registration_Number": "122-212-00",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROMAX 750MG TAB",
            "Registration_Number": "160-212-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROMID 250MG F-C TABLET",
            "Registration_Number": "18-346-05",
            "Active_ingredient": "CIPROFLOXACIN ",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROMID 500MG F-C TABLET",
            "Registration_Number": "17-346-05",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROMID 750MG F.C. TABLETS",
            "Registration_Number": "21-346-07",
            "Active_ingredient": "CIPROFLOXACIN ",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROQUIN",
            "Registration_Number": "3-371-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROQUIN",
            "Registration_Number": "4-371-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPRO-SOL I.V Infusion",
            "Registration_Number": "286-149-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Infusion",
            "ROA": "Parenteral",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "MAXIMAL800MG PER DAY for 14 days then review",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROXEN 250MG FILM COATED TABLET",
            "Registration_Number": "32-368-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROXEN 500MG FILM COATED TABLET",
            "Registration_Number": "33-368-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROXEN 750MG FILM COATED TABLET",
            "Registration_Number": "34-368-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EMICIPRO 500MG F.C. TABLETS",
            "Registration_Number": "27-444-07",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "NEOCIPRO 500MG F.C. TABLETS",
            "Registration_Number": "9-584-09",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "OMACIP 250MG TABLETS",
            "Registration_Number": "22-390-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "OMACIP 500MG TABLETS",
            "Registration_Number": "21-390-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "QUINOX 250 MG F- C TAB.",
            "Registration_Number": "79-277-00",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "QUINOX 500 MG TAB.",
            "Registration_Number": "80-277-00",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "QUINOX 750MG F- C TABLET",
            "Registration_Number": "172-277-05",
            "Active_ingredient": "CIPROFLOXACIN HYDROCHLORIDE",
            "ATC_Code": "J01MA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "QUINOX 200 mg solution for infusion",
            "Registration_Number": "299-277-16",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "MAXIMAL800MG PER DAY for 14 days then review",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROGRAM 250 mg film-coated tablet",
            "Registration_Number": "33-437-16",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROGRAM 500 mg film-coated tablet",
            "Registration_Number": "34-437-16",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROGRAM 750 mg film-coated tablet",
            "Registration_Number": "35-437-16",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPRO-SOL  2 MG/ML I.V. INFUSION SOLUTION",
            "Registration_Number": "468-149-18",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Intravenous infusion ",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "MAXIMAL800MG PER DAY for 14 days then review",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TOPISTIN 2MG/ML SOL. FOR I.V INFUSION",
            "Registration_Number": "1-904-19",
            "Active_ingredient": "CIPROFLOXACIN ",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for infusion ",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "MAXIMAL800MG PER DAY for 14 days then review",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIFOGRU 2MG/ML VIAL",
            "Registration_Number": "24-5286-19",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for infusion ",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "MAXIMAL800MG PER DAY for 14 days then review",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIFOGRU 2MG/ML VIAL",
            "Registration_Number": "23-5286-19",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for infusion ",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "MAXIMAL800MG PER DAY for 14 days then review",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "QUREX XL 1000 mg film-coated tablet",
            "Registration_Number": "119-124-19",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "1000",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "SARF 250MG TAB",
            "Registration_Number": "144-186-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "SARF 500MG TAB",
            "Registration_Number": "145-186-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "SARF 750MG TAB.",
            "Registration_Number": "146-186-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "750mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1000 mg per dayfor 14 days then review. Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOFLOX 500MG F.C. TABLET",
            "Registration_Number": "37-390-12",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LAVOXIN 500 mg solution for infusion",
            "Registration_Number": "310-277-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "750 MG PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use Levofloxacin plus ceftriaxone if patients are not severely ill and no resistant risk factors. Use Levofloxacin plus aminoglycosides in severely ill patients and no resistant risk factors. Use Levofloxacin plus aminoglycosides as a second line to piperacillin or cefotaxime or ceftazidime therapy in pateints who are severely ill and with pseudomonus resistant sp. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 5 mg/ml Infusion",
            "Registration_Number": "249-334-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "750 MG PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use Levofloxacin plus ceftriaxone if patients are not severely ill and no resistant risk factors. Use Levofloxacin plus aminoglycosides in severely ill patients and no resistant risk factors. Use Levofloxacin plus aminoglycosides as a second line to piperacillin or cefotaxime or ceftazidime therapy in pateints who are severely ill and with pseudomonus resistant sp. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 5 mg/ml Infusion",
            "Registration_Number": "250-334-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "750 MG PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use Levofloxacin plus ceftriaxone if patients are not severely ill and no resistant risk factors. Use Levofloxacin plus aminoglycosides in severely ill patients and no resistant risk factors. Use Levofloxacin plus aminoglycosides as a second line to piperacillin or cefotaxime or ceftazidime therapy in pateints who are severely ill and with pseudomonus resistant sp. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVODIS 5 mg/ml Solution For Injection",
            "Registration_Number": "6-560-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "750 MG PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use Levofloxacin plus ceftriaxone if patients are not severely ill and no resistant risk factors. Use Levofloxacin plus aminoglycosides in severely ill patients and no resistant risk factors. Use Levofloxacin plus aminoglycosides as a second line to piperacillin or cefotaxime or ceftazidime therapy in pateints who are severely ill and with pseudomonus resistant sp. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LOXAMOX 250MG/50ML SOL. FOR IV INFUSION",
            "Registration_Number": "17-5286-19",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION FOR INFUSION",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "750 MG PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use Levofloxacin plus ceftriaxone if patients are not severely ill and no resistant risk factors. Use Levofloxacin plus aminoglycosides in severely ill patients and no resistant risk factors. Use Levofloxacin plus aminoglycosides as a second line to piperacillin or cefotaxime or ceftazidime therapy in pateints who are severely ill and with pseudomonus resistant sp. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LOXAMOX 500MG/100ML SOL. FOR INFUSION",
            "Registration_Number": "18-5286-19",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION FOR INFUSION",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "750 MG PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use Levofloxacin plus ceftriaxone if patients are not severely ill and no resistant risk factors. Use Levofloxacin plus aminoglycosides in severely ill patients and no resistant risk factors. Use Levofloxacin plus aminoglycosides as a second line to piperacillin or cefotaxime or ceftazidime therapy in pateints who are severely ill and with pseudomonus resistant sp. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 500MG-100ML SOLUTION FOR I.V. INFUSION",
            "Registration_Number": "135-334-10",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "750 MG PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use Levofloxacin plus ceftriaxone if patients are not severely ill and no resistant risk factors. Use Levofloxacin plus aminoglycosides in severely ill patients and no resistant risk factors. Use Levofloxacin plus aminoglycosides as a second line to piperacillin or cefotaxime or ceftazidime therapy in pateints who are severely ill and with pseudomonus resistant sp. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVANIC 5 MG -1 ML SOLUTION I.V INFUSION",
            "Registration_Number": "46-23-03",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "5",
            "G_or_B": "B",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "750 MG PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use Levofloxacin plus ceftriaxone if patients are not severely ill and no resistant risk factors. Use Levofloxacin plus aminoglycosides in severely ill patients and no resistant risk factors. Use Levofloxacin plus aminoglycosides as a second line to piperacillin or cefotaxime or ceftazidime therapy in pateints who are severely ill and with pseudomonus resistant sp. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 500MG FILM COATED TABLETS",
            "Registration_Number": "162-334-12",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOX 500MG FILM COATED TABLET",
            "Registration_Number": "273-212-11",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOX 750MG FILM COATED TABLET",
            "Registration_Number": "274-212-11",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVANIC 250MG F.C TAB",
            "Registration_Number": "43-23-02",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVANIC 500MG F.C TAB",
            "Registration_Number": "44-23-02",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOFLOXACIN Sandoz 500 mg film-coated tablet",
            "Registration_Number": "96-116-15",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVACIN 500 mg film-coated tablet",
            "Registration_Number": "78-539-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVACIN 750 mg film-coated tablet",
            "Registration_Number": "79-539-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVAQUIN 250 mg film-coated tablet",
            "Registration_Number": "67-370-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVAQUIN 500 mg film-coated tablet",
            "Registration_Number": "68-370-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVON 500 mg film-coated tablet",
            "Registration_Number": "18-968-16",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVON 750 mg film-coated tablet",
            "Registration_Number": "19-968-16",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 250 mg film-coated tablet",
            "Registration_Number": "238-334-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 750 mg film-coated tablet",
            "Registration_Number": "239-334-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "PRINCEOXIN 500 mg film-coated tablet",
            "Registration_Number": "32-249-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "PRINCEOXIN 250 mg film-coated tablet",
            "Registration_Number": "31-249-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVFLOX 500 mg film-coated tablet",
            "Registration_Number": "48-437-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVANIX 500 mg film-coated tablet",
            "Registration_Number": "13-584-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVANIX 500 mg film-coated tablet",
            "Registration_Number": "14-584-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EVOX 250MG FILM COATED TABLET",
            "Registration_Number": "18-535-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EVOX 500MG FILM COATED TABLET",
            "Registration_Number": "19-535-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EVOX 750MG FILM COATED TABLET",
            "Registration_Number": "20-535-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LIVADOR 750MG F.C.TABLET",
            "Registration_Number": "117-124-18",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet  ",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LIVADOR 250 MG FILM COATED TABLET",
            "Registration_Number": "121-124-19",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LIVADOR 500 MG FILM COATED TABLET",
            "Registration_Number": "120-124-19",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOBAT 500 MG FILM COATED TABLET",
            "Registration_Number": "30-590-19",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "FLOXMED 500MG F.C.TABLET",
            "Registration_Number": "16-631-19",
            "Active_ingredient": "LEVOFLOXACIN (AS HEMIHYDRATE)",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "FILM COATED TABLET",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EMIFLOC 500 mg Film-coated Tablet",
            "Registration_Number": "42-444-19",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "MAXIMAL750 MG PER DAY for 14 days then review Extend treatment for 2 weeks if patient remains symptomatic",
            "Notes_1": "ST: Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. Start oral levofloxacin in outpatient setting after trying ciprofloxacin OR ofloxacin. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "JEDCOFLOCIN 200MG TABLETS",
            "Registration_Number": "4-461-10",
            "Active_ingredient": "OFLOXACIN",
            "ATC_Code": "J01MA01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "G",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "OFLACIN 200MG TAB",
            "Registration_Number": "8-295-02",
            "Active_ingredient": "OFLOXACIN",
            "ATC_Code": "J01MA01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "G",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TARIVID 200MG F-C TAB",
            "Registration_Number": "37-23-94",
            "Active_ingredient": "OFLOXACIN",
            "ATC_Code": "J01MA01",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "B",
            "Notes_1": "Ofloxacin, ciprofloxacin and levofloxacin are first line for outpatient not at risk of sexually transmitted disease. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PIPERACILLIN - TAZOPACTAM SANDOZ 2.25GM VIAL",
            "Registration_Number": "85-116-12",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2, 0.25",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "18g PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use piperacillin as first line therapy in severely ill patients and with no resistant risk factors. Second line will be floroquinolones and Aminoglycosides. Use piperacillin ( with or without Aminoglycosides) as first line therapy in severely ill patients and with resistant organisms ( beta lactamase E. Coli, Pseudomonous Sp., and floroquinolones resistance Pseudomonous sp.). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PIPERACILLIN - TAZOPACTAM SANDOZ 4.5GM VIAL",
            "Registration_Number": "86-116-12",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "18g PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use piperacillin as first line therapy in severely ill patients and with no resistant risk factors. Second line will be floroquinolones and Aminoglycosides. Use piperacillin ( with or without Aminoglycosides) as first line therapy in severely ill patients and with resistant organisms ( beta lactamase E. Coli, Pseudomonous Sp., and floroquinolones resistance Pseudomonous sp.). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PRIZMA 2GM/0.25GM POWDER FOR I.V. INFUSION",
            "Registration_Number": "138-334-11",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2000, 250",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "18g PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use piperacillin as first line therapy in severely ill patients and with no resistant risk factors. Second line will be floroquinolones and Aminoglycosides. Use piperacillin ( with or without Aminoglycosides) as first line therapy in severely ill patients and with resistant organisms ( beta lactamase E. Coli, Pseudomonous Sp., and floroquinolones resistance Pseudomonous sp.). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PRIZMA 4GM-0.5GM POWDER FOR I.V INFUSION",
            "Registration_Number": "124-334-09",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "18g PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use piperacillin as first line therapy in severely ill patients and with no resistant risk factors. Second line will be floroquinolones and Aminoglycosides. Use piperacillin ( with or without Aminoglycosides) as first line therapy in severely ill patients and with resistant organisms ( beta lactamase E. Coli, Pseudomonous Sp., and floroquinolones resistance Pseudomonous sp.). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "TAZOCIN 2.25G VIAL",
            "Registration_Number": "24-47-94",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2000, 250",
            "G_or_B": "B",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "18g PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use piperacillin as first line therapy in severely ill patients and with no resistant risk factors. Second line will be floroquinolones and Aminoglycosides. Use piperacillin ( with or without Aminoglycosides) as first line therapy in severely ill patients and with resistant organisms ( beta lactamase E. Coli, Pseudomonous Sp., and floroquinolones resistance Pseudomonous sp.). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "TAZOCIN 4.5GM VIAL + EDTA",
            "Registration_Number": "1-497-05",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "B",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "18g PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use piperacillin as first line therapy in severely ill patients and with no resistant risk factors. Second line will be floroquinolones and Aminoglycosides. Use piperacillin ( with or without Aminoglycosides) as first line therapy in severely ill patients and with resistant organisms ( beta lactamase E. Coli, Pseudomonous Sp., and floroquinolones resistance Pseudomonous sp.). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "TAZORAX 2.25 GM Powder for injection",
            "Registration_Number": "270-277-13",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2, 0.25",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "18g PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use piperacillin as first line therapy in severely ill patients and with no resistant risk factors. Second line will be floroquinolones and Aminoglycosides. Use piperacillin ( with or without Aminoglycosides) as first line therapy in severely ill patients and with resistant organisms ( beta lactamase E. Coli, Pseudomonous Sp., and floroquinolones resistance Pseudomonous sp.). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "TAZORAX 4.5 GM Powder for injection",
            "Registration_Number": "271-277-13",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "18g PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use piperacillin as first line therapy in severely ill patients and with no resistant risk factors. Second line will be floroquinolones and Aminoglycosides. Use piperacillin ( with or without Aminoglycosides) as first line therapy in severely ill patients and with resistant organisms ( beta lactamase E. Coli, Pseudomonous Sp., and floroquinolones resistance Pseudomonous sp.). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PIPERACILLIN - TAZOPACTAM SANDOZ 4.5GM VIAL",
            "Registration_Number": "103-116-17",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "18g PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "PA: Use piperacillin as first line therapy in severely ill patients and with no resistant risk factors. Second line will be floroquinolones and Aminoglycosides. Use piperacillin ( with or without Aminoglycosides) as first line therapy in severely ill patients and with resistant organisms ( beta lactamase E. Coli, Pseudomonous Sp., and floroquinolones resistance Pseudomonous sp.). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAMAX 200MG CAPSULE",
            "Registration_Number": "48-539-10",
            "Active_ingredient": "CEFIXIME ",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAMAX 400MG CAPSULE",
            "Registration_Number": "47-539-10",
            "Active_ingredient": "CEFIXIME ",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFIM 200MG CAPSULES",
            "Registration_Number": "28-498-09",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFIM 400MG CAPSULES",
            "Registration_Number": "26-498-09",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFRAX 100MG/5ML POWDER FOR ORAL SUSPENSION",
            "Registration_Number": "38-390-12",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "20",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFRAX 200MG CAPSULES",
            "Registration_Number": "36-390-11",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFRAX 400MG CAPSULES",
            "Registration_Number": "35-390-11",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MAGNACEF 100MG\\5ML SUSP",
            "Registration_Number": "7-295-02",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MAGNACEF 200MG CAP.",
            "Registration_Number": "11-295-03",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MAGNACEF 400MG CAP",
            "Registration_Number": "9-295-02",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "SUPRAX 100 SUSP",
            "Registration_Number": "82-172-93",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "SUPRAX 200 CAPS",
            "Registration_Number": "77-172-92",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "SUPRAX 400 CAPS",
            "Registration_Number": "76-172-92",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "SUPRAX D 400MG TABLET",
            "Registration_Number": "166-172-08",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "WINEX 100MG\\5ML ORAL SUSP",
            "Registration_Number": "183-277-07",
            "Active_ingredient": "CEFIXIME TRIHYDRATE",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "WINEX 200MG CAP",
            "Registration_Number": "144-277-03",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "WINEX 400MG CAP",
            "Registration_Number": "145-277-03",
            "Active_ingredient": "CEFIXIME",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MIXIF 400 mg Capsules",
            "Registration_Number": "103-124-17",
            "Active_ingredient": "CEFIXIME TRIHYDRATE",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule, hard",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MIXIF 200 mg Capsules",
            "Registration_Number": "108-124-18",
            "Active_ingredient": "CEFIXIME TRIHYDRATE",
            "ATC_Code": "J01DD08",
            "Dosage_Form": "Capsule, hard",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "400MG. SINGLE DOSE",
            "Notes_1": "Cefixime is first line oral regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAXON 1GM I.M+5 ML LIDOCAINE VIAL",
            "Registration_Number": "93-334-04",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAXON 1GM I.V VIAL",
            "Registration_Number": "94-334-04",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAXON 500 MG I.M+5 ML LIDOCAINE VIAL",
            "Registration_Number": "91-334-04",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAXON 500 MG I.V VIAL",
            "Registration_Number": "92-334-04",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MEGION 0.25GM I.V - I.M INJECTION",
            "Registration_Number": "70-116-07",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MEGION 0.5GM I.V INJECTION",
            "Registration_Number": "71-116-07",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MEGION 1GM I.V - I.M INJECTION",
            "Registration_Number": "72-116-07",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MEGION 2GM POW. FOR SOLU. FOR INJ OR INF",
            "Registration_Number": "76-116-08",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MESPORIN 1000 I.M.",
            "Registration_Number": "13-222-05",
            "Active_ingredient": "CEFTRIAXONE, LIDOCAINE",
            "ATC_Code": "J01DD54  ",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MESPORIN 1000 I.V.",
            "Registration_Number": "14-222-05",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MESPORIN 2000 I.V.",
            "Registration_Number": "12-222-05",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MESPORIN 500 I.M.",
            "Registration_Number": "16-222-05",
            "Active_ingredient": "CEFTRIAXONE, LIDOCAINE",
            "ATC_Code": "J01DD54  ",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MESPORIN 500 I.V.",
            "Registration_Number": "15-222-05",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ROCEPHIN 1GM i.m. + 3.5 ML SOLVENT",
            "Registration_Number": "249-24-03",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "B",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ROCEPHIN 1GM i.v. + 10 ML SOLVENT",
            "Registration_Number": "248-24-03",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "B",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ROCEPHIN 500MG i.m. + 2 ML SOLVENT",
            "Registration_Number": "247-24-03",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ROXCEF 250MG I.M INJECTION",
            "Registration_Number": "97-119-00",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ROXCEF 250MG I.V INJECTION",
            "Registration_Number": "98-119-00",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "SAMIXON 1GM VIAL",
            "Registration_Number": "119-172-98",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "SAMIXON 1GM VIAL + SOLVENT",
            "Registration_Number": "122-172-99",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "SAMIXON 500MG VIAL",
            "Registration_Number": "120-172-98",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "SAMIXON 500MG VIAL + SOLVENT",
            "Registration_Number": "121-172-99",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "TRIAXONE 0.5G I.M VIAL+5ML SOLV.LIDOCAIN",
            "Registration_Number": "43-277-98",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "TRIAXONE 1GM VIAL I.M+5ML SOLV.LIDOCAINE",
            "Registration_Number": "45-277-98",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "TRIAXONE 500MG VIAL I.V+5MLWATER FOR INJ",
            "Registration_Number": "44-277-98",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "TRIAXONE1GM VIAL I.V +10ML WATER FOR INJ",
            "Registration_Number": "46-277-98",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PROTEDEX 500 mg powder for solution for injection",
            "Registration_Number": "31-432-15",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PROTEDEX 1 g powder for solution for injection",
            "Registration_Number": "32-432-15",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PROTEDEX 2 g powder for solution for injection",
            "Registration_Number": "33-432-15",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAJECT 500 mg IV",
            "Registration_Number": "3-666-16",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAJECT 1 g IV",
            "Registration_Number": "4-666-16",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAJECT 500 mg IM",
            "Registration_Number": "5-666-16",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intramuscular",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAJECT 1 g IM",
            "Registration_Number": "6-666-16",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ROXONE 1 gm Powder for Solution for Injection",
            "Registration_Number": "9-718-18",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder and solvent for solution for injection/infusion",
            "ROA": "Intramuscular,Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin ( or ceftazidime or cefepime) and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 0.25GM I.M. VIAL + SOLVENT",
            "Registration_Number": "132-186-01",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin ( or ceftazidime or cefepime) and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 0.25GM I.V. VIAL + SOLVENT",
            "Registration_Number": "131-186-01",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin ( or ceftazidime or cefepime) and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 0.25GM I.V. VIAL + SOLVENT",
            "Registration_Number": "196-186-03",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin ( or ceftazidime or cefepime) and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 1GM I.M. VIAL + SOLVENT",
            "Registration_Number": "130-186-01",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin ( or ceftazidime or cefepime) and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 1GM I.V. VIAL + SOLVENT",
            "Registration_Number": "129-186-01",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin ( or ceftazidime or cefepime) and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 1GM I.V. VIAL + SOLVENT",
            "Registration_Number": "197-186-03",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin ( or ceftazidime or cefepime) and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 500MG I.M. VIAL + SOLVENT",
            "Registration_Number": "187-186-02",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin ( or ceftazidime or cefepime) and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 500MG I.V. VIAL + SOLVENT",
            "Registration_Number": "186-186-02",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin ( or ceftazidime or cefepime) and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 500MG I.V. VIAL + SOLVENT",
            "Registration_Number": "199-186-03",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST",
            "Quantity_Limit_Adults": "MAXIMAL FOR Ceftriaxone 2 G PER DAY for 14 days then review CAN BE EXTENDED FOR MOR 2 WEEKS",
            "Notes_1": "Ceftriaxone is first line regimen for outpatient at risk of sexually transmitted diseasses to cover Neisseria gonorrhoeae and Chlamydia trachomatis infections in addition to other common bacterial pathogens. CU: use Ceftraixone and levfloxacillin in patients who are severely ill and with no risk resistance factor. ST: use Ceftriaxone ( with or without aminoglycosides) as second line therapy after piperacillin ( or ceftazidime or cefepime) and aminoglycosides in severely ill patients and floroquinoloes pseudomonous resistant sp. "
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTUM 1 g",
            "Registration_Number": "43-276-97",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTUM 1 g Powder for injection",
            "Registration_Number": "42-276-97",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTUM 2 g",
            "Registration_Number": "44-276-97",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTUM 2 g",
            "Registration_Number": "45-276-97",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTUM 500 mg",
            "Registration_Number": "40-276-97",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTUM 500 mg",
            "Registration_Number": "41-276-97",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PARZIDIME 1 GM POWDER FOR SOLUTION FOR Injection*",
            "Registration_Number": "82-116-10",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ZIDIME 1GM GLASS VIAL IV-IM",
            "Registration_Number": "59-277-99",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ZIDIME 2GM I.V INJ",
            "Registration_Number": "61-277-99",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTA-Z 1 g powder for solution for injection",
            "Registration_Number": "235-334-16",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Parenteral",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "NEGACEF 0.5 g INJ.",
            "Registration_Number": "134-186-01",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "NEGACEF 1GM VIAL",
            "Registration_Number": "133-186-01",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "NEGACEF 2GM Injection*",
            "Registration_Number": "277-186-10",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2g",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "6G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CLAFORAN 500 MG I.M.-I.V.VIALS",
            "Registration_Number": "7-37-84",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "2 G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FOXIME 1GM VIAL+5ML SOLVENT LIDOCAINE IM",
            "Registration_Number": "41-277-98",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "2 G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FOXIME 1GM VIAL+5ML WATER FOR INJ IV USE",
            "Registration_Number": "40-277-98",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "2 G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FOXIME 500MG VIAL+AMP OF WATER IM-IV USE",
            "Registration_Number": "39-277-98",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "2 G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "TOTAM 1GM IV\\IM INJECTION",
            "Registration_Number": "90-334-04",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "2 G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PRIMOCEF 0.5 GM I.M- I.V VIAL",
            "Registration_Number": "151-186-01",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intramuscular,Intravenous (not otherwise specified)",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "2 G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PRIMOCEF 1 g Powder for injection",
            "Registration_Number": "153-186-01",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intramuscular",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "2 G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PRIMOCEF 1 GM I.V VIAL",
            "Registration_Number": "152-186-01",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "2 G. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Fourth-generation cephalosporins",
            "Trade_Name": "PROTEC 1 GM Injection*",
            "Registration_Number": "186-277-07",
            "Active_ingredient": "CEFEPIME HYDROCHLORIDE",
            "ATC_Code": "J01DE01",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). Thiis should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Fourth-generation cephalosporins",
            "Trade_Name": "PROTEC 2 GM Injection*",
            "Registration_Number": "187-277-07",
            "Active_ingredient": "CEFEPIME HYDROCHLORIDE",
            "ATC_Code": "J01DE01",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). Thiis should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Fourth-generation cephalosporins",
            "Trade_Name": "CEFAFOUR 1gm IV/IM Vial",
            "Registration_Number": "256-334-17",
            "Active_ingredient": "CEFEPIME HYDROCHLORIDE",
            "ATC_Code": "J01DE01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). Thiis should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Fourth-generation cephalosporins",
            "Trade_Name": "CEFAFOUR 2 gm IV/IM Vial",
            "Registration_Number": "257-334-17",
            "Active_ingredient": "CEFEPIME HYDROCHLORIDE",
            "ATC_Code": "J01DE01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). Thiis should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Fourth-generation cephalosporins",
            "Trade_Name": "DELTACEF 1 gm Vial",
            "Registration_Number": "2-674-18",
            "Active_ingredient": "CEFEPIME HYDROCHLORIDE",
            "ATC_Code": "J01DE01",
            "Dosage_Form": "Powder for solution for injection/infusion",
            "ROA": "Intramuscular and Intravenous",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). Thiis should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Fourth-generation cephalosporins",
            "Trade_Name": "DELTACEF 2 gm Vial",
            "Registration_Number": "3-674-18",
            "Active_ingredient": "CEFEPIME HYDROCHLORIDE",
            "ATC_Code": "J01DE01",
            "Dosage_Form": "Powder for solution for injection/infusion",
            "ROA": "Intramuscular and Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Notes_1": "PA: Use Ceftazidime or Cefotaxime ( as alternative to piperacillin)  with aminoglycosides as a first line therapy in severely ill pateints and no resistant risk factor. Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients with resistant pseudomonous sp. as first line therapy (each as an alternative to piperacillin). Ceftazidime and cefepem (with or wothout aminoglycosides) are used in severely ill patients and floroquinolones resistance sp. (each as an alternative to piperacillin). Thiis should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "TIENAM 500 MG VIAL I.V.",
            "Registration_Number": "23-82-91",
            "Active_ingredient": "IMIPENEM, CILASTATIN",
            "ATC_Code": "J01DH51",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500, 500",
            "G_or_B": "B",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "4g. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This shoud be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "LASTINEM 500 mg powder for solution for infusion",
            "Registration_Number": "5-796-15",
            "Active_ingredient": "IMIPENEM, CILASTATIN",
            "ATC_Code": "J01DH51",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous drip",
            "Strength": "500, 500",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "4g. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This shoud be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "Imesta 500 mg/500 mg Powder For IV Infusion (10S)",
            "Registration_Number": "418-212-19",
            "Active_ingredient": "IMIPENEM , CILASTATIN",
            "ATC_Code": "J01DH51",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous",
            "Strength": "500 , 500",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "4g. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This shoud be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "Imesta 500 mg/500 mg Powder For IV Infusion (1Vial)",
            "Registration_Number": "419-212-19",
            "Active_ingredient": "IMIPENEM , CILASTATIN",
            "ATC_Code": "J01DH51",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous",
            "Strength": "500 , 500",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "4g. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This shoud be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "IMIPENEM-CILASTATIN LABATEC 500/500 VIAL",
            "Registration_Number": "2-902-19",
            "Active_ingredient": "IMIPENEM , CILASTATIN",
            "ATC_Code": "J01DH51",
            "Dosage_Form": "Powder for solution for infusion ",
            "ROA": "Intravenous",
            "Strength": "500 , 500",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "4g. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This shoud be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "RONEM 1GM",
            "Registration_Number": "2-796-13",
            "Active_ingredient": "MEROPENEM",
            "ATC_Code": "J01DH02",
            "Dosage_Form": "Powder for solution for injection or infusion",
            "ROA": "Parenteral",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1000mg. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This should be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "RONEM 500MG",
            "Registration_Number": "1-796-13",
            "Active_ingredient": "MEROPENEM",
            "ATC_Code": "J01DH02",
            "Dosage_Form": "Powder for solution for injection or infusion",
            "ROA": "Parenteral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1000mg. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This should be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "ARCHIFAR 500 mg powder for solution for injection or infusion",
            "Registration_Number": "4-718-16",
            "Active_ingredient": "MEROPENEM",
            "ATC_Code": "J01DH02",
            "Dosage_Form": "Powder for solution for injection or infusion",
            "ROA": "Intravenous",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1000mg. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This should be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "ARCHIFAR 1000 mg powder for solution for injection or infusion",
            "Registration_Number": "5-718-16",
            "Active_ingredient": "MEROPENEM",
            "ATC_Code": "J01DH02",
            "Dosage_Form": "Powder for solution for injection or infusion",
            "ROA": "Intravenous",
            "Strength": "1000",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1000mg. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This should be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "MIRAN 0.5 g powder for injection",
            "Registration_Number": "294-186-16",
            "Active_ingredient": "MEROPENEM",
            "ATC_Code": "J01DH02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1000mg. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This should be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "MIRAN 1 g powder for injection",
            "Registration_Number": "295-186-16",
            "Active_ingredient": "MEROPENEM",
            "ATC_Code": "J01DH02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1000mg. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This should be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "MERONEM 1GM VIAL I-V",
            "Registration_Number": "23-110-18",
            "Active_ingredient": "MEROPENEM",
            "ATC_Code": "J01DH02",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "B",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1000mg. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This should be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "MERONEM 500MG VIAL I-V",
            "Registration_Number": "24-110-18",
            "Active_ingredient": "MEROPENEM",
            "ATC_Code": "J01DH02",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1000mg. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This should be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "MEROPENEM 1GM POW. FOR SOL. FOR INJ./INF.",
            "Registration_Number": "7-174-18",
            "Active_ingredient": "MEROPENEM TRIHYDRATE",
            "ATC_Code": "J01DH02",
            "Dosage_Form": "Powder for solution for injection or infusion ",
            "ROA": "Intravenous",
            "Strength": "1000",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1000mg. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This should be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "MEROPENEM 500GM POW. FOR SOL. FOR INJ./INF.",
            "Registration_Number": "8-174-18",
            "Active_ingredient": "MEROPENEM TRIHYDRATE",
            "ATC_Code": "J01DH02",
            "Dosage_Form": "Powder for solution for injection or infusion ",
            "ROA": "Intravenous",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1000mg. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This should be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Carbapenems",
            "Trade_Name": "INVANZ 1 gm Powder for Concentrate for Solution for Infusion",
            "Registration_Number": "29-698-18",
            "Active_ingredient": "ERTAPENEM SODIUM",
            "ATC_Code": "J01DH03",
            "Dosage_Form": "Powder for concentrate for solution for infusion",
            "ROA": "Intravenous",
            "Strength": "1",
            "G_or_B": "B",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1000mg. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks.",
            "Notes_1": "PA: Reserved for severely ill patients (inpatient) and with reisitant micro organisms. They should be used in folorquinolones resistant organism and extended spectrum beta lactamase producing E.Coli. In this case 1st line is piperacillin, second line Carbapenem ( start Ertapenem then Imipenem or meropenem ). In pseudomonus sp., First line is  piperacillin ( with or without aminoglycosides), second line are floroquinolones with aminoglycsides or carbapenem (imipenem or meropenem). In resistance to floroquinolones, first line is piperacillin with aminoglycosides; second line ceftriaxone and aminoglycosides or Ertapenem. This should be confirmed by a specialist.\r\n"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "APO-DOXY 100MG CAPS",
            "Registration_Number": "1-249-97",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "200MG. for 10 days",
            "Notes_1": "CU: first choice therapy with either Single dose of 250 mg ceftriaxone IM or single dose of cefixime 400 mg orally for outpatients at risk for sexually transmitted infection"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DORYX CAPS 100MG",
            "Registration_Number": "1-217-92",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "200MG. for 10 days",
            "Notes_1": "CU: first choice therapy with either Single dose of 250 mg ceftriaxone IM or single dose of cefixime 400 mg orally for outpatients at risk for sexually transmitted infection"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DOXYCIN",
            "Registration_Number": "122-325-04",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "200MG. for 10 days",
            "Notes_1": "CU: first choice therapy with either Single dose of 250 mg ceftriaxone IM or single dose of cefixime 400 mg orally for outpatients at risk for sexually transmitted infection"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DOXYDAR",
            "Registration_Number": "19-124-96",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "200MG. for 10 days",
            "Notes_1": "CU: first choice therapy with either Single dose of 250 mg ceftriaxone IM or single dose of cefixime 400 mg orally for outpatients at risk for sexually transmitted infection"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DUMOXIN SYRUP 10MG-ML",
            "Registration_Number": "50-49-81",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "10",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "200MG. for 10 days",
            "Notes_1": "CU: first choice therapy with either Single dose of 250 mg ceftriaxone IM or single dose of cefixime 400 mg orally for outpatients at risk for sexually transmitted infection"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DUMOXIN TAB 100 MG",
            "Registration_Number": "49-49-81",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "200MG. for 10 days",
            "Notes_1": "CU: first choice therapy with either Single dose of 250 mg ceftriaxone IM or single dose of cefixime 400 mg orally for outpatients at risk for sexually transmitted infection"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "TABOCINE 100",
            "Registration_Number": "14-277-97",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule, hard",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "200MG. for 10 days",
            "Notes_1": "CU: first choice therapy with either Single dose of 250 mg ceftriaxone IM or single dose of cefixime 400 mg orally for outpatients at risk for sexually transmitted infection"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "VIBRAMYCIN 100MG TABLET",
            "Registration_Number": "1-5029-18",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "B",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "200MG. for 10 days",
            "Notes_1": "CU: first choice therapy with either Single dose of 250 mg ceftriaxone IM or single dose of cefixime 400 mg orally for outpatients at risk for sexually transmitted infection"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DURADOX 100 MG CAPS",
            "Registration_Number": "109-186-99",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU",
            "Quantity_Limit_Adults": "200MG. for 10 days",
            "Notes_1": "CU: first choice therapy with either Single dose of 250 mg ceftriaxone IM or single dose of cefixime 400 mg orally for outpatients at risk for sexually transmitted infection"
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BACTRIM FORTE TAB",
            "Registration_Number": "82-212-98",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "800, 160",
            "G_or_B": "B",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BACTRIM PED SYRUP (200+40mg-5ML)",
            "Registration_Number": "24-24-80",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8",
            "G_or_B": "B",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BACTRIM SUSP(200+40MG-5ML)",
            "Registration_Number": "72-212-97",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8",
            "G_or_B": "B",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BALKATRIN SUSP( 200+40MG-5ML)",
            "Registration_Number": "41-119-82",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BALKATRIN SUSP( 200+40MG-5ML)",
            "Registration_Number": "42-119-82",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BALKATRIN TAB",
            "Registration_Number": "40-119-82",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400, 80",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "SEPTRIN PAED TAB",
            "Registration_Number": "36-8-82",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100, 20",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "ZOTRIM FORTE TAB.",
            "Registration_Number": "61-334-01",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "800, 160",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "ZOTRIM SUSP.",
            "Registration_Number": "60-334-01",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "SEPTRIN 240MG SUSP",
            "Registration_Number": "15-887-17",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "SEPTRIN PAED TAB",
            "Registration_Number": "21-186-86",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "100, 20mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "TRIMOL SUSP.",
            "Registration_Number": "22-186-86",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "TRIMOL SUSP.",
            "Registration_Number": "30-186-87",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA",
            "Quantity_Limit_Adults": "1920 MG PER DAY. 10 to 14 day. Extend treatment for 2 weeks if patient remains symptomatic.",
            "Notes_1": "PA: Co-trimoxazole should be reserved as a second line therapy for outpatient setting in patients who are not at risk of sexually transmitted disease and intolerant to floroquinolones. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "AMINOGLYCOSIDE ANTIBACTERIALS",
            "Drug_Sub_Class": "Other aminoglycosides",
            "Trade_Name": "GENTAM 20MG-2ML AMP",
            "Registration_Number": "14-212-93",
            "Active_ingredient": "GENTAMICIN",
            "ATC_Code": "J01GB03",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "10",
            "G_or_B": "B",
            "Prescribing_edits": "PA, CU, QL",
            "Quantity_Limit_Adults": "7 mg per kg IV every 24 hours. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks. QL: do not exceed 5 days treatment.",
            "Notes_1": "PA: Aminoglycosides should only be used for the treatment of infection in critically ill patiens and for infections with organisms resistant to less toxic therapies. CU: can't be used as monotherapy and should be combined with other antibiotics piperacillin, ceftazidime, cefepim and cefotaxim. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "AMINOGLYCOSIDE ANTIBACTERIALS",
            "Drug_Sub_Class": "Other aminoglycosides",
            "Trade_Name": "GENTAM 80MG-2ML AMP",
            "Registration_Number": "15-212-93",
            "Active_ingredient": "GENTAMICIN",
            "ATC_Code": "J01GB03",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "40",
            "G_or_B": "B",
            "Prescribing_edits": "PA, CU, QL",
            "Quantity_Limit_Adults": "7 mg per kg IV every 24 hours. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks. QL: do not exceed 5 days treatment.",
            "Notes_1": "PA: Aminoglycosides should only be used for the treatment of infection in critically ill patiens and for infections with organisms resistant to less toxic therapies. CU: can't be used as monotherapy and should be combined with other antibiotics piperacillin, ceftazidime, cefepim and cefotaxim. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "AMINOGLYCOSIDE ANTIBACTERIALS",
            "Drug_Sub_Class": "Other aminoglycosides",
            "Trade_Name": "AMIKIN AMP 100MG-2ML",
            "Registration_Number": "31-212-95",
            "Active_ingredient": "AMIKACIN",
            "ATC_Code": "J01GB06",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "50",
            "G_or_B": "B",
            "Prescribing_edits": "PA, CU, QL",
            "Quantity_Limit_Adults": "15 mg per kg IV every 24 hours. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks. Do not exceed 5 days treatment.",
            "Notes_1": "PA: Aminoglycosides should only be used for the treatment of infection in critically ill patiens and for infections with organisms resistant to less toxic therapies. CU: can't be used as monotherapy and should be combined with other antibiotics piperacillin, ceftazidime, cefepim and cefotaxim. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "AMINOGLYCOSIDE ANTIBACTERIALS",
            "Drug_Sub_Class": "Other aminoglycosides",
            "Trade_Name": "AMIKIN AMP 500MG-2ML",
            "Registration_Number": "30-212-95",
            "Active_ingredient": "AMIKACIN",
            "ATC_Code": "J01GB06",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "250",
            "G_or_B": "B",
            "Prescribing_edits": "PA, CU, QL",
            "Quantity_Limit_Adults": "15 mg per kg IV every 24 hours. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks. Do not exceed 5 days treatment.",
            "Notes_1": "PA: Aminoglycosides should only be used for the treatment of infection in critically ill patiens and for infections with organisms resistant to less toxic therapies. CU: can't be used as monotherapy and should be combined with other antibiotics piperacillin, ceftazidime, cefepim and cefotaxim. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "AMINOGLYCOSIDE ANTIBACTERIALS",
            "Drug_Sub_Class": "Other aminoglycosides",
            "Trade_Name": "MIACIN 100MG-2ML AMP",
            "Registration_Number": "87-172-93",
            "Active_ingredient": "AMIKACIN",
            "ATC_Code": "J01GB06",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "50",
            "G_or_B": "G",
            "Prescribing_edits": "PA, CU, QL",
            "Quantity_Limit_Adults": "15 mg per kg IV every 24 hours. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks. Do not exceed 5 days treatment.",
            "Notes_1": "PA: Aminoglycosides should only be used for the treatment of infection in critically ill patiens and for infections with organisms resistant to less toxic therapies. CU: can't be used as monotherapy and should be combined with other antibiotics piperacillin, ceftazidime, cefepim and cefotaxim. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "AMINOGLYCOSIDE ANTIBACTERIALS",
            "Drug_Sub_Class": "Other aminoglycosides",
            "Trade_Name": "MIACIN 500MG-2ML AMP",
            "Registration_Number": "88-172-93",
            "Active_ingredient": "AMIKACIN",
            "ATC_Code": "J01GB06",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA, CU, QL",
            "Quantity_Limit_Adults": "15 mg per kg IV every 24 hours. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks. Do not exceed 5 days treatment.",
            "Notes_1": "PA: Aminoglycosides should only be used for the treatment of infection in critically ill patiens and for infections with organisms resistant to less toxic therapies. CU: can't be used as monotherapy and should be combined with other antibiotics piperacillin, ceftazidime, cefepim and cefotaxim. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "AMINOGLYCOSIDE ANTIBACTERIALS",
            "Drug_Sub_Class": "Other aminoglycosides",
            "Trade_Name": "MIKACIN 100MG-2ML INJ.",
            "Registration_Number": "142-186-01",
            "Active_ingredient": "AMIKACIN",
            "ATC_Code": "J01GB06",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "50mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, CU, QL",
            "Quantity_Limit_Adults": "15 mg per kg IV every 24 hours. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks. Do not exceed 5 days treatment.",
            "Notes_1": "PA: Aminoglycosides should only be used for the treatment of infection in critically ill patiens and for infections with organisms resistant to less toxic therapies. CU: can't be used as monotherapy and should be combined with other antibiotics piperacillin, ceftazidime, cefepim and cefotaxim. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bacterial Prostatitis",
            "ICD_Code": "N41.0",
            "Drug_Class": "AMINOGLYCOSIDE ANTIBACTERIALS",
            "Drug_Sub_Class": "Other aminoglycosides",
            "Trade_Name": "MIKACIN 500MG-2 ML AMP",
            "Registration_Number": "154-186-02",
            "Active_ingredient": "AMIKACIN",
            "ATC_Code": "J01GB06",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "250mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, CU, QL",
            "Quantity_Limit_Adults": "15 mg per kg IV every 24 hours. Continue treatment until patient is afebrile, then transition to oral regimen (group B) for an additional 2 to 4 weeks. Do not exceed 5 days treatment.",
            "Notes_1": "PA: Aminoglycosides should only be used for the treatment of infection in critically ill patiens and for infections with organisms resistant to less toxic therapies. CU: can't be used as monotherapy and should be combined with other antibiotics piperacillin, ceftazidime, cefepim and cefotaxim. This should be confirmed by a specialist."
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Lithium",
            "Trade_Name": "LITAREX. TAB 564mg",
            "Registration_Number": "46-49-81",
            "Active_ingredient": "LITHIUM CITRATE",
            "ATC_Code": "N05AN01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "564 MG",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, PA, ST",
            "Quantity_Limit_Adults": "based on lithium serum level",
            "Quantity_Limit_Pediatrics": "based on lithium serum level",
            "Notes_1": "Lithium is essential for  treatment of acute bipolar depression.  ST: Second line in elderly and pediatrics. AGE: it should be used in children > 12 years old.\r\nPA: Lithium therapy should not be initiated unless adequate facilities for routine monitoring of serum concentrations are available",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Lithium",
            "Trade_Name": "LITHIOFOR 660MG TAB",
            "Registration_Number": "1-157-85",
            "Active_ingredient": "LITHIUM SULPHATE",
            "ATC_Code": "N05AN01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "660 MG",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, PA, ST",
            "Quantity_Limit_Adults": "based on lithium serum level",
            "Quantity_Limit_Pediatrics": "based on lithium serum level",
            "Notes_1": "Lithium is essential for  treatment of acute bipolar depression.  ST: Second line in elderly and pediatrics. AGE: it should be used in children > 12 years old.\r\nPA: Lithium therapy should not be initiated unless adequate facilities for routine monitoring of serum concentrations are available",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ABILIFY MAINTENA 400 mg Powder And Solvent For Prolonged-Release",
            "Registration_Number": "39-136-17",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "POWDER, FOR SOLUTION",
            "ROA": "INTRAMUSCULAR",
            "Strength": "400mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "400 mg monthly",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARIPEX 10 mg tablet",
            "Registration_Number": "13-968-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARIPEX 15 mg tablet",
            "Registration_Number": "15-968-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARIPEX 5 mg tablet",
            "Registration_Number": "14-968-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARPENIA 1 mg/ml Oral Solution",
            "Registration_Number": "14-993-18",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "SOLUTION",
            "ROA": "ORAL",
            "Strength": "1mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARPENIA 10 mg ORODISPERSIBLE TABLET",
            "Registration_Number": "351-277-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARPENIA 10 mg tablet",
            "Registration_Number": "324-277-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARPENIA 15 mg ORODISPERSIBLE TABLET",
            "Registration_Number": "352-277-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARPENIA 15 mg tablet",
            "Registration_Number": "325-277-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ZOLINDA 10 mg tablet",
            "Registration_Number": "328-212-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ZOLINDA 15 mg tablet",
            "Registration_Number": "330-212-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ZOLINDA 5 mg tablet",
            "Registration_Number": "329-212-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ORYVA 10MG TABLET",
            "Registration_Number": "7-5173-19",
            "Active_ingredient": "ARIPIPRAZOLE ",
            "ATC_Code": "N05AX12 ",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ORYVA 15MG TABLET",
            "Registration_Number": "8-5173-19",
            "Active_ingredient": "ARIPIPRAZOLE ",
            "ATC_Code": "N05AX12 ",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ORYVA 5MG TABLET",
            "Registration_Number": "6-5173-19",
            "Active_ingredient": "ARIPIPRAZOLE ",
            "ATC_Code": "N05AX12 ",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU, ST (adults & elderly)",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "aripiprazole is essential as adjunctive therapy for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with weak level of evidence and is reserved for  refractory patients.ST (adults and elderly) :Aripiprazole is third line option in adults after First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine\r\n Third line in ELDERLY after quetiapine and lurasidone first line then lithium and lamotrigine as second line. CU: aripiprazole should be used as adjunctive therapy for bipolar I depression ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "DINOBAX 10 mg Tablet",
            "Registration_Number": "58-249-17",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "DINOBAX 5 mg Tablet",
            "Registration_Number": "57-249-17",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "LAPRIX 10MG COATED TABLET",
            "Registration_Number": "274-277-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "LAPRIX 5MG COATED TABLET",
            "Registration_Number": "273-277-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLANA 10 mg orodispersible tablet",
            "Registration_Number": "76-539-15",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLANA 5 mg orodispersible tablet",
            "Registration_Number": "75-539-15",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 10MG FILM COATED TABLETS",
            "Registration_Number": "248-325-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 15MG FILM COATED TABLETS",
            "Registration_Number": "249-325-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 2.5MG FILM COATED TABLETS",
            "Registration_Number": "246-325-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "2.5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 20MG FILM COATED TABLETS",
            "Registration_Number": "250-325-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 5MG FILM COATED TABLETS",
            "Registration_Number": "245-325-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 7.5MG FILM COATED TABLETS",
            "Registration_Number": "247-325-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "7.5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLENZA 10 mg orally disintegrating tablet",
            "Registration_Number": "352-212-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, ORALLY DISINTEGRATING",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLENZA 15 mg orally disintegrating tablet",
            "Registration_Number": "353-212-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, ORALLY DISINTEGRATING",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLENZA 20 mg orally disintegrating tablet",
            "Registration_Number": "354-212-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, ORALLY DISINTEGRATING",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLENZA 5 mg orally disintegrating tablet",
            "Registration_Number": "351-212-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, ORALLY DISINTEGRATING",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OZAPIN 10 mg orally disintegrating tablet",
            "Registration_Number": "25-968-17",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OZAPIN 5 mg orally disintegrating tablet",
            "Registration_Number": "24-968-17",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "PRANZA 10 mg film-coated tablet",
            "Registration_Number": "215-334-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "PRANZA 5 mg film-coated tablet",
            "Registration_Number": "214-334-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "PRANZA ODT 10 mg",
            "Registration_Number": "213-334-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "PRANZA ODT 5 mg",
            "Registration_Number": "212-334-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "PREXAL 10MG FILM COATED TABLETS",
            "Registration_Number": "17-535-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "PREXAL 5MG FILM COATED TABLETS",
            "Registration_Number": "16-535-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ZOLAN 10 MG FILM-COATED  TABLET",
            "Registration_Number": "182-368-18",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03 ",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ZOLAN 5 MG FILM-COATED  TABLET",
            "Registration_Number": "181-368-18",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03 ",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ZYLANZA 10 mg Orodispersible Tablet",
            "Registration_Number": "4-5035-17",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ZYLANZA 5 mg Orodispersible Tablet",
            "Registration_Number": "3-5035-17",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ZYPREXA 10MG F.C.TAB",
            "Registration_Number": "13-5117-19",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "10mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ZYPREXA 5MG COATED TABLETS",
            "Registration_Number": "12-5117-19",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "Coated tablet",
            "ROA": "Oral",
            "Strength": "5mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 5 mg Orodispersible Tablet",
            "Registration_Number": "292-325-18",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "Orodispersible tablet",
            "ROA": "Oral",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 10 mg Orodispersible Tablet",
            "Registration_Number": "293-325-18",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "Orodispersible tablet",
            "ROA": "Oral",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "20 mg",
            "Notes_1": "Olanzapine is essential for treatment of bipolar depression although not approved by EMC but is recommended by guidelines with strong level of evidence and is reserved for refractory patients. ST: should be used after trying First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine in adults.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ESPERAL 100 mg Film Coated Tablet",
            "Registration_Number": "114-124-18",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ESPERAL 200 mg Film Coated Tablet",
            "Registration_Number": "115-124-18",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ESPERAL 25 mg Film Coated Tablet",
            "Registration_Number": "113-124-18",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ESPERAL 300 mg Film Coated Tablet",
            "Registration_Number": "116-124-18",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETAL 50 mg XR extended-release tablet",
            "Registration_Number": "243-334-17",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "50mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETAL XR 150 mg film-coated tablet",
            "Registration_Number": "191-334-15",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "150mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETAL XR 200 mg film-coated tablet",
            "Registration_Number": "190-334-15",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETAL XR 300 mg film-coated tablet",
            "Registration_Number": "192-334-15",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL 100 MG TAB",
            "Registration_Number": "51-7-01",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL 200 MG TAB",
            "Registration_Number": "52-7-01",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL 25 MG TAB",
            "Registration_Number": "50-7-01",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL 300MG F-C TABS",
            "Registration_Number": "56-7-06",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL STARTER PACK 10 TABLETS",
            "Registration_Number": "53-7-02",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "25 , 100 , 200mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL XL 200MG FILM COATED TABLET",
            "Registration_Number": "58-7-12",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL XL 300MG FILM COATED TABLET",
            "Registration_Number": "59-7-12",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL XL 400MG FILM COATED TABLET",
            "Registration_Number": "60-7-12",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL XL 50MG FILM COATED TABLET",
            "Registration_Number": "57-7-12",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "50mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN 100MG F.C.TABLET",
            "Registration_Number": "45-968-19",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04 ",
            "Dosage_Form": "tablet",
            "ROA": "Oral",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN 25MG F.C.TABLET",
            "Registration_Number": "44-968-19",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04 ",
            "Dosage_Form": "tablet",
            "ROA": "Oral",
            "Strength": "25mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN 150MG F.C.TABLET",
            "Registration_Number": "46-968-19",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04 ",
            "Dosage_Form": "tablet",
            "ROA": "Oral",
            "Strength": "150mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN 200MG F.C.TABLET",
            "Registration_Number": "47-968-19",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04 ",
            "Dosage_Form": "tablet",
            "ROA": "Oral",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ADAZIO 100 mg film-coated tablet",
            "Registration_Number": "267-325-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ADAZIO 200 mg film-coated tablet",
            "Registration_Number": "268-325-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ADAZIO 25 mg film-coated tablet",
            "Registration_Number": "266-325-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ADAZIO 300 mg film-coated tablet",
            "Registration_Number": "269-325-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ATAPINA 100MG FILM COATED TABLET",
            "Registration_Number": "55-539-13",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ATAPINA 200MG FILM COATED TABLET",
            "Registration_Number": "56-539-13",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ATAPINA 25MG FILM COATED TABLET",
            "Registration_Number": "54-539-13",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ATAPINA 300MG FILM COATED TABLET",
            "Registration_Number": "57-539-13",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN XR 150MG TABLETS",
            "Registration_Number": "39-968-18",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04 ",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "150mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN XR 200 mg tablet",
            "Registration_Number": "28-968-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN XR 300 mg tablet",
            "Registration_Number": "29-968-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN XR 400 mg tablet",
            "Registration_Number": "30-968-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUENTA XR 200MG PROLONGED-RELEASE TABLET",
            "Registration_Number": "28-892-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUENTA XR 300MG PROLONGED-RELEASE TABLET",
            "Registration_Number": "29-892-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUENTA XR 50MG PROLONGED-RELEASE TABLET",
            "Registration_Number": "27-892-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "50mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUET 100 mg Film-coated Tablet",
            "Registration_Number": "2-976-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUET 200 mg Film-coated Tablet",
            "Registration_Number": "3-976-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETTA 100 mg film-coated tablet",
            "Registration_Number": "320-212-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETTA 150 mg film-coated tablet",
            "Registration_Number": "369-212-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "150mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETTA 200 mg film-coated tablet",
            "Registration_Number": "321-212-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETTA 25 mg film-coated tablet",
            "Registration_Number": "319-212-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETTA 300 mg film-coated tablet",
            "Registration_Number": "322-212-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETTA XR 200 mg tablet",
            "Registration_Number": "345-212-16",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETTA XR 300 mg tablet",
            "Registration_Number": "346-212-16",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETTA XR 400 mg tablet",
            "Registration_Number": "347-212-16",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUZAL 100 mg Tablets",
            "Registration_Number": "39-535-19",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUZAL 100 mg Tablets",
            "Registration_Number": "38-535-19",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUZAL 200 mg Tablets",
            "Registration_Number": "40-535-19",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUZAL 200 mg Tablets",
            "Registration_Number": "41-535-19",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUZAL 25 mg Tablets",
            "Registration_Number": "37-535-19",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUZAL 25 mg Tablets",
            "Registration_Number": "36-535-19",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUZAL 300 mg Tablets",
            "Registration_Number": "42-535-19",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUZAL 300 mg Tablets",
            "Registration_Number": "43-535-19",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUZAL 400 mg Tablets",
            "Registration_Number": "45-535-19",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUZAL 400 mg Tablets",
            "Registration_Number": "44-535-19",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "REZAL XR 200 mg extended-release tablet",
            "Registration_Number": "354-277-16",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "REZAL XR 300 mg extended-release tablet",
            "Registration_Number": "355-277-16",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "REZAL XR 50 mg extended-release tablet",
            "Registration_Number": "353-277-16",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "50mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEQUIT 100 mg Film Coated Tablets",
            "Registration_Number": "165-368-18",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEQUIT 200 mg Film Coated Tablets",
            "Registration_Number": "166-368-18",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEQUIT 25 mg Film Coated Tablets",
            "Registration_Number": "164-368-18",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEQUIT 300 mg Film Coated Tablets",
            "Registration_Number": "167-368-18",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SERCAND 100 mg film-coated tablet",
            "Registration_Number": "38-249-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SERCAND 200 mg film-coated tablet",
            "Registration_Number": "41-249-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SERCAND 25 mg film-coated tablet",
            "Registration_Number": "36-249-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SERCAND 300 mg film-coated tablet",
            "Registration_Number": "43-249-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROGEN 100 mg Film Coated Tablet",
            "Registration_Number": "19-5035-18",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROGEN 200 mg Film Coated Tablet",
            "Registration_Number": "20-5035-18",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROGEN 25 mg Film Coated Tablet",
            "Registration_Number": "18-5035-18",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROGEN 300 mg Film Coated Tablet",
            "Registration_Number": "21-5035-18",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SETININ 100 mg film-coated tablet",
            "Registration_Number": "22-170-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SETININ 200 mg film-coated tablet",
            "Registration_Number": "23-170-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SETININ 300 mg film-coated tablet",
            "Registration_Number": "24-170-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SICOPIN 100 mg film-coated tablet",
            "Registration_Number": "100-116-16",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SICOPIN 200 mg film-coated tablet",
            "Registration_Number": "100-116-16",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SICOPIN 300 mg film-coated tablet",
            "Registration_Number": "102-116-16",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "300 mg",
            "Notes_1": "Quetiapine is essential for treatment of bipolar I depression as first line option in adults an elderly",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "DEPAKINE 200MG TABS",
            "Registration_Number": "18-883-18",
            "Active_ingredient": "VALPROATE SODIUM",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST,G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "Divalproex monotherapy or combinations is essential although not EMC approved but FDA approved and recommended by guidelines for treatment of bipolar depression with strong level of evidence.\r\nST: Divalproex as monotherapy is considered as second line in adults.Divalproex is considered as third line in elderly.\r\nGender: should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "DEPAKINE 200MG-ML SOLU.",
            "Registration_Number": "22-883-18",
            "Active_ingredient": "VALPROATE SODIUM",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Oral solution",
            "ROA": "Oral",
            "Strength": "200mg/ml",
            "G_or_B": "B",
            "Prescribing_edits": "ST,G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "Divalproex monotherapy or combinations is essential although not EMC approved but FDA approved and recommended by guidelines for treatment of bipolar depression with strong level of evidence.\r\nST: Divalproex as monotherapy is considered as second line in adults.Divalproex is considered as third line in elderly.\r\nGender: should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "DEPAKINE 500MG TABS",
            "Registration_Number": "21-883-18",
            "Active_ingredient": "VALPROATE SODIUM",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST,G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "Divalproex monotherapy or combinations is essential although not EMC approved but FDA approved and recommended by guidelines for treatment of bipolar depression with strong level of evidence.\r\nST: Divalproex as monotherapy is considered as second line in adults.Divalproex is considered as third line in elderly.\r\nGender: should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "DEPAKINE 57.64MG-ML SYRUP",
            "Registration_Number": "11-883-16",
            "Active_ingredient": "VALPROATE SODIUM",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40mg/ml",
            "G_or_B": "B",
            "Prescribing_edits": "ST,G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "Divalproex monotherapy or combinations is essential although not EMC approved but FDA approved and recommended by guidelines for treatment of bipolar depression with strong level of evidence.\r\nST: Divalproex as monotherapy is considered as second line in adults.Divalproex is considered as third line in elderly.\r\nGender: should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "DEPAKINE CHRONO 500MG TABS",
            "Registration_Number": "26-883-19",
            "Active_ingredient": "VALPROATE SODIUM",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST,G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "Divalproex monotherapy or combinations is essential although not EMC approved but FDA approved and recommended by guidelines for treatment of bipolar depression with strong level of evidence.\r\nST: Divalproex as monotherapy is considered as second line in adults.Divalproex is considered as third line in elderly.\r\nGender: should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "EPIVAL 200MG\\5ML SYRUP",
            "Registration_Number": "27-271-17",
            "Active_ingredient": "VALPROATE SODIUM",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "SYRUP",
            "ROA": "ORAL",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST,G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "Divalproex monotherapy or combinations is essential although not EMC approved but FDA approved and recommended by guidelines for treatment of bipolar depression with strong level of evidence.\r\nST: Divalproex as monotherapy is considered as second line in adults.Divalproex is considered as third line in elderly.\r\nGender: should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "VALOPIN 200 MG E-C TABLETS",
            "Registration_Number": "250-186-08",
            "Active_ingredient": "VALPROATE SODIUM",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "Gastro-resistant tablet",
            "ROA": "Oral",
            "Strength": "200mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "Divalproex monotherapy or combinations is essential although not EMC approved but FDA approved and recommended by guidelines for treatment of bipolar depression with strong level of evidence.\r\nST: Divalproex as monotherapy is considered as second line in adults.Divalproex is considered as third line in elderly.\r\nGender: should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "VALOPRA 200 MG-ML SOLUTION",
            "Registration_Number": "137-334-10",
            "Active_ingredient": "VALPROATE SODIUM",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "SOLUTION",
            "ROA": "ORAL",
            "Strength": "200mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST,G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "Divalproex monotherapy or combinations is essential although not EMC approved but FDA approved and recommended by guidelines for treatment of bipolar depression with strong level of evidence.\r\nST: Divalproex as monotherapy is considered as second line in adults.Divalproex is considered as third line in elderly.\r\nGender: should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Fatty acid derivatives",
            "Trade_Name": "VALOPRA 57.64 MG-ML SYRUP",
            "Registration_Number": "136-334-10",
            "Active_ingredient": "VALPROATE SODIUM",
            "ATC_Code": "N03AG01",
            "Dosage_Form": "SYRUP",
            "ROA": "ORAL",
            "Strength": "57.64mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST,G",
            "Quantity_Limit_Adults": "60 mg/kg/day",
            "Notes_1": "Divalproex monotherapy or combinations is essential although not EMC approved but FDA approved and recommended by guidelines for treatment of bipolar depression with strong level of evidence.\r\nST: Divalproex as monotherapy is considered as second line in adults.Divalproex is considered as third line in elderly.\r\nGender: should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Carboxamide derivatives",
            "Trade_Name": "CARBATOL 200MG TAB",
            "Registration_Number": "40-124-96",
            "Active_ingredient": "CARBAMAZEPINE",
            "ATC_Code": "N03AF01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1.6 mg",
            "Quantity_Limit_Pediatrics": "no available data",
            "Notes_1": " Carbamazepine is essential for management of bipolar depression.ST: Third line in adults after \r\nFirst line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive)\r\nSecond line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Carboxamide derivatives",
            "Trade_Name": "TEGRETOL 2% oral suspension",
            "Registration_Number": "121-11-88",
            "Active_ingredient": "CARBAMAZEPINE",
            "ATC_Code": "N03AF01",
            "Dosage_Form": "SUSPENSION",
            "ROA": "ORAL",
            "Strength": "2%",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1.6 mg",
            "Quantity_Limit_Pediatrics": "no available data",
            "Notes_1": " Carbamazepine is essential for management of bipolar depression.ST: Third line in adults after \r\nFirst line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive)\r\nSecond line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Carboxamide derivatives",
            "Trade_Name": "TEGRETOL CR 200MG SCORED TAB",
            "Registration_Number": "131-9-16",
            "Active_ingredient": "CARBAMAZEPINE",
            "ATC_Code": "N03AF01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1.6 mg",
            "Quantity_Limit_Pediatrics": "no available data",
            "Notes_1": " Carbamazepine is essential for management of bipolar depression.ST: Third line in adults after \r\nFirst line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive)\r\nSecond line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Carboxamide derivatives",
            "Trade_Name": "TEGRETOL CR 400MG SCORED TAB",
            "Registration_Number": "127-11-93",
            "Active_ingredient": "CARBAMAZEPINE",
            "ATC_Code": "N03AF01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1.6 mg",
            "Quantity_Limit_Pediatrics": "no available data",
            "Notes_1": " Carbamazepine is essential for management of bipolar depression.ST: Third line in adults after \r\nFirst line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive)\r\nSecond line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Carboxamide derivatives",
            "Trade_Name": "TEGRETOL TAB 200MG",
            "Registration_Number": "77-11-80",
            "Active_ingredient": "CARBAMAZEPINE",
            "ATC_Code": "N03AF01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1.6 mg",
            "Quantity_Limit_Pediatrics": "no available data",
            "Notes_1": " Carbamazepine is essential for management of bipolar depression.ST: Third line in adults after \r\nFirst line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive)\r\nSecond line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMOTRIX 50MG TABLET",
            "Registration_Number": "2-718-13",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "50 MG",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LOXOL 50MG TABLET",
            "Registration_Number": "147-334-11",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "50 MG",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "64-276-02",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "50 MG",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMIRA 50 MG TABLET",
            "Registration_Number": "356-212-17",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "50 MG",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "64-276-02",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "CHEWABLE TABLETS",
            "ROA": "ORAL",
            "Strength": "100 MG",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMOTRIX 100MG TABLET",
            "Registration_Number": "3-718-13",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "100 MG",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LOXOL 100MG TABLET",
            "Registration_Number": "148-334-11",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "100 MG",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "64-276-02",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "100 MG",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "64-276-02",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "CHEWABLE TABLETS",
            "ROA": "ORAL",
            "Strength": "25 MG",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "64-276-02",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "CHEWABLE TABLETS",
            "ROA": "ORAL",
            "Strength": "25 MG",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMOTRIX 25MG TABLET",
            "Registration_Number": "1-718-13",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "25 MG",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LOXOL 25MG TABLET",
            "Registration_Number": "146-334-11",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "25 MG",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "64-276-02",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "25 MG",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMIRA 25 MG TABLET",
            "Registration_Number": "355-212-17",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "25 MG",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMICTAL",
            "Registration_Number": "64-276-02",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "CHEWABLE TABLETS",
            "ROA": "ORAL",
            "Strength": "5MG_",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LOXOL 200MG TABLET",
            "Registration_Number": "149-334-11",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "200 MG",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "LAMIRA 100 MG TABLET",
            "Registration_Number": "357-212-17",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "100MG",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "SEIZET 100 mg Chewable/Dispersible Tablet",
            "Registration_Number": "147-334-11",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLET, CHEWABLE",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIEPILEPTICS",
            "Drug_Sub_Class": "Other antiepileptics",
            "Trade_Name": "SEIZET 25 mg Chewable/Dispersible Tablet",
            "Registration_Number": "10-5286-19",
            "Active_ingredient": "LAMOTRIGINE",
            "ATC_Code": "N03AX09",
            "Dosage_Form": "TABLET, CHEWABLE",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Without interacting agents or valporate:400mg, With valproate: 200 mg/day ",
            "Quantity_Limit_Pediatrics": "without inducers:200 mg,With inducers or valproate: 100 mg,With inducers but not valproate: 400 mg",
            "Notes_1": "essential for treatment of acute depressive episodes in patients with bipolar I disorder as monotherapy or as adjunctive therapy in adults as first line option.\r\n",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "WELLBUTRIN XL 150 EXTENDED RELEASE F.C.TABLET",
            "Registration_Number": "29-432-10",
            "Active_ingredient": "BUPROPION HCL",
            "ATC_Code": "N06AX12",
            "Dosage_Form": "EXTENDED RELEASE TABLETS",
            "ROA": "ORAL",
            "Strength": "150 MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "450 mg",
            "Notes_1": "Bupropion is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: should be used as second line treatment for acute bipolar I depression after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex. ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "WELLBUTRIN XL 300 EXTENDED RELEASE F.C.TABLET",
            "Registration_Number": "30-432-10",
            "Active_ingredient": "BUPROPION HCL",
            "ATC_Code": "N06AX12",
            "Dosage_Form": "EXTENDED RELEASE TABLETS",
            "ROA": "ORAL",
            "Strength": "300 MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "450 mg",
            "Notes_1": "Bupropion is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: should be used as second line treatment for acute bipolar I depression after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex. ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ANXETIN 20MG CAPSULES",
            "Registration_Number": "78-124-08",
            "Active_ingredient": "FLUOXETINE",
            "ATC_Code": "N06AB03",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "EVOREX 20MG CAP",
            "Registration_Number": "79-334-02",
            "Active_ingredient": "FLUOXETINE",
            "ATC_Code": "N06AB03",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "FLOZAK",
            "Registration_Number": "66-325-02",
            "Active_ingredient": "FLUOXETINE",
            "ATC_Code": "N06AB03",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "FLUOXETIN HEXAL 20MG CAPSULES",
            "Registration_Number": "8-349-09",
            "Active_ingredient": "FLUOXETINE",
            "ATC_Code": "N06AB03",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "FLUOXONE 20MG COATED TABLETS",
            "Registration_Number": "2-32-09",
            "Active_ingredient": "FLUOXETINE",
            "ATC_Code": "N06AB03",
            "Dosage_Form": "TABLET, COATED",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "FLUZYN 20MG CAPSULES",
            "Registration_Number": "23-498-08",
            "Active_ingredient": "FLUOXETINE",
            "ATC_Code": "N06AB03",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "LINZ 20 MG CAPSULE",
            "Registration_Number": "129-277-02",
            "Active_ingredient": "FLUOXETINE",
            "ATC_Code": "N06AB03",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "OXETINE 20MG F.C. TABLETS",
            "Registration_Number": "54-171-07",
            "Active_ingredient": "FLUOXETINE",
            "ATC_Code": "N06AB03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "PROZAC 20MG CAPSULES",
            "Registration_Number": "2-5396-19",
            "Active_ingredient": "FLUOXETINE",
            "ATC_Code": "N06AB03",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "20mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SALIPAX 20",
            "Registration_Number": "11-222-01",
            "Active_ingredient": "FLUOXETINE",
            "ATC_Code": "N06AB03",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "CIPRALEX 10 MG F.C. TABLETS",
            "Registration_Number": "2-972-15",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "10mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "CIPRALEX 10 MG F.C. TABLETS",
            "Registration_Number": "3-972-15",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "10mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "CIPRALEX 20MG F.C. TABLETS",
            "Registration_Number": "4-972-15",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "20mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "CITOXAL 10 mg film-coated tablet",
            "Registration_Number": "12-430-17",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "CITOXAL 20 mg film-coated tablet",
            "Registration_Number": "13-430-17",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "CITOXAL 5 mg film-coated tablet",
            "Registration_Number": "11-430-17",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "DEPRALEX 10MG FILM COATED TABLET",
            "Registration_Number": "277-277-14",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "DEPRALEX 20MG FILM COATED TABLET",
            "Registration_Number": "278-277-14",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ENTAPRO 10MG FILM COATED TABLETS",
            "Registration_Number": "267-212-10",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ENTAPRO 20MG FILM COATED TABLETS",
            "Registration_Number": "268-212-10",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ENTAPRO 5 MG FILM COATED TABLETS",
            "Registration_Number": "269-212-10",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ESCIPRA 10MG FILM COATED TABLET",
            "Registration_Number": "62-437-19",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ESCIPRA 20MG FILM COATED TABLET",
            "Registration_Number": "63-437-19",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ESCITALAX 10MG FILM COATED TABLET",
            "Registration_Number": "23-5015-18",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ESCITALAX 15MG FILM COATED TABLET",
            "Registration_Number": "22-5015-18",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ESCITALAX 20MG FILM COATED TABLET",
            "Registration_Number": "21-5015-18",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ESCITAM 10 mg film-coated tablet",
            "Registration_Number": "14-972-17",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ESCITAM 20 mg film-coated tablet",
            "Registration_Number": "15-972-17",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SETAPRO 10 mg film-coated tablet",
            "Registration_Number": "142-368-16",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SETAPRO 20 mg film-coated tablet",
            "Registration_Number": "141-368-16",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ZELAX 10MG FILM COATED CAPLET",
            "Registration_Number": "9-535-11",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ZELAX 20MG FILM COATED CAPLET",
            "Registration_Number": "10-535-11",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ZEVAC  10 mg Tablets",
            "Registration_Number": "6-645-17",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "ZEVAC  20 mg Tablets",
            "Registration_Number": "7-645-17",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "DAMESTA 10MG F.C.TABLET",
            "Registration_Number": "40-968-19",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10 ",
            "Dosage_Form": "FILM COATED TABLET",
            "ROA": "Oral",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "DAMESTA  20MG F.C.TABLET",
            "Registration_Number": "41-968-19",
            "Active_ingredient": "ESCITALOPRAM OXALATE",
            "ATC_Code": "N06AB10 ",
            "Dosage_Form": "FILM COATED TABLET",
            "ROA": "Oral",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "20 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "FAVERIN 100MG EC TABS",
            "Registration_Number": "15-137-90",
            "Active_ingredient": "FLUVOXAMINE MALEATE",
            "ATC_Code": "N06AB08",
            "Dosage_Form": "ENTERIC COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "100 MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "300 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "FAVERIN 50MG EC TABS",
            "Registration_Number": "14-137-90",
            "Active_ingredient": "FLUVOXAMINE MALEATE",
            "ATC_Code": "N06AB08",
            "Dosage_Form": "ENTERIC COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "50 MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "300 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "AXOR 20 MG FILM-COATED TABLET",
            "Registration_Number": "256-325-14",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "20 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "PAROXAT 20 MG F-C TABLETS",
            "Registration_Number": "247-212-08",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "20 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "PAXITAB 20MG TABLET",
            "Registration_Number": "249-277-12",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "20 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SEROXAT 20MG TABLETS",
            "Registration_Number": "89-276-11",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "20 MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SEROXAT TAB 20MG",
            "Registration_Number": "35-1-94",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "20 MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "AXOR 40 MG FILM-COATED TABLET",
            "Registration_Number": "257-325-14",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "40 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "PAXITAB 40MG TABLET",
            "Registration_Number": "250-277-12",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "40 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "AXOR 30 MG FILM-COATED TABLET",
            "Registration_Number": "258-325-14",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "30 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "PAROXAT 30MG F-C TABLETS",
            "Registration_Number": "246-212-08",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "30 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "PAROXAT 10 MG F-C TABLETS",
            "Registration_Number": "248-212-08",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "10 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SEROXAT CR 12.5MG TABLETS",
            "Registration_Number": "14-420-11",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "CONTROLLED RELEASE TABLETS",
            "ROA": "ORAL",
            "Strength": "12.5 MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SEROXAT CR 25MG TABLETS",
            "Registration_Number": "13-420-11",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "CONTROLLED RELEASE TABLETS",
            "ROA": "ORAL",
            "Strength": "25 MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "PADO 20MG FILM COATED TABLET",
            "Registration_Number": "39-271-18",
            "Active_ingredient": "PAROXETINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N06AB05",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "20 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "50 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SOLOTIK 50MG F-C TABLETS",
            "Registration_Number": "180-172-14",
            "Active_ingredient": "SERTRALINE (AS HCL)",
            "ATC_Code": "N06AB06",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "50 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "200 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SOLOTIK 50MG F-C TABLETS",
            "Registration_Number": "180-172-14",
            "Active_ingredient": "SERTRALINE (AS HCL)",
            "ATC_Code": "N06AB06",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "50 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "200 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "RIASERTAL 50 MG FILM-COATED TABLET",
            "Registration_Number": "192-325-07",
            "Active_ingredient": "SERTRALINE (AS HCL)",
            "ATC_Code": "N06AB06",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "50 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "200 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SETRAL 50MG F.C. TABLETS",
            "Registration_Number": "48-171-06",
            "Active_ingredient": "SERTRALINE (AS HCL)",
            "ATC_Code": "N06AB06",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "50 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "200 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SETRAL 50MG F.C. TABLETS",
            "Registration_Number": "48-171-06",
            "Active_ingredient": "SERTRALINE (AS HCL)",
            "ATC_Code": "N06AB06",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "50 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "200 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "LUSTRAL 50MG TAB",
            "Registration_Number": "61-212-97",
            "Active_ingredient": "SERTRALINE (AS HCL)",
            "ATC_Code": "N06AB06",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "50 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "200 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SOLOTIK 100MG F-C TABLETS",
            "Registration_Number": "169-172-10",
            "Active_ingredient": "SERTRALINE (AS HCL)",
            "ATC_Code": "N06AB06",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "100 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "200 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SOLOTIK 100MG F-C TABLETS",
            "Registration_Number": "169-172-10",
            "Active_ingredient": "SERTRALINE (AS HCL)",
            "ATC_Code": "N06AB06",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "100 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "200 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "RIASERTAL 100 MG FILM-COATED TABLET",
            "Registration_Number": "193-325-07",
            "Active_ingredient": "SERTRALINE (AS HCL)",
            "ATC_Code": "N06AB06",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "100 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "200 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Selective serotonin reuptake inhibitors",
            "Trade_Name": "SETRAL 100MG F.C. TABLETS",
            "Registration_Number": "49-171-06",
            "Active_ingredient": "SERTRALINE (AS HCL)",
            "ATC_Code": "N06AB06",
            "Dosage_Form": "FILM COATED TABLETS",
            "ROA": "ORAL",
            "Strength": "100 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "200 MG",
            "Notes_1": "SSRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence. ST: after quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), CU:  should be used as adjunctive to lithium or divalproex.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "PRISTIQ 50MG EXTENDED RELEASE TABLETS",
            "Registration_Number": "1-707-10",
            "Active_ingredient": "DESVENLAFAXINE (AS SUCCINATE)",
            "ATC_Code": "N06AX23",
            "Dosage_Form": "EXTENDED RELEASE TABLETS",
            "ROA": "ORAL",
            "Strength": "50 MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "100MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "DELAXIN 30 MG DELAYED-RELEASE CAPSULE",
            "Registration_Number": "216-334-16",
            "Active_ingredient": "DULOXETINE (AS HCL)",
            "ATC_Code": "N06AX21",
            "Dosage_Form": "DELAYED-RELEASE CAPSULES",
            "ROA": "ORAL",
            "Strength": "30 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "120 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "CYMBALTA 30MG HARD GASTRO-RESISTANT CAP.",
            "Registration_Number": "2-362-10",
            "Active_ingredient": "DULOXETINE (AS HCL)",
            "ATC_Code": "N06AX21",
            "Dosage_Form": "GASTRO-RESISTANT CAPSULE",
            "ROA": "ORAL",
            "Strength": "30 MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "120 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "MODEXA 30 MG GASTRO-RESISTANT CAPSULE",
            "Registration_Number": "359-277-16",
            "Active_ingredient": "DULOXETINE (AS HCL)",
            "ATC_Code": "N06AX21",
            "Dosage_Form": "GASTRO-RESISTANT CAPSULE",
            "ROA": "ORAL",
            "Strength": "30 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "120 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "DELAXIN 60 MG DELAYED-RELEASE CAPSULE",
            "Registration_Number": "217-334-16",
            "Active_ingredient": "DULOXETINE (AS HCL)",
            "ATC_Code": "N06AX21",
            "Dosage_Form": "DELAYED-RELEASE CAPSULES",
            "ROA": "ORAL",
            "Strength": "60 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "120 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "CYMBALTA 60MG HARD GASTRO-RESISTANT CAP",
            "Registration_Number": "1-362-06",
            "Active_ingredient": "DULOXETINE (AS HCL)",
            "ATC_Code": "N06AX21",
            "Dosage_Form": "GASTRO-RESISTANT CAPSULE",
            "ROA": "ORAL",
            "Strength": "60 MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "120 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "MODEXA 60 MG GASTRO-RESISTANT CAPSULE",
            "Registration_Number": "360-277-16",
            "Active_ingredient": "DULOXETINE (AS HCL)",
            "ATC_Code": "N06AX21",
            "Dosage_Form": "GASTRO-RESISTANT CAPSULE",
            "ROA": "ORAL",
            "Strength": "60 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "120 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "EFEXOR XR 150 MG CAPSULES",
            "Registration_Number": "6-892-13",
            "Active_ingredient": "VENLAFAXINE",
            "ATC_Code": "N06AX16",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "150mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "EFEXOR XR 75 MG CAPSULES",
            "Registration_Number": "5-892-13",
            "Active_ingredient": "VENLAFAXINE",
            "ATC_Code": "N06AX16",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "75mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "FENIXOR 25MG TAB.",
            "Registration_Number": "190-368-19",
            "Active_ingredient": "VENLAFAXINE",
            "ATC_Code": "N06AX16 ",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "FENIXOR 37.5MG TAB.",
            "Registration_Number": "189-368-19",
            "Active_ingredient": "VENLAFAXINE",
            "ATC_Code": "N06AX16 ",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "37.5mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "FENIXOR 50MG TAB.",
            "Registration_Number": "188-368-19",
            "Active_ingredient": "VENLAFAXINE",
            "ATC_Code": "N06AX16 ",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "50mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "FENIXOR 75MG TAB.",
            "Registration_Number": "187-368-19",
            "Active_ingredient": "VENLAFAXINE",
            "ATC_Code": "N06AX16 ",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "75mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "VEXAL XR 150 MG EXTENDED RELEASE CAPSULE",
            "Registration_Number": "141-334-11",
            "Active_ingredient": "VENLAFAXINE",
            "ATC_Code": "N06AX16",
            "Dosage_Form": "CAPSULE, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "150mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "VEXAL XR 37.5 MG EXTENDED RELEASE CAPSULE",
            "Registration_Number": "140-334-11",
            "Active_ingredient": "VENLAFAXINE",
            "ATC_Code": "N06AX16",
            "Dosage_Form": "CAPSULE, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "37.5mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "VEXAL XR 75 MG EXTENDED RELEASE CAPSULE",
            "Registration_Number": "139-334-11",
            "Active_ingredient": "VENLAFAXINE",
            "ATC_Code": "N06AX16",
            "Dosage_Form": "CAPSULE, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "75mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "VENAXINE XR 150 MG CAPSULES",
            "Registration_Number": "291-325-18",
            "Active_ingredient": "VENLAFAXINE HYDROCHLORIDE",
            "ATC_Code": "N06AX16 ",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "150mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "VENAXINE XR 75 MG CAPSULES",
            "Registration_Number": "290-325-18",
            "Active_ingredient": "VENLAFAXINE HYDROCHLORIDE",
            "ATC_Code": "N06AX16 ",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "75mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "VENEX XR 150MG CAPSULE",
            "Registration_Number": "292-212-14",
            "Active_ingredient": "VENLAFAXINE HYDROCHLORIDE",
            "ATC_Code": "N06AX16",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "150mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "VENEX XR 37.5 MG CAPSULE",
            "Registration_Number": "362-212-17",
            "Active_ingredient": "VENLAFAXINE HYDROCHLORIDE",
            "ATC_Code": "N06AX16",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "37.5mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Other antidepressants",
            "Trade_Name": "VENEX XR 75MG CAPSULE",
            "Registration_Number": "291-212-14",
            "Active_ingredient": "VENLAFAXINE HYDROCHLORIDE",
            "ATC_Code": "N06AX16",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "75mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "375 MG",
            "Notes_1": "SNRI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Monoamine oxidase inhibitors, non-selective",
            "Trade_Name": "PARNATE 10 MG. TAB.",
            "Registration_Number": "8-1-80",
            "Active_ingredient": "TRANYLCYPROMINE SULPHATE",
            "ATC_Code": "N06AF04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "60 mg ",
            "Notes_1": "MOAI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Monoamine oxidase A inhibitors",
            "Trade_Name": "AURORIX 150MG TAB",
            "Registration_Number": "4-813-13",
            "Active_ingredient": "MOCLOBEMIDE",
            "ATC_Code": "N06AG02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "150",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "600mg",
            "Notes_1": "MOAI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANTIDEPRESSANTS",
            "Drug_Sub_Class": "Monoamine oxidase A inhibitors",
            "Trade_Name": "AURORIX 300MG TAB",
            "Registration_Number": "5-813-13",
            "Active_ingredient": "MOCLOBEMIDE",
            "ATC_Code": "N06AG02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "300",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "600mg",
            "Notes_1": "MOAI is not EMC approved but is recommended by guidelines used for management for bipolar depression with strong level of evidence as third line option. First line: quetiapine, lurasidone+ lithium/divalproex, lithium, lamotrigine, lurasidone, lamotrigine(adjunctive), Second line:  divalproex, SSRI/bupropion (adjunctive), olanzapine+ fluoxetine. CU : used as adjunctive therapy.",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "LIPID MODIFYING AGENTS, PLAIN",
            "Drug_Sub_Class": "Other lipid modifying agents",
            "Trade_Name": "OMACOR1000 MG SOFT GELATIN CAPSULES",
            "Registration_Number": "9-114-08",
            "Active_ingredient": "OMEGA-3 ACID ETHYL ESTERS",
            "ATC_Code": "C10AX06",
            "Dosage_Form": "SOFT GELATIN CAPSULES",
            "ROA": "ORAL",
            "Strength": "1000 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "1g",
            "Notes_1": "essential drug as adjunctive therapy for treatment of acute bipolar depression type I . (not approved by EMC for this indication but is recommended by Canadian guidelines with high level of eviednce.)\r\nCU: should be used as adjuctive therapy.ST: is used as third line therapy in acute bipolar I depression after (quetiapine, lithium , divalproex , lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "LIPID MODIFYING AGENTS, PLAIN",
            "Drug_Sub_Class": "Other lipid modifying agents",
            "Trade_Name": "OMEGANA 1000MG SOFT CAPSULE",
            "Registration_Number": "4-5145-19",
            "Active_ingredient": "OMEGA-3 ACID ETHYL ESTERS",
            "ATC_Code": "C10AX06",
            "Dosage_Form": "SOFT GELATIN CAPSULES",
            "ROA": "ORAL",
            "Strength": "1000 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "1g",
            "Notes_1": "essential drug as adjunctive therapy for treatment of acute bipolar depression type I . (not approved by EMC for this indication but is recommended by Canadian guidelines with high level of eviednce.)\r\nCU: should be used as adjuctive therapy.ST: is used as third line therapy in acute bipolar I depression after (quetiapine, lithium , divalproex , lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "LIPID MODIFYING AGENTS, PLAIN",
            "Drug_Sub_Class": "Other lipid modifying agents",
            "Trade_Name": "OMEGANA 1000MG SOFT CAPSULE",
            "Registration_Number": "4-5145-19",
            "Active_ingredient": "OMEGA-3 ACID ETHYL ESTERS",
            "ATC_Code": "C10AX06",
            "Dosage_Form": "SOFT GELATIN CAPSULES",
            "ROA": "ORAL",
            "Strength": "1000 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "1g",
            "Notes_1": "essential drug as adjunctive therapy for treatment of acute bipolar depression type I . (not approved by EMC for this indication but is recommended by Canadian guidelines with high level of eviednce.)\r\nCU: should be used as adjuctive therapy.ST: is used as third line therapy in acute bipolar I depression after (quetiapine, lithium , divalproex , lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANESTHETICS, GENERAL",
            "Drug_Sub_Class": "Other general anesthetics",
            "Trade_Name": "TEKAM 10MG-ML 10ML VIAL",
            "Registration_Number": "92-172-94",
            "Active_ingredient": "KETAMINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N01AX03",
            "Dosage_Form": "SOLUTION FOR INJECTION",
            "ROA": "INTRAVENOUS (NOT OTHERWISE SPECIFIED)",
            "Strength": "10 MG/ML",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "Based on response and tolerability",
            "Notes_1": "ketamine is essential although not approved by EMC but recommended by Canadian and British guidelines  for patients who are refractory to first and second-line treatments, as well as for those in need of rapid response for management of acute bipolar depression.Not  CU: is used as adjunctive therapy  ST:  third line after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine)",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ANESTHETICS, GENERAL",
            "Drug_Sub_Class": "Other general anesthetics",
            "Trade_Name": "TEKAM 50MG-ML 10ML VIAL",
            "Registration_Number": "93-172-94",
            "Active_ingredient": "KETAMINE (AS HYDROCHLORIDE)",
            "ATC_Code": "N01AX03",
            "Dosage_Form": "SOLUTION FOR INJECTION",
            "ROA": "INTRAVENOUS (NOT OTHERWISE SPECIFIED)",
            "Strength": "50 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "Based on response and tolerability",
            "Notes_1": "ketamine is essential although not approved by EMC but recommended by Canadian and British guidelines  for patients who are refractory to first and second-line treatments, as well as for those in need of rapid response for management of acute bipolar depression.Not  CU: is used as adjunctive therapy  ST:  third line after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine)",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "ALL OTHER THERAPEUTIC PRODUCTS",
            "Drug_Sub_Class": "Antidotes",
            "Trade_Name": "ACETYLCYSTEINE 200MG/ML INJECTION",
            "Registration_Number": "1-5077-17",
            "Active_ingredient": "ACETYLCYSTEINE",
            "ATC_Code": "V03AB23",
            "Dosage_Form": "CONCENTRATE FOR SOLUTION FOR INFUSION",
            "ROA": "IV",
            "Strength": "200 MG/ML",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "no available data",
            "Notes_1": " N-acetylcysteine is essential as adjunctive therapy for treatment of acute bipolar depression type I. (not approved by EMC for this indication but is recommended by Canadian guidelines with moderate level of evidence.) CU: should be used as adjunctive therapy.\r\nST: is used as third line therapy in acute bipolar I depression after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "ACC 200MG POWDER FOR ORAL SOLUTION",
            "Registration_Number": "6-349-09",
            "Active_ingredient": "ACETYLCYSTEINE",
            "ATC_Code": "R05CB01",
            "Dosage_Form": "POWDER FOR SOLUTION",
            "ROA": "ORAL",
            "Strength": "200 MG_",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "no available data",
            "Notes_1": " N-acetylcysteine is essential as adjunctive therapy for treatment of acute bipolar depression type I. (not approved by EMC for this indication but is recommended by Canadian guidelines with moderate level of evidence.) CU: should be used as adjunctive therapy.\r\nST: is used as third line therapy in acute bipolar I depression after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "ACC LONG 600MG EFFERVESCENT TABLETS",
            "Registration_Number": "7-349-09",
            "Active_ingredient": "ACETYLCYSTEINE",
            "ATC_Code": "R05CB01",
            "Dosage_Form": "EFFERVESCENT TABLETS",
            "ROA": "ORAL",
            "Strength": "600 MG",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "no available data",
            "Notes_1": " N-acetylcysteine is essential as adjunctive therapy for treatment of acute bipolar depression type I. (not approved by EMC for this indication but is recommended by Canadian guidelines with moderate level of evidence.) CU: should be used as adjunctive therapy.\r\nST: is used as third line therapy in acute bipolar I depression after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "FLUIMUCIL 100MG/1GM GRANULES FOR ORAL SOLUTION",
            "Registration_Number": "5-462-11",
            "Active_ingredient": "ACETYLCYSTEINE",
            "ATC_Code": "R05CB01",
            "Dosage_Form": "EFFERVESCENT GRANULES",
            "ROA": "ORAL",
            "Strength": "100 MG/G",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "no available data",
            "Notes_1": " N-acetylcysteine is essential as adjunctive therapy for treatment of acute bipolar depression type I. (not approved by EMC for this indication but is recommended by Canadian guidelines with moderate level of evidence.) CU: should be used as adjunctive therapy.\r\nST: is used as third line therapy in acute bipolar I depression after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "FLUIMUCIL 200MG/1GM GRANULES FOR ORAL SOLUTION",
            "Registration_Number": "4-462-11",
            "Active_ingredient": "ACETYLCYSTEINE",
            "ATC_Code": "R05CB01",
            "Dosage_Form": "EFFERVESCENT GRANULES",
            "ROA": "ORAL",
            "Strength": "200 MG/G",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "no available data",
            "Notes_1": " N-acetylcysteine is essential as adjunctive therapy for treatment of acute bipolar depression type I. (not approved by EMC for this indication but is recommended by Canadian guidelines with moderate level of evidence.) CU: should be used as adjunctive therapy.\r\nST: is used as third line therapy in acute bipolar I depression after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "DOPAMINERGIC AGENTS",
            "Drug_Sub_Class": "Dopamine agonists",
            "Trade_Name": "SIFROL 0.18 MG (EQU.0.25MG) TAB",
            "Registration_Number": "81-68-00",
            "Active_ingredient": "PRAMIPEXOLE",
            "ATC_Code": "N04BC05",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "0.18MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "2.5 mg",
            "Notes_1": "Pramipexole is essential as adjunctive therapy for treatment-resistant acute bipolar depression type I . (not approved by EMC for this indication but is recommended by Canadian  and British guidelines wiyh moderate level of evidence.) \r\nCU: should be used as adjunctive therapy. ST: is used as third line therapy in acute bipolar I depression after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "DOPAMINERGIC AGENTS",
            "Drug_Sub_Class": "Dopamine agonists",
            "Trade_Name": "SIFROL 0.7MG (EQU. 1.00MG) TAB",
            "Registration_Number": "82-68-00",
            "Active_ingredient": "PRAMIPEXOLE",
            "ATC_Code": "N04BC05",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "0.7MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "2.5 mg",
            "Notes_1": "Pramipexole is essential as adjunctive therapy for treatment-resistant acute bipolar depression type I . (not approved by EMC for this indication but is recommended by Canadian  and British guidelines wiyh moderate level of evidence.) \r\nCU: should be used as adjunctive therapy. ST: is used as third line therapy in acute bipolar I depression after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "DOPAMINERGIC AGENTS",
            "Drug_Sub_Class": "Dopamine agonists",
            "Trade_Name": "SIFROL 0.088 MG (EQU.0.125MG) TAB",
            "Registration_Number": "80-68-00",
            "Active_ingredient": "PRAMIPEXOLE",
            "ATC_Code": "N04BC05",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "0.088MG",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "2.5 mg",
            "Notes_1": "Pramipexole is essential as adjunctive therapy for treatment-resistant acute bipolar depression type I . (not approved by EMC for this indication but is recommended by Canadian  and British guidelines wiyh moderate level of evidence.) \r\nCU: should be used as adjunctive therapy. ST: is used as third line therapy in acute bipolar I depression after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "THYROID PREPARATIONS",
            "Drug_Sub_Class": "Thyroid hormones",
            "Trade_Name": "ELTROXIN 0.05MG TAB",
            "Registration_Number": "34-972-18",
            "Active_ingredient": "LEVOTHYROXINE (THYROXINE) SODIUM",
            "ATC_Code": "H03AA01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "0.05mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "300mcg",
            "Notes_1": "levothyroxine is essential as adjunctive therapy for treatment of acute bipolar depression type I and II. (not approved by EMC for this indication but is recommended by Canadian guidelines with oderate level of evidence.) CU: should be used as adjunctive therapy. ST: is used as third line therapy  after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "THYROID PREPARATIONS",
            "Drug_Sub_Class": "Thyroid hormones",
            "Trade_Name": "ELTROXIN 0.1MG TAB",
            "Registration_Number": "18-887-17",
            "Active_ingredient": "LEVOTHYROXINE (THYROXINE) SODIUM",
            "ATC_Code": "H03AA01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "0.1mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "300mcg",
            "Notes_1": "levothyroxine is essential as adjunctive therapy for treatment of acute bipolar depression type I and II. (not approved by EMC for this indication but is recommended by Canadian guidelines with oderate level of evidence.) CU: should be used as adjunctive therapy. ST: is used as third line therapy  after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "THYROID PREPARATIONS",
            "Drug_Sub_Class": "Thyroid hormones",
            "Trade_Name": "EUTHYROX",
            "Registration_Number": "17-887-17",
            "Active_ingredient": "LEVOTHYROXINE (THYROXINE) SODIUM",
            "ATC_Code": "H03AA01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "0.1mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "300mcg",
            "Notes_1": "levothyroxine is essential as adjunctive therapy for treatment of acute bipolar depression type I and II. (not approved by EMC for this indication but is recommended by Canadian guidelines with oderate level of evidence.) CU: should be used as adjunctive therapy. ST: is used as third line therapy  after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "THYROID PREPARATIONS",
            "Drug_Sub_Class": "Thyroid hormones",
            "Trade_Name": "EUTHYROX",
            "Registration_Number": "55-22-06",
            "Active_ingredient": "LEVOTHYROXINE (THYROXINE) SODIUM",
            "ATC_Code": "H03AA01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "0.15mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "300mcg",
            "Notes_1": "levothyroxine is essential as adjunctive therapy for treatment of acute bipolar depression type I and II. (not approved by EMC for this indication but is recommended by Canadian guidelines with oderate level of evidence.) CU: should be used as adjunctive therapy. ST: is used as third line therapy  after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "THYROID PREPARATIONS",
            "Drug_Sub_Class": "Thyroid hormones",
            "Trade_Name": "EUTHYROX",
            "Registration_Number": "54-22-06",
            "Active_ingredient": "LEVOTHYROXINE (THYROXINE) SODIUM",
            "ATC_Code": "H03AA01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "0.025mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "300mcg",
            "Notes_1": "levothyroxine is essential as adjunctive therapy for treatment of acute bipolar depression type I and II. (not approved by EMC for this indication but is recommended by Canadian guidelines with oderate level of evidence.) CU: should be used as adjunctive therapy. ST: is used as third line therapy  after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "THYROID PREPARATIONS",
            "Drug_Sub_Class": "Thyroid hormones",
            "Trade_Name": "EUTHYROX",
            "Registration_Number": "57-22-06",
            "Active_ingredient": "LEVOTHYROXINE (THYROXINE) SODIUM",
            "ATC_Code": "H03AA01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "0.05mg",
            "G_or_B": "B",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "300mcg",
            "Notes_1": "levothyroxine is essential as adjunctive therapy for treatment of acute bipolar depression type I and II. (not approved by EMC for this indication but is recommended by Canadian guidelines with oderate level of evidence.) CU: should be used as adjunctive therapy. ST: is used as third line therapy  after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "THYROID PREPARATIONS",
            "Drug_Sub_Class": "Thyroid hormones",
            "Trade_Name": "L- THYROX HEXAL 100MCG TABLETS",
            "Registration_Number": "56-22-06",
            "Active_ingredient": "LEVOTHYROXINE (THYROXINE) SODIUM",
            "ATC_Code": "H03AA01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "0.1mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "300mcg",
            "Notes_1": "levothyroxine is essential as adjunctive therapy for treatment of acute bipolar depression type I and II. (not approved by EMC for this indication but is recommended by Canadian guidelines with oderate level of evidence.) CU: should be used as adjunctive therapy. ST: is used as third line therapy  after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "THYROID PREPARATIONS",
            "Drug_Sub_Class": "Thyroid hormones",
            "Trade_Name": "L- THYROX HEXAL 150MCG TABLETS",
            "Registration_Number": "11-349-09",
            "Active_ingredient": "LEVOTHYROXINE (THYROXINE) SODIUM",
            "ATC_Code": "H03AA01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "150µg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "300mcg",
            "Notes_1": "levothyroxine is essential as adjunctive therapy for treatment of acute bipolar depression type I and II. (not approved by EMC for this indication but is recommended by Canadian guidelines with oderate level of evidence.) CU: should be used as adjunctive therapy. ST: is used as third line therapy  after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Bipolar I Depression",
            "ICD_Code": "F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, F31.7",
            "Drug_Class": "THYROID PREPARATIONS",
            "Drug_Sub_Class": "Thyroid hormones",
            "Trade_Name": "L- THYROX HEXAL 50MCG TABLETS",
            "Registration_Number": "12-349-09",
            "Active_ingredient": "LEVOTHYROXINE (THYROXINE) SODIUM",
            "ATC_Code": "H03AA01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "0.05mg",
            "G_or_B": "G",
            "Prescribing_edits": "CU,ST",
            "Quantity_Limit_Adults": "300mcg",
            "Notes_1": "levothyroxine is essential as adjunctive therapy for treatment of acute bipolar depression type I and II. (not approved by EMC for this indication but is recommended by Canadian guidelines with oderate level of evidence.) CU: should be used as adjunctive therapy. ST: is used as third line therapy  after (quetiapine, lithium, divalproex, lamotrigine SSRI, bupropion and fluoxetine/olanzapine) ",
            "Appendix": "Appendix_5"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "AMOXIL 250MG CAP.",
            "Registration_Number": "5-212-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "90mg/kg for 5 days",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "AMOXIL 500MG CAP.",
            "Registration_Number": "6-212-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "90mg/kg for 5 days",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "AMOXIL POWDER FOR ORAL SUSPENSION 125MG-5ML",
            "Registration_Number": "7-212-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "25mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "AMOXIL POWDER FOR ORAL SUSPENSION FORTE 250MG-5ML",
            "Registration_Number": "8-212-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "50mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "E-MOX 125MG DRY MIX.",
            "Registration_Number": "21-201-96",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "125mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "E-MOX 250MG DRY MIX.",
            "Registration_Number": "22-201-96",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "250mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "E-MOX 500MG CAPS",
            "Registration_Number": "23-201-96",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "GLOMOX 500MG CAP",
            "Registration_Number": "2-444-03",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 125MG-5ML POWDER FOR ORAL SUSPENSION",
            "Registration_Number": "88-212-98",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "25mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 200MG-5ML POWDER FOR SUSPENSION",
            "Registration_Number": "230-212-08",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 250MG CAPS",
            "Registration_Number": "78-212-98",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 250MG-5ML POWDER FOR ORAL SUSPENSION",
            "Registration_Number": "89-212-98",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "50mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 400MG-5ML POWDER FOR SUSPENSION",
            "Registration_Number": "231-212-08",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "80mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 500MG CAPS",
            "Registration_Number": "79-212-98",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 875 mg film-coated tablet",
            "Registration_Number": "255-212-09",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "875mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "JULPHAMOX 250MG CAPSULE",
            "Registration_Number": "114-186-00",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "JULPHAMOX 250MG SUSP.",
            "Registration_Number": "136-186-01",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "JULPHAMOX 500MG CAPSULES",
            "Registration_Number": "115-186-00",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "MOXIDAD CAPSULES 250MG",
            "Registration_Number": "5-124-92",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "MOXIDAD FORTE",
            "Registration_Number": "6-124-92",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "NEOMOX 125MG-5ML SUSPENSION",
            "Registration_Number": "3-584-08",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "25mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "NEOMOX 250MG-5ML SUSPENSION",
            "Registration_Number": "2-584-08",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "50mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OMACILLIN 100MG-ML ORAL DROPS",
            "Registration_Number": "15-390-06",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "SOLUTION/ DROPS",
            "ROA": "ORAL",
            "Strength": "100mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OMACILLIN 125MG-5ML POWDER FOR ORAL SUSP",
            "Registration_Number": "20-390-06",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "25mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OMACILLIN 250MG CAP",
            "Registration_Number": "2-390-03",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OMACILLIN 500MG CAPSULES",
            "Registration_Number": "14-390-06",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 125MG-5ML SUSP",
            "Registration_Number": "47-116-93",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "SUSPENSION",
            "ROA": "ORAL",
            "Strength": "25mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 250MG CAPS",
            "Registration_Number": "49-116-93",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 250MG-5ML SUSP.",
            "Registration_Number": "48-116-93",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "SUSPENSION",
            "ROA": "ORAL",
            "Strength": "50mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 500MG TAB",
            "Registration_Number": "50-116-93",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 500MG-5ML POWDER FOR ORAL SUSP.",
            "Registration_Number": "66-116-06",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "100mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "PENAMOX 250MG-5ML SUSP.",
            "Registration_Number": "17-172-92",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "SUSPENSION",
            "ROA": "ORAL",
            "Strength": "50mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "PENAMOX CAPS 500 MG",
            "Registration_Number": "19-172-92",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "REMOX 125MG-5ML SUSPENSION",
            "Registration_Number": "15-334-99",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "25mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "REMOX 250 MG CAPSULES",
            "Registration_Number": "17-334-99",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "REMOX 250MG -5ML SUSPENSION",
            "Registration_Number": "16-334-99",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "50mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "REMOX 500 MG CAPSULES",
            "Registration_Number": "18-334-99",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "ULTRAMOX FORTE 250MG-5ML SUSP.",
            "Registration_Number": "64-119-89",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "POWDER, FOR SUSPENSION",
            "ROA": "ORAL",
            "Strength": "50mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "ULTRAMOX FORTE CAPS 500MG",
            "Registration_Number": "72-119-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "Adult dose 500mg 3 times a day for 5 days",
            "Quantity_Limit_Pediatrics": "Child 1 to 11 month 125mg  3 times a day for 5 days, Child 1 to 4 years 250mg 3 times a day for 5 days, Child 5 to 17 years 500mg 3 times a day for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin.                                      "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "APO-DOXY 100MG CAPS",
            "Registration_Number": "1-249-97",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST (pediatrics), Age",
            "Quantity_Limit_Adults": "200mg on first day, then 100mg qd for 5days ",
            "Quantity_Limit_Pediatrics": "200mg on first day, then 100mg qd for 5days ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST (Pediatrics): In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin. Age: do not use Doxycycline under 12 years old.",
            "Notes_2": "Avoid in children under 8  and from 8 to 11 years use only if there is no adequate alternatives; contra-indicated in pregnancy and breast feeding"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DORYX CAPS 100MG",
            "Registration_Number": "1-217-92",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST (pediatrics), Age",
            "Quantity_Limit_Adults": "200mg on first day, then 100mg qd for 5days ",
            "Quantity_Limit_Pediatrics": "200mg on first day, then 100mg qd for 5days ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST (Pediatrics): In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin. Age: do not use Doxycycline under 12 years old.",
            "Notes_2": "Avoid in children under 8  and from 8 to 11 years use only if there is no adequate alternatives; contra-indicated in pregnancy and breast feeding"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DOXYCIN",
            "Registration_Number": "122-325-04",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST (pediatrics), Age",
            "Quantity_Limit_Adults": "200mg on first day, then 100mg qd for 5days ",
            "Quantity_Limit_Pediatrics": "200mg on first day, then 100mg qd for 5days ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST (Pediatrics): In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin. Age: do not use Doxycycline under 12 years old.",
            "Notes_2": "Avoid in children under 8  and from 8 to 11 years use only if there is no adequate alternatives; contra-indicated in pregnancy and breast feeding"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DOXYDAR",
            "Registration_Number": "19-124-96",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST (pediatrics), Age",
            "Quantity_Limit_Adults": "200mg on first day, then 100mg qd for 5days ",
            "Quantity_Limit_Pediatrics": "200mg on first day, then 100mg qd for 5days ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST (Pediatrics): In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin. Age: do not use Doxycycline under 12 years old.",
            "Notes_2": "Avoid in children under 8  and from 8 to 11 years use only if there is no adequate alternatives; contra-indicated in pregnancy and breast feeding"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DUMOXIN SYRUP 10MG-ML",
            "Registration_Number": "50-49-81",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "SYRUP",
            "ROA": "ORAL",
            "Strength": "10mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST (pediatrics), Age",
            "Quantity_Limit_Adults": "200mg on first day, then 100mg qd for 5days ",
            "Quantity_Limit_Pediatrics": "200mg on first day, then 100mg qd for 5days ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST (Pediatrics): In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin. Age: do not use Doxycycline under 12 years old.",
            "Notes_2": "Avoid in children under 8  and from 8 to 11 years use only if there is no adequate alternatives; contra-indicated in pregnancy and breast feeding"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DUMOXIN TAB 100 MG",
            "Registration_Number": "49-49-81",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST (pediatrics), Age",
            "Quantity_Limit_Adults": "200mg on first day, then 100mg qd for 5days ",
            "Quantity_Limit_Pediatrics": "200mg on first day, then 100mg qd for 5days ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST (Pediatrics): In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin. Age: do not use Doxycycline under 12 years old.",
            "Notes_2": "Avoid in children under 8  and from 8 to 11 years use only if there is no adequate alternatives; contra-indicated in pregnancy and breast feeding"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DURADOX 100 MG CAPS",
            "Registration_Number": "109-186-99",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST (pediatrics), Age",
            "Quantity_Limit_Adults": "200mg on first day, then 100mg qd for 5days ",
            "Quantity_Limit_Pediatrics": "200mg on first day, then 100mg qd for 5days ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST (Pediatrics): In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin. Age: do not use Doxycycline under 12 years old.",
            "Notes_2": "Avoid in children under 8  and from 8 to 11 years use only if there is no adequate alternatives; contra-indicated in pregnancy and breast feeding"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "TABOCINE 100",
            "Registration_Number": "14-277-97",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "CAPSULE",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST (pediatrics), Age",
            "Quantity_Limit_Adults": "200mg on first day, then 100mg qd for 5days ",
            "Quantity_Limit_Pediatrics": "200mg on first day, then 100mg qd for 5days ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST (Pediatrics): In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin. Age: do not use Doxycycline under 12 years old.",
            "Notes_2": "Avoid in children under 8  and from 8 to 11 years use only if there is no adequate alternatives; contra-indicated in pregnancy and breast feeding"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "VIBRAMYCIN 100MG TABLET",
            "Registration_Number": "1-5029-18",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100mg",
            "G_or_B": "B",
            "Prescribing_edits": "PA, ST (pediatrics), Age",
            "Quantity_Limit_Adults": "200mg on first day, then 100mg qd for 5days ",
            "Quantity_Limit_Pediatrics": "200mg on first day, then 100mg qd for 5days ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST (Pediatrics): In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin. Age: do not use Doxycycline under 12 years old.",
            "Notes_2": "Avoid in children under 8  and from 8 to 11 years use only if there is no adequate alternatives; contra-indicated in pregnancy and breast feeding"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIDAR",
            "Registration_Number": "73-124-06",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIDAR 500 mg film-coated tablet",
            "Registration_Number": "72-124-06",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIDAR",
            "Registration_Number": "81-124-08",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIMAC 500 mg film-coated tablet",
            "Registration_Number": "170-325-05",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT 125 MG - 5 ML SUSPENSION",
            "Registration_Number": "149-277-03",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT 250 MG - 5 ML SUSPENSION",
            "Registration_Number": "150-277-03",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT 250 MG FILM COATED",
            "Registration_Number": "131-277-02",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT 500 MG FILM COATED TAB",
            "Registration_Number": "132-277-02",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT XL 500 MG EXTENDED RELEASE TAB.",
            "Registration_Number": "164-277-05",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Modified-release tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT XL 500MG EXTENDED RELEASE TABLETS",
            "Registration_Number": "216-277-11",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIVA 250 MG TABLET",
            "Registration_Number": "32-498-11",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "EMIMYCIN 500 MG TABLETS",
            "Registration_Number": "30-444-08",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERACID 250MG TABLET",
            "Registration_Number": "45-171-04",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERACID 500MG FILM COATED TABLETS",
            "Registration_Number": "69-171-10",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID 125MG-5ML SUSP",
            "Registration_Number": "2-139-94",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "B",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID 250MG TAB",
            "Registration_Number": "1-139-93",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID 500MG COATED TAB",
            "Registration_Number": "9-138-99",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID XL 500MG TAB",
            "Registration_Number": "10-138-01",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID XL 500MG TAB",
            "Registration_Number": "13-138-04",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLARIMID 250MG F.C. TABLETS",
            "Registration_Number": "26-346-09",
            "Active_ingredient": "CLARITHROMYCIN ",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLARIMID 250MG-5ML SUSPENSION",
            "Registration_Number": "25-346-08",
            "Active_ingredient": "CLARITHROMYCIN ",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLARIMID 500MG F.C. TABLETS",
            "Registration_Number": "27-346-09",
            "Active_ingredient": "CLARITHROMYCIN ",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult:  250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "RESCLAR 500MG TABLETS",
            "Registration_Number": "12-584-10",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult:  250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLARE 500 mg film-coated tablet",
            "Registration_Number": "45-437-16",
            "Active_ingredient": "CLARITHROMYCIN ",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult:  250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIDAR XL 500 mg Tablet",
            "Registration_Number": "109-124-18",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Sustain release Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult:  250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLAMYCIN 250 MG TABLET",
            "Registration_Number": "168-186-02",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": " adult : 250mg to 500mg twice a day for 5days",
            "Quantity_Limit_Pediatrics": "Child 1 month - 11 year (body weight upto 8 kg) 7.5mg per kg twice daily for five days, Child 1 month - 11 year (body weight upto 8 -11 kg) 62.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 12 -19 kg) 125mg  twice daily for five days, Child 1 month - 11 year (body weight upto 20 -99 kg) 187.5mg  twice daily for five days, Child 1 month - 11 year (body weight upto 30 -40 kg) 250mg  twice daily for five days, 12 - 17 years 250 to 500mg twice daily for 5 days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  ",
            "Notes_2": "avoid in people who are predisposed to prolong QT interval."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYC 250MG CAPS",
            "Registration_Number": "2-217-93",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "250mg to 500mg four times a day or 500mg to 1,000mg twice a day for 5days ",
            "Quantity_Limit_Pediatrics": "5 days treatment",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHRODAR",
            "Registration_Number": "16-124-85",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Gastro-resistant tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "250mg to 500mg four times a day or 500mg to 1,000mg twice a day for 5days ",
            "Quantity_Limit_Pediatrics": "5 days treatment",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHRODAR 400MG FORT TAB",
            "Registration_Number": "17-124-96",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "250mg to 500mg four times a day or 500mg to 1,000mg twice a day for 5days ",
            "Quantity_Limit_Pediatrics": "5 days treatment",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHROMIL 200MG-5ML SUSP.",
            "Registration_Number": "61-119-89",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "250mg to 500mg four times a day or 500mg to 1,000mg twice a day for 5days ",
            "Quantity_Limit_Pediatrics": "Child 1 -23 months 125mg 4 times a day for 5 days alternatively 250mg twice daily for five days, Child 2 -7 years 250mg 4 times a day for 5 days alternatively 500mg twice daily for five days, Child 8 -17 years 250 to 500mg 4 times a day for 5 days alternatively 500 -1000mg twice daily for five days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHROMIL FORTE 400MG-5MLSUSP.",
            "Registration_Number": "62-119-89",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "80",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "250mg to 500mg four times a day or 500mg to 1,000mg twice a day for 5days ",
            "Quantity_Limit_Pediatrics": "Child 1 -23 months 125mg 4 times a day for 5 days alternatively 250mg twice daily for five days, Child 2 -7 years 250mg 4 times a day for 5 days alternatively 500mg twice daily for five days, Child 8 -17 years 250 to 500mg 4 times a day for 5 days alternatively 500 -1000mg twice daily for five days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "OMATHROCIN ORAL DROPS 100 MG- 2.5 ML",
            "Registration_Number": "18-390-06",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Oral drops*",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "250mg to 500mg four times a day or 500mg to 1,000mg twice a day for 5days ",
            "Quantity_Limit_Pediatrics": "Child 1 -23 months 125mg 4 times a day for 5 days alternatively 250mg twice daily for five days, Child 2 -7 years 250mg 4 times a day for 5 days alternatively 500mg twice daily for five days, Child 8 -17 years 250 to 500mg 4 times a day for 5 days alternatively 500 -1000mg twice daily for five days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "OMATHROCIN 200 ORAL SUSPENSION",
            "Registration_Number": "25-390-08",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "250mg to 500mg four times a day or 500mg to 1,000mg twice a day for 5days ",
            "Quantity_Limit_Pediatrics": "Child 1 -23 months 125mg 4 times a day for 5 days alternatively 250mg twice daily for five days, Child 2 -7 years 250mg 4 times a day for 5 days alternatively 500mg twice daily for five days, Child 8 -17 years 250 to 500mg 4 times a day for 5 days alternatively 500 -1000mg twice daily for five days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "OMATHROCIN 250 MG TABLET",
            "Registration_Number": "19-390-06",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "250mg to 500mg four times a day or 500mg to 1,000mg twice a day for 5days ",
            "Quantity_Limit_Pediatrics": "Child 1 -23 months 125mg 4 times a day for 5 days alternatively 250mg twice daily for five days, Child 2 -7 years 250mg 4 times a day for 5 days alternatively 500mg twice daily for five days, Child 8 -17 years 250 to 500mg 4 times a day for 5 days alternatively 500 -1000mg twice daily for five days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "RYTHINATE SUSP. 200MG-5ML",
            "Registration_Number": "25-172-88",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "250mg to 500mg four times a day or 500mg to 1,000mg twice a day for 5days ",
            "Quantity_Limit_Pediatrics": "Child 1 -23 months 125mg 4 times a day for 5 days alternatively 250mg twice daily for five days, Child 2 -7 years 250mg 4 times a day for 5 days alternatively 500mg twice daily for five days, Child 8 -17 years 250 to 500mg 4 times a day for 5 days alternatively 500 -1000mg twice daily for five days,",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "EROMYCIN 200MG-5ML SUSP",
            "Registration_Number": "101-186-99",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "250mg to 500mg four times a day or 500mg to 1,000mg twice a day for 5days ",
            "Quantity_Limit_Pediatrics": "Child 1 -23 months 125mg 4 times a day for 5 days alternatively 250mg twice daily for five days, Child 2 -7 years 250mg 4 times a day for 5 days alternatively 500mg twice daily for five days, Child 8 -17 years 250 to 500mg 4 times a day for 5 days alternatively 500 -1000mg twice daily for five days,",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "EROMYCIN 250MG TABLET",
            "Registration_Number": "216-186-04",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA, ST",
            "Quantity_Limit_Adults": "250mg to 500mg four times a day or 500mg to 1,000mg twice a day for 5days ",
            "Quantity_Limit_Pediatrics": "Child 1 -23 months 125mg 4 times a day for 5 days alternatively 250mg twice daily for five days, Child 2 -7 years 250mg 4 times a day for 5 days alternatively 500mg twice daily for five days, Child 8 -17 years 250 to 500mg 4 times a day for 5 days alternatively 500 -1000mg twice daily for five days, ",
            "Notes_1": "PA: Antibiotic therapy should be initiated after confirming that the acute cough is as a result of pneumonia, upper airway cough syndrome from bacterial sinusitis, or Bordetella pertussis infection in the lower respiratory tract (whooping cough), if given early in the illness, or from exacerbations of bronchiectasis or severe chronic bronchitis in current or previous smokers with severe airflow obstruction.  ST: In Adults, use doxycycline first then try amoxicillin or erythromycin or clarithromycin. In children with confirmed need for antibiotic therapy, use amoxicillin first then doxycycline or erythromycin or clarithromycin.                                  "
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "BRUFEN 400 MG TAB",
            "Registration_Number": "15-138-81",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "BRUFEN TAB 600MG",
            "Registration_Number": "16-138-87",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "600",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "DOLORAZ 100MG-5ML SUSPENSION",
            "Registration_Number": "70-171-10",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "EMIFEN 100MG-5ML SUSPENSION",
            "Registration_Number": "17-444-05",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "EMIFEN 600 MG F-C TAB",
            "Registration_Number": "20-444-06",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "600",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "FENBID SPANSULES 300MG",
            "Registration_Number": "29-1-87",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Prolonged-release capsule*",
            "ROA": "Oral",
            "Strength": "300",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "FENBID SPANSULES 300MG",
            "Registration_Number": "2-1-89",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Prolonged-release capsule*",
            "ROA": "Oral",
            "Strength": "300",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "IBUGESIC",
            "Registration_Number": "43-124-96",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "I-PROFEN 400MG TABLET",
            "Registration_Number": "43-352-04",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "JAZOFEN 200 MG TAB",
            "Registration_Number": "19-334-99",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "JAZOFEN 400MG TAB",
            "Registration_Number": "20-334-99",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "MEDAFEN 100MG-5ML SUSPENSION",
            "Registration_Number": "27-490-06",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "NUROFEN 100MG-5ML PAEDIATRIC SUSPENSION",
            "Registration_Number": "23-65-94",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "NUROFEN 200MG TAB",
            "Registration_Number": "1-65-81",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "NUROFEN 200MG TAB",
            "Registration_Number": "2-65-81",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "OMAFEN 400 MG F.C TABLETS",
            "Registration_Number": "5-390-03",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "PROF 100MG-5ML SUSP",
            "Registration_Number": "92-277-01",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "PROF 400 MG TAB",
            "Registration_Number": "96-277-01",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "PROF 600 MG TAB",
            "Registration_Number": "97-277-01",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "600",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "SAPOFEN 200MG F.C TAB",
            "Registration_Number": "164-212-02",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "SAPOFEN 400MG TAB",
            "Registration_Number": "25-212-94",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "SAPOFEN 600 MG TAB",
            "Registration_Number": "106-212-99",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "600",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "SAPOFEN JUNIOR 100MG-5ML SUSPENSION",
            "Registration_Number": "104-212-99",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "SAPOFEN JUNIOR 100MG-5ML SUSPENSION",
            "Registration_Number": "105-212-99",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "SPEDIFEN 400MG GRANULES",
            "Registration_Number": "2-462-10",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Granules",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "2,400 mg/day",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "SPEDIFEN 600MG GRANULES",
            "Registration_Number": "3-462-10",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Granules",
            "ROA": "Oral",
            "Strength": "600",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "2,400 mg/day",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "NUROFEN 400 DOUBLE STRENGTH TABLET",
            "Registration_Number": "1-5055-17",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "NUROFEN FOR CHILDREN STRAWBERRY ORAL SUSPENSION",
            "Registration_Number": "4-677-17",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "ADVIL 200MG TAB",
            "Registration_Number": "8-625-19",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "ADVIL 200MG TAB",
            "Registration_Number": "41-31-00",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "PROFINAL 200MG TAB",
            "Registration_Number": "16-186-85",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "PROFINAL 400 mg film-coated tablets",
            "Registration_Number": "43-186-89",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "400mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "PROFINAL 600 mg tablet",
            "Registration_Number": "60-186-97",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "600mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "PROFINAL SUSP 100MG-5ML",
            "Registration_Number": "74-186-98",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "PROFINAL SUSP 100MG-5ML",
            "Registration_Number": "212-186-03",
            "Active_ingredient": "IBUPROFEN",
            "ATC_Code": "M01AE01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3,200 mg/day ",
            "Quantity_Limit_Pediatrics": "40 mg/kg/day ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "NAPROTEX 250MG-TAB.",
            "Registration_Number": "14-249-99",
            "Active_ingredient": "NAPROXEN",
            "ATC_Code": "M01AE02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "10 mg/kg/dose ",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "NAPROTEX 500 mg tablet",
            "Registration_Number": "15-249-99",
            "Active_ingredient": "NAPROXEN",
            "ATC_Code": "M01AE02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "10 mg/kg/dose ",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "NAPROX 250MG TAB",
            "Registration_Number": "106-172-97",
            "Active_ingredient": "NAPROXEN",
            "ATC_Code": "M01AE02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "10 mg/kg/dose ",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "NAPROX D.S 500MG TAB",
            "Registration_Number": "107-172-97",
            "Active_ingredient": "NAPROXEN",
            "ATC_Code": "M01AE02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "10 mg/kg/dose ",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "PROXEPAIN",
            "Registration_Number": "172-325-06",
            "Active_ingredient": "NAPROXEN",
            "ATC_Code": "M01AE02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "220",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "10 mg/kg/dose ",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "PROXEPAIN",
            "Registration_Number": "173-325-06",
            "Active_ingredient": "NAPROXEN",
            "ATC_Code": "M01AE02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "220",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "10 mg/kg/dose ",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "RIAPROXEN 250 mg film-coated tablet",
            "Registration_Number": "82-325-03",
            "Active_ingredient": "NAPROXEN",
            "ATC_Code": "M01AE02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "10 mg/kg/dose ",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "RIAPROXEN 500 mg film-coated tablet",
            "Registration_Number": "83-325-03",
            "Active_ingredient": "NAPROXEN",
            "ATC_Code": "M01AE02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "10 mg/kg/dose ",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "ALEVE 220 mg film-coated tablet",
            "Registration_Number": "7-949-16",
            "Active_ingredient": "NAPROXEN",
            "ATC_Code": "M01AE02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "220",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "10 mg/kg/dose ",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "PROXEN F.C. TAB 250MG",
            "Registration_Number": "4-328-19",
            "Active_ingredient": "NAPROXEN",
            "ATC_Code": "M01AE02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "10 mg/kg/dose ",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "PROXEN F.C TAB 500MG",
            "Registration_Number": "5-328-19",
            "Active_ingredient": "NAPROXEN",
            "ATC_Code": "M01AE02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "10 mg/kg/dose ",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "ALLERFIN SYRUP 2.5MG-5ML",
            "Registration_Number": "2-119-82",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE",
            "ATC_Code": "R06AB04",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.5",
            "G_or_B": "G",
            "Quantity_Limit_Adults": " adult :24 mg/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day. ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "ALLERFIN TABLETS 4MG",
            "Registration_Number": "3-119-82",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE",
            "ATC_Code": "R06AB04",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": " adult :24 mg/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day. ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "HISTANT 4 MG TABLETS",
            "Registration_Number": "32-352-04",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE",
            "ATC_Code": "R06AB04",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": " adult :24 mg/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day. ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "HISTANT SYRUP",
            "Registration_Number": "7-352-01",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE",
            "ATC_Code": "R06AB04",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": " adult :24 mg/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day. ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "HISTOP 2MG-5ML SYRUP",
            "Registration_Number": "18-212-94",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE",
            "ATC_Code": "R06AB04",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": " adult :24 mg/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day. ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "HISTOP TAB 4MG",
            "Registration_Number": "23-212-94",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE",
            "ATC_Code": "R06AB04",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": " adult :24 mg/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day. ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "PHENIRAM 2MG\\5ML SYRUP",
            "Registration_Number": "3-490-05",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE",
            "ATC_Code": "R06AB04",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": " adult :24 mg/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day. ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "PHENIRAM 4MG TABLET",
            "Registration_Number": "5-490-05",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE",
            "ATC_Code": "R06AB04",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "24 mg/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day. ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "CHLOROHISTOL SYRUP 2 MG - 5 ML",
            "Registration_Number": "33-186-88",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE (CHLORPHENAMINE MALEATE)",
            "ATC_Code": "R06AB04",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.4mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "24 mg/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day. ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "CHLOROHISTOL TAB 4 MG.",
            "Registration_Number": "19-186-86",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE (CHLORPHENAMINE MALEATE)",
            "ATC_Code": "R06AB04",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "4mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "24 mg/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day. ",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Other antihistamines for systemic use",
            "Trade_Name": "CIPTADINE TAB 4MG",
            "Registration_Number": "32-172-87",
            "Active_ingredient": "CYPROHEPTADINE HYDROCHLORIDE",
            "ATC_Code": "R06AX02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "32 mg/day",
            "Quantity_Limit_Pediatrics": "12-16mg/day",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Other antihistamines for systemic use",
            "Trade_Name": "PERIACTIN 4MG TABLETS",
            "Registration_Number": "6-313-10",
            "Active_ingredient": "CYPROHEPTADINE HYDROCHLORIDE",
            "ATC_Code": "R06AX02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "32 mg/day",
            "Quantity_Limit_Pediatrics": "12-16mg/day",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",
            "Drug_Sub_Class": "Antihistamines for topical use",
            "Trade_Name": "EXYLIN SYRUP 14MG-5ML",
            "Registration_Number": "17-212-94",
            "Active_ingredient": "DIPHENHYDRAMINE HYDROCHLORIDE",
            "ATC_Code": "D04AA32  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "2.8",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "200mg/24hours",
            "Quantity_Limit_Pediatrics": "50-150mg/day",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",
            "Drug_Sub_Class": "Antihistamines for topical use",
            "Trade_Name": "EZIPECT 12.5MG-5ML SYRUP",
            "Registration_Number": "115-277-01",
            "Active_ingredient": "DIPHENHYDRAMINE HYDROCHLORIDE",
            "ATC_Code": "D04AA32  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "2.5",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "200mg/24hours",
            "Quantity_Limit_Pediatrics": "50-150mg/day",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",
            "Drug_Sub_Class": "Antihistamines for topical use",
            "Trade_Name": "DRAMYLIN PEDIATRIC SYRUP",
            "Registration_Number": "21-352-02",
            "Active_ingredient": "DIPHENHYDRAMINE HYDROCHLORIDE, MENTHOL",
            "ATC_Code": "D04AA32  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "7, 0.55",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "200mg/24hours",
            "Quantity_Limit_Pediatrics": "50-150mg/day",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",
            "Drug_Sub_Class": "Antihistamines for topical use",
            "Trade_Name": "EXYLIN PEDIATRIC SYRUP",
            "Registration_Number": "56-212-97",
            "Active_ingredient": "DIPHENHYDRAMINE, MENTHOL",
            "ATC_Code": "D04AA32  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "1.4, 0.11",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "200mg/24hours",
            "Quantity_Limit_Pediatrics": "50-150mg/day",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Aminoalkyl ethers",
            "Trade_Name": "AMYDRAMINE II SUGAR FREE SYRUP",
            "Registration_Number": "104-186-99",
            "Active_ingredient": "DIPHENHYDRAMINE HYDROCHLORIDE",
            "ATC_Code": "R06AA02",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "2.5mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "200mg/24hours",
            "Quantity_Limit_Pediatrics": "50-150mg/day",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Aminoalkyl ethers",
            "Trade_Name": "AMYDRAMINE PAEDIATRIC SYRUP",
            "Registration_Number": "78-186-99",
            "Active_ingredient": "DIPHENHYDRAMINE HYDROCHLORIDE, MENTHOL",
            "ATC_Code": "R06AA52",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "7, 0.55mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "200mg/24hours",
            "Quantity_Limit_Pediatrics": "50-150mg/day",
            "Notes_1": "Off Label use in Acute Cough"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANXIOLYTICS",
            "Drug_Sub_Class": "Diphenylmethane derivatives",
            "Trade_Name": "ATARAX SYRUP",
            "Registration_Number": "3-432-83",
            "Active_ingredient": "HYDROXYZINE HYDROCHLORIDE",
            "ATC_Code": "N05BB01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "2",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "100mg/day",
            "Quantity_Limit_Pediatrics": "50-100mg/day",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Elderly patients are particularly susceptible to side effects, manufacturers advice avoid or reduce dose, children have an increased susceptibility to side effects particularly CNS effects, Glaucoma: Use with caution in patients with narrow-angle glaucoma; Respiratory disease: Use with caution in patients with asthma or chronic obstructive pulmonary disease (COPD)."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANXIOLYTICS",
            "Drug_Sub_Class": "Diphenylmethane derivatives",
            "Trade_Name": "ATARAX TABLETS 10 MG",
            "Registration_Number": "2-432-83",
            "Active_ingredient": "HYDROXYZINE HYDROCHLORIDE",
            "ATC_Code": "N05BB01  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "10",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "100mg/day",
            "Quantity_Limit_Pediatrics": "50-100mg/day",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Elderly patients are particularly susceptible to side effects, manufacturers advice avoid or reduce dose, children have an increased susceptibility to side effects particularly CNS effects, Glaucoma: Use with caution in patients with narrow-angle glaucoma; Respiratory disease: Use with caution in patients with asthma or chronic obstructive pulmonary disease (COPD)."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANXIOLYTICS",
            "Drug_Sub_Class": "Diphenylmethane derivatives",
            "Trade_Name": "ATARAX TABLETS 25 MG",
            "Registration_Number": "1-432-83",
            "Active_ingredient": "HYDROXYZINE HYDROCHLORIDE",
            "ATC_Code": "N05BB01  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "100mg/day",
            "Quantity_Limit_Pediatrics": "50-100mg/day",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Elderly patients are particularly susceptible to side effects, manufacturers advice avoid or reduce dose, children have an increased susceptibility to side effects particularly CNS effects, Glaucoma: Use with caution in patients with narrow-angle glaucoma; Respiratory disease: Use with caution in patients with asthma or chronic obstructive pulmonary disease (COPD)."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Phenothiazine derivatives",
            "Trade_Name": "HISTAZIN 5MG\\5ML SYRUP",
            "Registration_Number": "21-271-03",
            "Active_ingredient": "PROMETHAZINE",
            "ATC_Code": "R06AD02  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "1.2",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "37.5mg/day",
            "Quantity_Limit_Pediatrics": "12.5 mg/dose every 6 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Children under 6 years should not be given, OTC cough and cold medications containing promethazine.  MHRA/CHM adivce (April 2009)"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Phenothiazine derivatives",
            "Trade_Name": "PROMANTINE SYRUP",
            "Registration_Number": "10-120-86",
            "Active_ingredient": "PROMETHAZINE",
            "ATC_Code": "R06AD02  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "1.2",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "37.5mg/day",
            "Quantity_Limit_Pediatrics": "12.5 mg/dose every 6 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Children under 6 years should not be given, OTC cough and cold medications containing promethazine.  MHRA/CHM adivce (April 2009)"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Phenothiazine derivatives",
            "Trade_Name": "PROMETIN 5MG\\5ML SYRUP",
            "Registration_Number": "23-352-02",
            "Active_ingredient": "PROMETHAZINE",
            "ATC_Code": "R06AD02  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "1",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "37.5mg/day",
            "Quantity_Limit_Pediatrics": "12.5 mg/dose every 6 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Children under 6 years should not be given, OTC cough and cold medications containing promethazine.  MHRA/CHM adivce (April 2009)"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Phenothiazine derivatives",
            "Trade_Name": "HISTALOC 25MG F.C. TABLETS",
            "Registration_Number": "264-186-09",
            "Active_ingredient": "PROMETHAZINE",
            "ATC_Code": "R06AD02",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "25mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "37.5mg/day",
            "Quantity_Limit_Pediatrics": "12.5 mg/dose every 6 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Children under 6 years should not be given, OTC cough and cold medications containing promethazine.  MHRA/CHM adivce (April 2009)"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Phenothiazine derivatives",
            "Trade_Name": "HISTALOC 5MG-5ML SYRUP",
            "Registration_Number": "72-186-98",
            "Active_ingredient": "PROMETHAZINE",
            "ATC_Code": "R06AD02",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "1mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "37.5mg/day",
            "Quantity_Limit_Pediatrics": "12.5 mg/dose every 6 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Children under 6 years should not be given, OTC cough and cold medications containing promethazine.  MHRA/CHM adivce (April 2009)"
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "NASAL DECONGESTANTS FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Sympathomimetics",
            "Trade_Name": "ACTIFED SYRUP",
            "Registration_Number": "22-432-03",
            "Active_ingredient": "TRIPROLIDINE, PSEUDOEPHEDRINE",
            "ATC_Code": "R01BA52  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.25, 6",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "4 doses/24 hours",
            "Quantity_Limit_Pediatrics": "4 doses in 24 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease). Diabetes: Use with caution in patients with diabetes mellitus. Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "NASAL DECONGESTANTS FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Sympathomimetics",
            "Trade_Name": "ACTIFED TAB",
            "Registration_Number": "88-276-07",
            "Active_ingredient": "TRIPROLIDINE, PSEUDOEPHEDRINE",
            "ATC_Code": "R01BA52  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "2.5, 60",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "4 doses/24 hours",
            "Quantity_Limit_Pediatrics": "4 doses in 24 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease). Diabetes: Use with caution in patients with diabetes mellitus. Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "NASAL DECONGESTANTS FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Sympathomimetics",
            "Trade_Name": "ACTIFED TAB",
            "Registration_Number": "68-276-02",
            "Active_ingredient": "TRIPROLIDINE, PSEUDOEPHEDRINE",
            "ATC_Code": "R01BA52  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "2.5 , 60",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "4 doses/24 hours",
            "Quantity_Limit_Pediatrics": "4 doses in 24 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease). Diabetes: Use with caution in patients with diabetes mellitus. Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "NASAL DECONGESTANTS FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Sympathomimetics",
            "Trade_Name": "COLFED 120ML",
            "Registration_Number": "92-119-00",
            "Active_ingredient": "TRIPROLIDINE, PSEUDOEPHEDRINE",
            "ATC_Code": "R01BA52  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.25, 6",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "4 doses/24 hours",
            "Quantity_Limit_Pediatrics": "4 doses in 24 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease). Diabetes: Use with caution in patients with diabetes mellitus. Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "NASAL DECONGESTANTS FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Sympathomimetics",
            "Trade_Name": "NEOCOLD SYRUP",
            "Registration_Number": "10-584-09",
            "Active_ingredient": "TRIPROLIDINE, PSEUDOEPHEDRINE",
            "ATC_Code": "R01BA52  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.25, 6",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "4 doses/24 hours",
            "Quantity_Limit_Pediatrics": "4 doses in 24 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease). Diabetes: Use with caution in patients with diabetes mellitus. Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "NASAL DECONGESTANTS FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Sympathomimetics",
            "Trade_Name": "RINOFED SYRUP",
            "Registration_Number": "3-334-99",
            "Active_ingredient": "TRIPROLIDINE, PSEUDOEPHEDRINE",
            "ATC_Code": "R01BA52  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.25, 6",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "4 doses/24 hours",
            "Quantity_Limit_Pediatrics": "4 doses in 24 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease). Diabetes: Use with caution in patients with diabetes mellitus. Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "NASAL DECONGESTANTS FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Sympathomimetics",
            "Trade_Name": "RINOFED TAB",
            "Registration_Number": "64-334-02",
            "Active_ingredient": "TRIPROLIDINE, PSEUDOEPHEDRINE",
            "ATC_Code": "R01BA52  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "2.5 , 60",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "4 doses/24 hours",
            "Quantity_Limit_Pediatrics": "4 doses in 24 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease). Diabetes: Use with caution in patients with diabetes mellitus. Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "NASAL DECONGESTANTS FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Sympathomimetics",
            "Trade_Name": "TRIPOFED SYRUP",
            "Registration_Number": "17-352-02",
            "Active_ingredient": "TRIPROLIDINE, PSEUDOEPHEDRINE",
            "ATC_Code": "R01BA52  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.25, 6",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "4 doses/24 hours",
            "Quantity_Limit_Pediatrics": "4 doses in 24 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease). Diabetes: Use with caution in patients with diabetes mellitus. Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "NASAL DECONGESTANTS FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Sympathomimetics",
            "Trade_Name": "UNIFED SYRUP",
            "Registration_Number": "13-271-01",
            "Active_ingredient": "TRIPROLIDINE, PSEUDOEPHEDRINE",
            "ATC_Code": "R01BA52  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.25, 6",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "4 doses/24 hours",
            "Quantity_Limit_Pediatrics": "4 doses in 24 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease). Diabetes: Use with caution in patients with diabetes mellitus. Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "NASAL DECONGESTANTS FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Sympathomimetics",
            "Trade_Name": "SEDOFAN SYRUP.",
            "Registration_Number": "77-186-98",
            "Active_ingredient": "TRIPROLIDINE, PSEUDOEPHEDRINE",
            "ATC_Code": "R01BA52",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.25, 6mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "4 doses/24 hours",
            "Quantity_Limit_Pediatrics": "4 doses in 24 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease). Diabetes: Use with caution in patients with diabetes mellitus. Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "NASAL DECONGESTANTS FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Sympathomimetics",
            "Trade_Name": "SEDOFAN TAB",
            "Registration_Number": "75-186-98",
            "Active_ingredient": "TRIPROLIDINE, PSEUDOEPHEDRINE",
            "ATC_Code": "R01BA52",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "2.5 , 60mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "4 doses/24 hours",
            "Quantity_Limit_Pediatrics": "4 doses in 24 hours",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease). Diabetes: Use with caution in patients with diabetes mellitus. Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "NASAL DECONGESTANTS FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Sympathomimetics",
            "Trade_Name": "PROF Cold & Flu Film coated tablet",
            "Registration_Number": "287-277-14",
            "Active_ingredient": "IBUPROFEN, CHLORPHENIRAMINE, PSEUDOEPHEDRINE",
            "ATC_Code": "R01BA52  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200, 2, 30",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "4tablets/day",
            "Quantity_Limit_Pediatrics": "4tablets/day above 6 years",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection. Use with caution in diabetes, hypertension, IHD, hyperthyroidism, susceptibility to angle-closure gluacoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "SINE-UP SYRUP",
            "Registration_Number": "3-206-91",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE, PHENYLEPHERINE HYDROCHLORIDE",
            "ATC_Code": "R06AB04",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.5 , 1",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "40 mL/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day.",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": " Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "SOOLAN SYRUP 100 ML.",
            "Registration_Number": "17-186-85",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE, GLYCERYL GUAIACOLATE, PHENYLEPHRINE HCL",
            "ATC_Code": "R06AB54",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "1, 50, 2.5mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "40 mL/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day.",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": " Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIHISTAMINES FOR SYSTEMIC USE",
            "Drug_Sub_Class": "Substituted alkylamines",
            "Trade_Name": "ALLERGETIN SYRUP",
            "Registration_Number": "33-352-04",
            "Active_ingredient": "CHLORPHENIRAMINE MALEATE, PSEUDOEPHEDRINE",
            "ATC_Code": "R06AB04",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "2, 30",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "40 mL/24 hours",
            "Quantity_Limit_Pediatrics": "Child 1 to 23 months 1mg twice daily, Child 2-5 years 1mg 4 to 6 hours max 6mg/day, Child 6 -11 years 2mg every 4 to 6 hours max 12mg/day, Child 12 - 17 years 4mg every 4 to 6 hours max 24mg/day Adult 4mg every 4 to 6 hours max 24mg/day, Elderly 4mg every 4 to 6 hours max 12mg/day.",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": " Contraindicated in neonates, use with caution in epilepsy, urinary retention, susceptibility to angle-closure glaucoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "ADVIL COLD AND SINUS CAPLET",
            "Registration_Number": "42-31-01",
            "Active_ingredient": "IBUPROFEN, PSEUDOEPHEDRINE",
            "ATC_Code": "M01AE51",
            "Dosage_Form": "Coated tablet",
            "ROA": "Oral",
            "Strength": "200, 30",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "6 tablets/day",
            "Quantity_Limit_Pediatrics": "6 tablets/day above 12 years",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection. Use with caution in diabetes, hypertension, IHD, hyperthyroidism, susceptibility to angle-closure gluacoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "ADVIL COLD AND SINUS CAPLET",
            "Registration_Number": "46-31-03",
            "Active_ingredient": "IBUPROFEN, PSEUDOEPHEDRINE",
            "ATC_Code": "M01AE51",
            "Dosage_Form": "Coated tablet",
            "ROA": "Oral",
            "Strength": "200, 30",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "6 tablets/day",
            "Quantity_Limit_Pediatrics": "6 tablets/day above 12 years",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection. Use with caution in diabetes, hypertension, IHD, hyperthyroidism, susceptibility to angle-closure gluacoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "SAPOFEN COLD & FLU SUSPENSION",
            "Registration_Number": "270-212-11",
            "Active_ingredient": "IBUPROFEN, PSEUDOEPHEDRINE HCL",
            "ATC_Code": "M01AE51",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "20, 3",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "6 tablets/day",
            "Quantity_Limit_Pediatrics": "6 tablets/day above 12 years",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection. Use with caution in diabetes, hypertension, IHD, hyperthyroidism, susceptibility to angle-closure gluacoma."
        },
        {
            "Indication": "Acute Cough",
            "ICD_Code": "R05",
            "Drug_Class": "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",
            "Drug_Sub_Class": "Propionic acid derivatives",
            "Trade_Name": "SAPOFEN COLD & FLU TABLET",
            "Registration_Number": "137-212-01",
            "Active_ingredient": "IBUPROFEN, PSEUDOEPHEDRINE",
            "ATC_Code": "M01AE51",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "200, 30",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "6 tablets/day",
            "Quantity_Limit_Pediatrics": "6 tablets/day above 12 years",
            "Notes_1": "Off Label use in Acute Cough",
            "Notes_2": "Avoid active GI bleeding, history of GI bleeding and perforation related to previous NSAID therapy, sever heart failure, varicella infection. Use with caution in diabetes, hypertension, IHD, hyperthyroidism, susceptibility to angle-closure gluacoma."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "AMOXIL 250MG CAP.",
            "Registration_Number": "5-212-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "AMOXIL 500MG CAP.",
            "Registration_Number": "6-212-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "AMOXIL POWDER FOR ORAL SUSPENSION 125MG-5ML",
            "Registration_Number": "7-212-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "AMOXIL POWDER FOR ORAL SUSPENSION FORTE 250MG-5ML",
            "Registration_Number": "8-212-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "MOXIDAD CAPSULES 250MG",
            "Registration_Number": "5-124-92",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "MOXIDAD FORTE",
            "Registration_Number": "6-124-92",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "E-MOX 125MG DRY MIX.",
            "Registration_Number": "21-201-96",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "125",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "E-MOX 250MG DRY MIX.",
            "Registration_Number": "22-201-96",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "E-MOX 500MG CAPS",
            "Registration_Number": "23-201-96",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "GLOMOX 500MG CAP",
            "Registration_Number": "2-444-03",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 125MG-5ML POWDER FOR ORAL SUSPENSION",
            "Registration_Number": "88-212-98",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 200MG-5ML POWDER FOR SUSPENSION",
            "Registration_Number": "230-212-08",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 250MG CAPS",
            "Registration_Number": "78-212-98",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 250MG-5ML POWDER FOR ORAL SUSPENSION",
            "Registration_Number": "89-212-98",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 400MG-5ML POWDER FOR SUSPENSION",
            "Registration_Number": "231-212-08",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 500MG CAPS",
            "Registration_Number": "79-212-98",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 875 mg film-coated tablet",
            "Registration_Number": "255-212-09",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "875",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "NEOMOX 125MG-5ML SUSPENSION",
            "Registration_Number": "3-584-08",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "NEOMOX 250MG-5ML SUSPENSION",
            "Registration_Number": "2-584-08",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OMACILLIN 100MG-ML ORAL DROPS",
            "Registration_Number": "15-390-06",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral drops*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OMACILLIN 125MG-5ML POWDER FOR ORAL SUSP",
            "Registration_Number": "20-390-06",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OMACILLIN 250MG CAP",
            "Registration_Number": "2-390-03",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OMACILLIN 500MG CAPSULES",
            "Registration_Number": "14-390-06",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 125MG-5ML SUSP",
            "Registration_Number": "47-116-93",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 250MG CAPS",
            "Registration_Number": "49-116-93",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 250MG-5ML SUSP.",
            "Registration_Number": "48-116-93",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 500MG TAB",
            "Registration_Number": "50-116-93",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 500MG-5ML POWDER FOR ORAL SUSP.",
            "Registration_Number": "66-116-06",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "PENAMOX 250MG-5ML SUSP.",
            "Registration_Number": "17-172-92",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "PENAMOX CAPS 500 MG",
            "Registration_Number": "19-172-92",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "REMOX 125MG-5ML SUSPENSION",
            "Registration_Number": "15-334-99",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "REMOX 250 MG CAPSULES",
            "Registration_Number": "17-334-99",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "REMOX 250MG -5ML SUSPENSION",
            "Registration_Number": "16-334-99",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "REMOX 500 MG CAPSULES",
            "Registration_Number": "18-334-99",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "ULTRAMOX FORTE 250MG-5ML SUSP.",
            "Registration_Number": "64-119-89",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "ULTRAMOX FORTE CAPS 500MG",
            "Registration_Number": "72-119-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "JULPHAMOX 250MG CAPSULE",
            "Registration_Number": "114-186-00",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "JULPHAMOX 250MG SUSP.",
            "Registration_Number": "136-186-01",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "JULPHAMOX 500MG CAPSULES",
            "Registration_Number": "115-186-00",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "PA ",
            "Quantity_Limit_Adults": "up to 1000 mg three times a day for7-14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximal 500 mg three times a day for7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 1 GM TAB",
            "Registration_Number": "134-172-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875,125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 1.2 GM VIAL",
            "Registration_Number": "136-172-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1000, 200",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1200 q8hr",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 156MG-5ML SUSP",
            "Registration_Number": "108-172-97",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25, 6.2",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "500 mg three times for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 228MG\\5ML SUSP",
            "Registration_Number": "132-172-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40, 5.6",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 375 MG TAB.",
            "Registration_Number": "115-172-98",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250, 125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "375 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 457MG\\5ML SUSP",
            "Registration_Number": "133-172-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80, 11.4",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 600MG VIAL",
            "Registration_Number": "135-172-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500, 100",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1200 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN FORTE 312MG-5ML SUSP",
            "Registration_Number": "109-172-97",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.4",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "500 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN FORTE 625MG TAB",
            "Registration_Number": "116-172-98",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500, 125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "625 mg three times daily  for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOXIPLUS 1.2GM Powder for injection",
            "Registration_Number": "1-724-11",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Parenteral",
            "Strength": "1, 0.2",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1200 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN (ES) SUSPENSION",
            "Registration_Number": "116-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "120, 8.55",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 1 G TAB",
            "Registration_Number": "118-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "125-875",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 1.2GM VIAL",
            "Registration_Number": "114-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1000, 200",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1200 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 156 Mg-5 ML SUSPENSION",
            "Registration_Number": "121-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25, 6.2",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "500 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 228 MG-5ML SUSPENSION",
            "Registration_Number": "115-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40, 5.6",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 312 MG-5ML SUSPENSION",
            "Registration_Number": "120-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.4",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "500 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 457MG-5ML SUSPENSION",
            "Registration_Number": "112-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80, 11.4",

            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 600MG VIAL",
            "Registration_Number": "113-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500,100",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1200 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 625 MG TAB",
            "Registration_Number": "119-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500-125",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "500 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN INFANT DROP",
            "Registration_Number": "117-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "50, 12.5",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1200 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN SR TABLET",
            "Registration_Number": "111-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "1000, 62.5",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "2 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN TAB 375 MG",
            "Registration_Number": "122-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250, 125",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "375 mgthree times daily  for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CLAVODAR 1GM F.C. TABLETS",
            "Registration_Number": "91-124-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875,125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CLAVODAR 457MG/5ML SUSPENSION",
            "Registration_Number": "93-124-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "457, 5",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CLAVODAR 625GM FILM COATED TABLET",
            "Registration_Number": "94-124-11",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500-125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "625 mg three times for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CO AMOX - MEPHA 1000MG F.C. TABLETS",
            "Registration_Number": "28-222-09",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875, 125",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 1.2GM POW. FOR SOLN. FOR INJECTION- INFUSION",
            "Registration_Number": "80-116-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1000, 200",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1200 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 156.25MG-5ML POWDER FOR SUSP",
            "Registration_Number": "52-116-99",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25, 6.2",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "500 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 2.2GM POW. FOR SOLN. FOR INJECTION- INFUSION",
            "Registration_Number": "81-116-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "2000, 200",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1200 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 312.5 MG-5ML POWDER FOR SUSP",
            "Registration_Number": "53-116-99",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.4",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "500 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 457MG-5ML POW. FOR ORAL SUSPENSION",
            "Registration_Number": "78-116-09",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80, 11.4",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 600MG POW. FOR SOLN. FOR INJECTION- INFUSION",
            "Registration_Number": "79-116-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500, 100",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1200 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 625 MG F.C TAB",
            "Registration_Number": "51-116-99",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500,125",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "625 mg three times for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "GLOCLAV 1GM FILM COATED TABLETS",
            "Registration_Number": "32-444-09",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875, 125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "GLOCLAV 375MG TAB",
            "Registration_Number": "3-444-04",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250, 125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "375 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "GLOCLAV 625MG TABLET",
            "Registration_Number": "4-444-04",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500, 125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "625 mg three times for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 1GM TAB",
            "Registration_Number": "150-212-01",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875, 125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 228MG\\5ML SUSPENSION",
            "Registration_Number": "174-212-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40, 5.6",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 312.5 MG-5ML SUSPENSION",
            "Registration_Number": "77-212-98",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.5",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "500 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 375MG F.C.TAB",
            "Registration_Number": "74-212-98",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250, 125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "375 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 457MG\\5ML SUSPENSION",
            "Registration_Number": "175-212-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80, 11.4",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 62.5MG DROPS",
            "Registration_Number": "191-212-03",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.5",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "500 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 625MG F.C.TAB",
            "Registration_Number": "75-212-98",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500, 125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "625 mg three times for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 156 MG SUSP",
            "Registration_Number": "28-334-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25, 6.2",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "500 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 1GM TAB",
            "Registration_Number": "45-334-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875,125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 228 MG SUSP",
            "Registration_Number": "30-334-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40, 5.6",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 312MG SUSP",
            "Registration_Number": "29-334-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.4",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 375 MG TAB",
            "Registration_Number": "43-334-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250, 125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "375 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 457MG SUSP",
            "Registration_Number": "54-334-01",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80, 11.4",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 625 MG TAB",
            "Registration_Number": "74-334-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500, 125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "625 mg three times for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 625 MG TAB",
            "Registration_Number": "44-334-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500,125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "625 mg three times for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "OXICLAV 625MG F.C.TABLETS",
            "Registration_Number": "23-539-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500, 125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "625 mg three times for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "RAMOCLAV",
            "Registration_Number": "25-295-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "125, 31.25",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "500 mg three times daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "RAMOCLAV",
            "Registration_Number": "26-295-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "250, 62.50",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX ES 600 mg powder for oral suspension",
            "Registration_Number": "228-334-16",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "120, 8.6",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MOXICLAV 1 gm Film Coted Tablet",
            "Registration_Number": "8-718-18",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875, 125",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 1.2GM INJ.",
            "Registration_Number": "226-186-04",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1000, 200mg",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 1.2GM INJ.",
            "Registration_Number": "225-186-04",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1000, 200mg",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 156.25 MG POWDER FOR SUSP",
            "Registration_Number": "118-186-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25, 6.2mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 2X. 1000MG TABLETS",
            "Registration_Number": "240-186-06",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875, 125mg",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 2X. 457MG-5ML ORAL SUSPENSION",
            "Registration_Number": "241-186-06",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80, 11.4mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 375 MG TAB",
            "Registration_Number": "116-186-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250, 125mg",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 600MG INJ.",
            "Registration_Number": "223-186-04",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500, 100mg",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 600MG INJ.",
            "Registration_Number": "224-186-04",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500, 100mg",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 625 MG TAB",
            "Registration_Number": "117-186-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500, 125mg",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN ES SUSPENSION",
            "Registration_Number": "296-186-17",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "120, 8.58mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN FORTE 312.5MG POWDER FOR SUSP",
            "Registration_Number": "119-186-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "1 gm twice daily for upto 14 days",
            "Quantity_Limit_Pediatrics": "for pediatrics maximum  (500/125 mg three times a day for 7-14 days",
            "Notes_1": "PA: the prescriber should confirm the following before prescribing: 1) there is no risk for Ps infection. 2)case is mild with expected susceptible microorganisms."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PIPERACILLIN - TAZOPACTAM SANDOZ 2.25GM VIAL",
            "Registration_Number": "85-116-12",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2, 0.25",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "maximal dose 4.5 g four times a day ,Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Quantity_Limit_Pediatrics": "(maximum per dose 4.5 g four times a day) Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Notes_1": "PA: the prescriber should confirm need for IV therapy as it is First-choice intravenous antibiotics only if Pseudomonas is suspected in a critically ill patient. It is superior to quinolones antibiotic. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PIPERACILLIN - TAZOPACTAM SANDOZ 4.5GM VIAL",
            "Registration_Number": "86-116-12",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\nmaximal dose 4.5 g four times a day ,Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Quantity_Limit_Pediatrics": "(maximum per dose 4.5 g four times a day) Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Notes_1": "PA: the prescriber should confirm need for IV therapy as it is First-choice intravenous antibiotics only if Pseudomonas is suspected in a critically ill patient. It is superior to quinolones antibiotic. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PRIZMA 2GM/0.25GM POWDER FOR I.V. INFUSION",
            "Registration_Number": "138-334-11",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2000, 250",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\nmaximal dose 4.5 g four times a day ,Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Quantity_Limit_Pediatrics": "(maximum per dose 4.5 g four times a day) Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Notes_1": "PA: the prescriber should confirm need for IV therapy as it is First-choice intravenous antibiotics only if Pseudomonas is suspected in a critically ill patient. It is superior to quinolones antibiotic. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PRIZMA 4GM-0.5GM POWDER FOR I.V INFUSION",
            "Registration_Number": "124-334-09",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\nmaximal dose 4.5 g four times a day ,Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Quantity_Limit_Pediatrics": "(maximum per dose 4.5 g four times a day) Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Notes_1": "PA: the prescriber should confirm need for IV therapy as it is First-choice intravenous antibiotics only if Pseudomonas is suspected in a critically ill patient. It is superior to quinolones antibiotic. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "TAZOCIN 2.25G VIAL",
            "Registration_Number": "24-47-94",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2000, 250",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\nmaximal dose 4.5 g four times a day ,Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Quantity_Limit_Pediatrics": "(maximum per dose 4.5 g four times a day) Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Notes_1": "PA: the prescriber should confirm need for IV therapy as it is First-choice intravenous antibiotics only if Pseudomonas is suspected in a critically ill patient. It is superior to quinolones antibiotic. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "TAZOCIN 4.5GM VIAL + EDTA",
            "Registration_Number": "1-497-05",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\nmaximal dose 4.5 g four times a day ,Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Quantity_Limit_Pediatrics": "(maximum per dose 4.5 g four times a day) Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Notes_1": "PA: the prescriber should confirm need for IV therapy as it is First-choice intravenous antibiotics only if Pseudomonas is suspected in a critically ill patient. It is superior to quinolones antibiotic. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "TAZORAX 2.25 GM Powder for injection",
            "Registration_Number": "270-277-13",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2, 0.25",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\nmaximal dose 4.5 g four times a day ,Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Quantity_Limit_Pediatrics": "(maximum per dose 4.5 g four times a day) Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Notes_1": "PA: the prescriber should confirm need for IV therapy as it is First-choice intravenous antibiotics only if Pseudomonas is suspected in a critically ill patient. It is superior to quinolones antibiotic. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "TAZORAX 4.5 GM Powder for injection",
            "Registration_Number": "271-277-13",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\nmaximal dose 4.5 g four times a day ,Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Quantity_Limit_Pediatrics": "(maximum per dose 4.5 g four times a day) Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Notes_1": "PA: the prescriber should confirm need for IV therapy as it is First-choice intravenous antibiotics only if Pseudomonas is suspected in a critically ill patient. It is superior to quinolones antibiotic. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PIPERACILLIN - TAZOPACTAM SANDOZ 4.5GM VIAL",
            "Registration_Number": "103-116-17",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\nmaximal dose 4.5 g four times a day ,Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Quantity_Limit_Pediatrics": "(maximum per dose 4.5 g four times a day) Review intravenous antibiotics by 48 hours a total antibiotic course of 7 to 14 days",
            "Notes_1": "PA: the prescriber should confirm need for IV therapy as it is First-choice intravenous antibiotics only if Pseudomonas is suspected in a critically ill patient. It is superior to quinolones antibiotic. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Beta-lactamase resistant penicillins",
            "Trade_Name": "FLOXAPEN 250MG-5ML POWD.FOR SUSP",
            "Registration_Number": "59-48-90",
            "Active_ingredient": "FLUCLOXACILLIN",
            "ATC_Code": "J01CF05  ",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "flucloxacillin Oral:  500 mg every 6 h  (maximum: 2 g/day) for 14 days . IM/IV: 1 to 6 g/day in 3 to 6 divided doses. In cases of severe infection doses may be increased to 8 g/day in 3 to 4 divided doses (maximum: 2 g/dose [IM]; 12 g/day [IM/IV]).",
            "Quantity_Limit_Pediatrics": "Oral: Children <2 years: 62.5 to 125 mg every 6 hours (maximum: 500 mg/day) Children 2 to 10 years: 125 to 250 mg every 6 hours (maximum: 1 g/day)  Children >10 years: Refer to adult dosing.  IM, IV: Children: 25 to 50 mg/kg/day in 3 to 4 divided doses. In cases of severe infection, dose may be increased to 100 mg/kg/day in 3 to 4 divided doses (maximum single dose: 33 mg/kg).   Adolescents: Refer adult dosing",
            "Notes_1": " PA: Flucloxacillin: should be used for mild cases as first line therapy for treatment of methicillin-sensitive S. aureus (MSSA), and this should be confirmed by the prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Beta-lactamase resistant penicillins",
            "Trade_Name": "FLOXAPEN 500MG CAPS",
            "Registration_Number": "58-48-90",
            "Active_ingredient": "FLUCLOXACILLIN",
            "ATC_Code": "J01CF05  ",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "flucloxacillin Oral:  500 mg every 6 h  (maximum: 2 g/day) for 14 days . IM/IV: 1 to 6 g/day in 3 to 6 divided doses. In cases of severe infection doses may be increased to 8 g/day in 3 to 4 divided doses (maximum: 2 g/dose [IM]; 12 g/day [IM/IV]).",
            "Quantity_Limit_Pediatrics": "Oral: Children <2 years: 62.5 to 125 mg every 6 hours (maximum: 500 mg/day) Children 2 to 10 years: 125 to 250 mg every 6 hours (maximum: 1 g/day)  Children >10 years: Refer to adult dosing.  IM, IV: Children: 25 to 50 mg/kg/day in 3 to 4 divided doses. In cases of severe infection, dose may be increased to 100 mg/kg/day in 3 to 4 divided doses (maximum single dose: 33 mg/kg).   Adolescents: Refer adult dosing",
            "Notes_1": " PA: Flucloxacillin: should be used for mild cases as first line therapy for treatment of methicillin-sensitive S. aureus (MSSA), and this should be confirmed by the prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Beta-lactamase resistant penicillins",
            "Trade_Name": "FLOXAPEN CAPS 250MG",
            "Registration_Number": "28-48-87",
            "Active_ingredient": "FLUCLOXACILLIN",
            "ATC_Code": "J01CF05  ",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "flucloxacillin Oral:  500 mg every 6 h  (maximum: 2 g/day) for 14 days . IM/IV: 1 to 6 g/day in 3 to 6 divided doses. In cases of severe infection doses may be increased to 8 g/day in 3 to 4 divided doses (maximum: 2 g/dose [IM]; 12 g/day [IM/IV]).",
            "Quantity_Limit_Pediatrics": "Oral: Children <2 years: 62.5 to 125 mg every 6 hours (maximum: 500 mg/day) Children 2 to 10 years: 125 to 250 mg every 6 hours (maximum: 1 g/day)  Children >10 years: Refer to adult dosing.  IM, IV: Children: 25 to 50 mg/kg/day in 3 to 4 divided doses. In cases of severe infection, dose may be increased to 100 mg/kg/day in 3 to 4 divided doses (maximum single dose: 33 mg/kg).   Adolescents: Refer adult dosing",
            "Notes_1": " PA: Flucloxacillin: should be used for mild cases as first line therapy for treatment of methicillin-sensitive S. aureus (MSSA), and this should be confirmed by the prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Beta-lactamase resistant penicillins",
            "Trade_Name": "FLOXAPEN SYP 125MG-5ML",
            "Registration_Number": "29-48-87",
            "Active_ingredient": "FLUCLOXACILLIN",
            "ATC_Code": "J01CF05  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "flucloxacillin Oral:  500 mg every 6 h  (maximum: 2 g/day) for 14 days . IM/IV: 1 to 6 g/day in 3 to 6 divided doses. In cases of severe infection doses may be increased to 8 g/day in 3 to 4 divided doses (maximum: 2 g/dose [IM]; 12 g/day [IM/IV]).",
            "Quantity_Limit_Pediatrics": "Oral: Children <2 years: 62.5 to 125 mg every 6 hours (maximum: 500 mg/day) Children 2 to 10 years: 125 to 250 mg every 6 hours (maximum: 1 g/day)  Children >10 years: Refer to adult dosing.  IM, IV: Children: 25 to 50 mg/kg/day in 3 to 4 divided doses. In cases of severe infection, dose may be increased to 100 mg/kg/day in 3 to 4 divided doses (maximum single dose: 33 mg/kg).   Adolescents: Refer adult dosing",
            "Notes_1": " PA: Flucloxacillin: should be used for mild cases as first line therapy for treatment of methicillin-sensitive S. aureus (MSSA), and this should be confirmed by the prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Beta-lactamase resistant penicillins",
            "Trade_Name": "FLOXAPEN VIAL 250MG",
            "Registration_Number": "30-48-80",
            "Active_ingredient": "FLUCLOXACILLIN",
            "ATC_Code": "J01CF05  ",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "250",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "flucloxacillin Oral:  500 mg every 6 h  (maximum: 2 g/day) for 14 days . IM/IV: 1 to 6 g/day in 3 to 6 divided doses. In cases of severe infection doses may be increased to 8 g/day in 3 to 4 divided doses (maximum: 2 g/dose [IM]; 12 g/day [IM/IV]).",
            "Quantity_Limit_Pediatrics": "Oral: Children <2 years: 62.5 to 125 mg every 6 hours (maximum: 500 mg/day) Children 2 to 10 years: 125 to 250 mg every 6 hours (maximum: 1 g/day)  Children >10 years: Refer to adult dosing.  IM, IV: Children: 25 to 50 mg/kg/day in 3 to 4 divided doses. In cases of severe infection, dose may be increased to 100 mg/kg/day in 3 to 4 divided doses (maximum single dose: 33 mg/kg).   Adolescents: Refer adult dosing",
            "Notes_1": " PA: Flucloxacillin: should be used for mild cases as first line therapy for treatment of methicillin-sensitive S. aureus (MSSA), and this should be confirmed by the prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIDAR",
            "Registration_Number": "73-124-06",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIDAR 500 mg film-coated tablet",
            "Registration_Number": "72-124-06",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIDAR",
            "Registration_Number": "81-124-08",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIMAC 500 mg film-coated tablet",
            "Registration_Number": "170-325-05",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT 125 MG - 5 ML SUSPENSION",
            "Registration_Number": "149-277-03",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT 250 MG - 5 ML SUSPENSION",
            "Registration_Number": "150-277-03",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT 250 MG FILM COATED",
            "Registration_Number": "131-277-02",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT 500 MG FILM COATED TAB",
            "Registration_Number": "132-277-02",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT XL 500 MG EXTENDED RELEASE TAB.",
            "Registration_Number": "164-277-05",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Modified-release tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT XL 500MG EXTENDED RELEASE TABLETS",
            "Registration_Number": "216-277-11",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIVA 250 MG TABLET",
            "Registration_Number": "32-498-11",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "EMIMYCIN 500 MG TABLETS",
            "Registration_Number": "30-444-08",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERACID 250MG TABLET",
            "Registration_Number": "45-171-04",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERACID 500MG FILM COATED TABLETS",
            "Registration_Number": "69-171-10",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID 125MG-5ML SUSP",
            "Registration_Number": "2-139-94",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID 250MG TAB",
            "Registration_Number": "1-139-93",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID 500MG COATED TAB",
            "Registration_Number": "9-138-99",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID XL 500MG TAB",
            "Registration_Number": "10-138-01",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID XL 500MG TAB",
            "Registration_Number": "13-138-04",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLARIMID 250MG F.C. TABLETS",
            "Registration_Number": "26-346-09",
            "Active_ingredient": "CLARITHROMYCIN ",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLARIMID 250MG-5ML SUSPENSION",
            "Registration_Number": "25-346-08",
            "Active_ingredient": "CLARITHROMYCIN ",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLARIMID 500MG F.C. TABLETS",
            "Registration_Number": "27-346-09",
            "Active_ingredient": "CLARITHROMYCIN ",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "RESCLAR 500MG TABLETS",
            "Registration_Number": "12-584-10",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLARE 500 mg film-coated tablet",
            "Registration_Number": "45-437-16",
            "Active_ingredient": "CLARITHROMYCIN ",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIDAR XL 500 mg Tablet",
            "Registration_Number": "109-124-18",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Sustain release Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year",
            "Notes_2": "Macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of TORSADES de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, brady-arrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLAMYCIN 250 MG TABLET",
            "Registration_Number": "168-186-02",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "     PA",
            "Quantity_Limit_Adults": "\r\n500 mg twice a day for 7 -14 days",
            "Quantity_Limit_Pediatrics": "for  pediatrics maximal  dose 500 mg twice a day for 7-14 days",
            "Notes_1": "PA: Clarithromycin:  used for adult and pediatric patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber,  also in long term prophylaxis is indicated for patient who have three or more exacerbations per year"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTUM 1 g",
            "Registration_Number": "43-276-97",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks .",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTUM 1 g Powder for injection",
            "Registration_Number": "42-276-97",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks ",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTUM 2 g",
            "Registration_Number": "44-276-97",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks ",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTUM 2 g",
            "Registration_Number": "45-276-97",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks ",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTUM 500 mg",
            "Registration_Number": "40-276-97",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks ",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTUM 500 mg",
            "Registration_Number": "41-276-97",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks ",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PARZIDIME 1 GM POWDER FOR SOLUTION FOR Injection*",
            "Registration_Number": "82-116-10",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks ",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ZIDIME 1GM GLASS VIAL IV-IM",
            "Registration_Number": "59-277-99",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks ",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ZIDIME 2GM I.V INJ",
            "Registration_Number": "61-277-99",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks ",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FORTA-Z 1 g powder for solution for injection",
            "Registration_Number": "235-334-16",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Parenteral",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks ",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "NEGACEF 0.5 g INJ.",
            "Registration_Number": "134-186-01",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks ",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "NEGACEF 1GM VIAL",
            "Registration_Number": "133-186-01",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks ",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "NEGACEF 2GM Injection*",
            "Registration_Number": "277-186-10",
            "Active_ingredient": "CEFTAZIDIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2g",
            "G_or_B": "G",
            "Prescribing_edits": "  PA-CU     ",
            "Quantity_Limit_Adults": "IV: Usual dose: 2 g every  8 hours or 150 mg/kg/day divided  8 hours for 7-14 days for severe infections up to 3wks ",
            "Quantity_Limit_Pediatrics": "Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every   8 hours , maximum daily dose: 6 g/day",
            "Notes_1": "CU: Dual therapy, beta-lactam plus a quinolone or aminoglycosides PA: This Combination is controversial and is routinely not recommended, unless the patient has fluoroquinolones resistant Pseudomonas and is critically ill then will be used and this should be documented by prescriber."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "BACTALL 250MG TABLET",
            "Registration_Number": "43-171-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "BACTALL 500MG TABLET",
            "Registration_Number": "44-171-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIFLOX 200MG-100ML I.V. INFUSION",
            "Registration_Number": "115-334-09",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Parenteral",
            "Strength": "200",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIFLOX 200MG-100ML I.V. INFUSION",
            "Registration_Number": "100-334-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Parenteral",
            "Strength": "200",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIFLOX 250MG TABLET",
            "Registration_Number": "37-352-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIFLOX 500MG TABLET",
            "Registration_Number": "38-352-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROBAY 200 mg solution for infusion",
            "Registration_Number": "26-4-91",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "200",
            "G_or_B": "B",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROBAY 250MG TAB",
            "Registration_Number": "22-4-91",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROBAY 500MG TAB",
            "Registration_Number": "23-4-91",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROBAY 750MG TAB",
            "Registration_Number": "24-4-91",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "B",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROCIN 250MG TAB",
            "Registration_Number": "25-201-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROCIN 500MG TAB",
            "Registration_Number": "26-201-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPRODAR 500",
            "Registration_Number": "63-124-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLACIN 250 MG FILM COATED TABLETS",
            "Registration_Number": "16-295-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLACIN 500 MG FILM COATED TABLETS",
            "Registration_Number": "17-295-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLACIN 750 MG FILM COATED TABLETS",
            "Registration_Number": "18-295-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLOX 250MG TAB",
            "Registration_Number": "104-119-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLOX 500MG TAB",
            "Registration_Number": "105-119-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLOX 750MG TAB",
            "Registration_Number": "106-119-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROFLOXACIN 0.2% IN 0.9% SODIUM CHLORIDE INJECTION",
            "Registration_Number": "76-803-12",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "200",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROGEN",
            "Registration_Number": "98-325-03",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROHEXAL 250MG F.C. TABLETS",
            "Registration_Number": "17-349-10",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROHEXAL 500MG F.C. TABLETS",
            "Registration_Number": "18-349-10",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROLET 250MG F.C. TABLETS",
            "Registration_Number": "2-453-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROLET 500MG F.C. TABLETS",
            "Registration_Number": "1-453-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROLON 200 VIAL 100ML",
            "Registration_Number": "128-172-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "200",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROLON 500MG F.C. TABLETS",
            "Registration_Number": "157-172-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROLON 750MG F.C. TABLETS",
            "Registration_Number": "156-172-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROMAX 250 MG TABLET",
            "Registration_Number": "121-212-00",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROMAX 500 MG TABLET",
            "Registration_Number": "122-212-00",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROMAX 750MG TAB",
            "Registration_Number": "160-212-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROMID 250MG F-C TABLET",
            "Registration_Number": "18-346-05",
            "Active_ingredient": "CIPROFLOXACIN ",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROMID 500MG F-C TABLET",
            "Registration_Number": "17-346-05",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROMID 750MG F.C. TABLETS",
            "Registration_Number": "21-346-07",
            "Active_ingredient": "CIPROFLOXACIN ",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROQUIN",
            "Registration_Number": "3-371-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROQUIN",
            "Registration_Number": "4-371-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPRO-SOL I.V Infusion",
            "Registration_Number": "286-149-04",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Infusion",
            "ROA": "Parenteral",
            "Strength": "200",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROXEN 250MG FILM COATED TABLET",
            "Registration_Number": "32-368-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROXEN 500MG FILM COATED TABLET",
            "Registration_Number": "33-368-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROXEN 750MG FILM COATED TABLET",
            "Registration_Number": "34-368-02",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EMICIPRO 500MG F.C. TABLETS",
            "Registration_Number": "27-444-07",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "NEOCIPRO 500MG F.C. TABLETS",
            "Registration_Number": "9-584-09",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "OMACIP 250MG TABLETS",
            "Registration_Number": "22-390-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "OMACIP 500MG TABLETS",
            "Registration_Number": "21-390-06",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "QUINOX 250 MG F- C TAB.",
            "Registration_Number": "79-277-00",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "QUINOX 500 MG TAB.",
            "Registration_Number": "80-277-00",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "QUINOX 750MG F- C TABLET",
            "Registration_Number": "172-277-05",
            "Active_ingredient": "CIPROFLOXACIN HYDROCHLORIDE",
            "ATC_Code": "J01MA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "QUINOX 200 mg solution for infusion",
            "Registration_Number": "299-277-16",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROGRAM 250 mg film-coated tablet",
            "Registration_Number": "33-437-16",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROGRAM 500 mg film-coated tablet",
            "Registration_Number": "34-437-16",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPROGRAM 750 mg film-coated tablet",
            "Registration_Number": "35-437-16",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIPRO-SOL  2 MG/ML I.V. INFUSION SOLUTION",
            "Registration_Number": "468-149-18",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Intravenous infusion ",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TOPISTIN 2MG/ML SOL. FOR I.V INFUSION",
            "Registration_Number": "1-904-19",
            "Active_ingredient": "CIPROFLOXACIN ",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for infusion ",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIFOGRU 2MG/ML VIAL",
            "Registration_Number": "24-5286-19",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for infusion ",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "CIFOGRU 2MG/ML VIAL",
            "Registration_Number": "23-5286-19",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Solution for infusion ",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "QUREX XL 1000 mg film-coated tablet",
            "Registration_Number": "119-124-19",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "1000",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "SARF 250MG TAB",
            "Registration_Number": "144-186-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "SARF 500MG TAB",
            "Registration_Number": "145-186-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "SARF 750MG TAB.",
            "Registration_Number": "146-186-01",
            "Active_ingredient": "CIPROFLOXACIN",
            "ATC_Code": "J01MA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "750mg",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral :500 mg or 750 mg twice a day for 7 days then review all treatment course for 7-14 days, maximal daily dose 1500mg/day ,  for IV , ciprofloxacin 400 mg twice times or three times a day for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 to 11 years, 10-15 mg/kg two times a day (maximum 500 per dose) 12 to 17 years, 500-750 mg twice a day",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOFLOX 500MG F.C. TABLET",
            "Registration_Number": "37-390-12",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug ,",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LAVOXIN 500 mg solution for infusion",
            "Registration_Number": "310-277-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 5 mg/ml Infusion",
            "Registration_Number": "249-334-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 5 mg/ml Infusion",
            "Registration_Number": "250-334-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVODIS 5 mg/ml Solution For Injection",
            "Registration_Number": "6-560-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LOXAMOX 250MG/50ML SOL. FOR IV INFUSION",
            "Registration_Number": "17-5286-19",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION FOR INFUSION",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LOXAMOX 500MG/100ML SOL. FOR INFUSION",
            "Registration_Number": "18-5286-19",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION FOR INFUSION",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 500MG-100ML SOLUTION FOR I.V. INFUSION",
            "Registration_Number": "135-334-10",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "5",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVANIC 5 MG -1 ML SOLUTION I.V INFUSION",
            "Registration_Number": "46-23-03",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "5",
            "G_or_B": "B",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 500MG FILM COATED TABLETS",
            "Registration_Number": "162-334-12",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOX 500MG FILM COATED TABLET",
            "Registration_Number": "273-212-11",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOX 750MG FILM COATED TABLET",
            "Registration_Number": "274-212-11",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVANIC 250MG F.C TAB",
            "Registration_Number": "43-23-02",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVANIC 500MG F.C TAB",
            "Registration_Number": "44-23-02",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOFLOXACIN Sandoz 500 mg film-coated tablet",
            "Registration_Number": "96-116-15",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVACIN 500 mg film-coated tablet",
            "Registration_Number": "78-539-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVACIN 750 mg film-coated tablet",
            "Registration_Number": "79-539-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVAQUIN 250 mg film-coated tablet",
            "Registration_Number": "67-370-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVAQUIN 500 mg film-coated tablet",
            "Registration_Number": "68-370-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVON 500 mg film-coated tablet",
            "Registration_Number": "18-968-16",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVON 750 mg film-coated tablet",
            "Registration_Number": "19-968-16",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 250 mg film-coated tablet",
            "Registration_Number": "238-334-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 750 mg film-coated tablet",
            "Registration_Number": "239-334-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "PRINCEOXIN 500 mg film-coated tablet",
            "Registration_Number": "32-249-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "PRINCEOXIN 250 mg film-coated tablet",
            "Registration_Number": "31-249-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVFLOX 500 mg film-coated tablet",
            "Registration_Number": "48-437-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVANIX 500 mg film-coated tablet",
            "Registration_Number": "13-584-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVANIX 500 mg film-coated tablet",
            "Registration_Number": "14-584-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EVOX 250MG FILM COATED TABLET",
            "Registration_Number": "18-535-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EVOX 500MG FILM COATED TABLET",
            "Registration_Number": "19-535-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EVOX 750MG FILM COATED TABLET",
            "Registration_Number": "20-535-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LIVADOR 750MG F.C.TABLET",
            "Registration_Number": "117-124-18",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet  ",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LIVADOR 250 MG FILM COATED TABLET",
            "Registration_Number": "121-124-19",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LIVADOR 500 MG FILM COATED TABLET",
            "Registration_Number": "120-124-19",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOBAT 500 MG FILM COATED TABLET",
            "Registration_Number": "30-590-19",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "FLOXMED 500MG F.C.TABLET",
            "Registration_Number": "16-631-19",
            "Active_ingredient": "LEVOFLOXACIN (AS HEMIHYDRATE)",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "FILM COATED TABLET",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EMIFLOC 500 mg Film-coated Tablet",
            "Registration_Number": "42-444-19",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "  PA     ",
            "Quantity_Limit_Adults": "oral : 500 mg or 750 mg once a day for 7 days then review total for7-14 days treatment , for IV 500-750 mg once  a day ",
            "Quantity_Limit_Pediatrics": "for pediatrics ciprofloxacin is the prefered drug",
            "Notes_1": "PA: the prescriber should prescribe the drug as following:\r\n•Monotherapy: for stable patients If the suspicion of Pseudomonas is high \r\n•In combination with beta-lactam: for critically ill patient with resistant Pseudomonas infection ",
            "Notes_2": " Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against P. aeruginosa. Ciprofloxacin should be dosed 750 mg orally every 12 hours and levofloxacin 750 mg orally once daily."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "APO-DOXY 100MG CAPS",
            "Registration_Number": "1-249-97",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": " PA-AGE",
            "Quantity_Limit_Adults": "100 mg twice a day with or without loading dose 200 mg for total treatment for 7-14 days for adult",
            "Quantity_Limit_Pediatrics": "not prefered for pediatric less than 12  and years of age ,  and not recommended by guideline for pediatric patients only for adult patients",
            "Notes_1": "PA: Doxycycline for adult and pediatric >12 years of age patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber\r\nAGE: Doxycycline should not be prescribed for children < 12 years of age ",
            "Notes_2": " only to be used in mild cases and for susceptible microorganisms, contraindicated for pregnant and lactating mothers"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DORYX CAPS 100MG",
            "Registration_Number": "1-217-92",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": " PA-AGE",
            "Quantity_Limit_Adults": "101 mg twice a day with or without loading dose 200 mg for total treatment for 7-14 days for adult",
            "Quantity_Limit_Pediatrics": "not prefered for pediatric less than 12  and years of age ,  and not recommended by guideline for pediatric patients only for adult patients",
            "Notes_1": "PA: Doxycycline for adult and pediatric >12 years of age patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber\r\nAGE: Doxycycline should not be prescribed for children < 12 years of age ",
            "Notes_2": " only to be used in mild cases and for susceptible microorganisms, contraindicated for pregnant and lactating mothers"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DOXYCIN",
            "Registration_Number": "122-325-04",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": " PA-AGE",
            "Quantity_Limit_Adults": "102 mg twice a day with or without loading dose 200 mg for total treatment for 7-14 days for adult",
            "Quantity_Limit_Pediatrics": "not prefered for pediatric less than 12  and years of age ,  and not recommended by guideline for pediatric patients only for adult patients",
            "Notes_1": "PA: Doxycycline for adult and pediatric >12 years of age patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber\r\nAGE: Doxycycline should not be prescribed for children < 12 years of age ",
            "Notes_2": " only to be used in mild cases and for susceptible microorganisms, contraindicated for pregnant and lactating mothers"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DOXYDAR",
            "Registration_Number": "19-124-96",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": " PA-AGE",
            "Quantity_Limit_Adults": "103 mg twice a day with or without loading dose 200 mg for total treatment for 7-14 days for adult",
            "Quantity_Limit_Pediatrics": "not prefered for pediatric less than 12  and years of age ,  and not recommended by guideline for pediatric patients only for adult patients",
            "Notes_1": "PA: Doxycycline for adult and pediatric >12 years of age patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber\r\nAGE: Doxycycline should not be prescribed for children < 12 years of age ",
            "Notes_2": " only to be used in mild cases and for susceptible microorganisms, contraindicated for pregnant and lactating mothers"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DUMOXIN SYRUP 10MG-ML",
            "Registration_Number": "50-49-81",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "10",
            "G_or_B": "G",
            "Prescribing_edits": " PA-AGE",
            "Quantity_Limit_Adults": "104 mg twice a day with or without loading dose 200 mg for total treatment for 7-14 days for adult",
            "Quantity_Limit_Pediatrics": "not prefered for pediatric less than 12  and years of age ,  and not recommended by guideline for pediatric patients only for adult patients",
            "Notes_1": "PA: Doxycycline for adult and pediatric >12 years of age patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber\r\nAGE: Doxycycline should not be prescribed for children < 12 years of age ",
            "Notes_2": " only to be used in mild cases and for susceptible microorganisms, contraindicated for pregnant and lactating mothers"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DUMOXIN TAB 100 MG",
            "Registration_Number": "49-49-81",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": " PA-AGE",
            "Quantity_Limit_Adults": "105 mg twice a day with or without loading dose 200 mg for total treatment for 7-14 days for adult",
            "Quantity_Limit_Pediatrics": "not prefered for pediatric less than 12  and years of age ,  and not recommended by guideline for pediatric patients only for adult patients",
            "Notes_1": "PA: Doxycycline for adult and pediatric >12 years of age patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber\r\nAGE: Doxycycline should not be prescribed for children < 12 years of age ",
            "Notes_2": " only to be used in mild cases and for susceptible microorganisms, contraindicated for pregnant and lactating mothers"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "TABOCINE 100",
            "Registration_Number": "14-277-97",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule, hard",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": " PA-AGE",
            "Quantity_Limit_Adults": "106 mg twice a day with or without loading dose 200 mg for total treatment for 7-14 days for adult",
            "Quantity_Limit_Pediatrics": "not prefered for pediatric less than 12  and years of age ,  and not recommended by guideline for pediatric patients only for adult patients",
            "Notes_1": "PA: Doxycycline for adult and pediatric >12 years of age patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber\r\nAGE: Doxycycline should not be prescribed for children < 12 years of age ",
            "Notes_2": " only to be used in mild cases and for susceptible microorganisms, contraindicated for pregnant and lactating mothers"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "VIBRAMYCIN 100MG TABLET",
            "Registration_Number": "1-5029-18",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "B",
            "Prescribing_edits": " PA-AGE",
            "Quantity_Limit_Adults": "107 mg twice a day with or without loading dose 200 mg for total treatment for 7-14 days for adult",
            "Quantity_Limit_Pediatrics": "not prefered for pediatric less than 12  and years of age ,  and not recommended by guideline for pediatric patients only for adult patients",
            "Notes_1": "PA: Doxycycline for adult and pediatric >12 years of age patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber\r\nAGE: Doxycycline should not be prescribed for children < 12 years of age ",
            "Notes_2": " only to be used in mild cases and for susceptible microorganisms, contraindicated for pregnant and lactating mothers"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DURADOX 100 MG CAPS",
            "Registration_Number": "109-186-99",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": " PA-AGE",
            "Quantity_Limit_Adults": "107 mg twice a day with or without loading dose 200 mg for total treatment for 7-14 days for adult",
            "Quantity_Limit_Pediatrics": "not prefered for pediatric less than 12  and years of age ,  and not recommended by guideline for pediatric patients only for adult patients",
            "Notes_1": "PA: Doxycycline for adult and pediatric >12 years of age patients recommended only in mild cases for susceptible microorganisms and if they are allergic to penicillin and this should be documented by prescriber\r\nAGE: Doxycycline should not be prescribed for children < 12 years of age ",
            "Notes_2": " only to be used in mild cases and for susceptible microorganisms, contraindicated for pregnant and lactating mothers"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAXON 1GM I.M+5 ML LIDOCAINE VIAL",
            "Registration_Number": "93-334-04",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAXON 1GM I.V VIAL",
            "Registration_Number": "94-334-04",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAXON 500 MG I.M+5 ML LIDOCAINE VIAL",
            "Registration_Number": "91-334-04",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAXON 500 MG I.V VIAL",
            "Registration_Number": "92-334-04",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MEGION 0.25GM I.V - I.M INJECTION",
            "Registration_Number": "70-116-07",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MEGION 0.5GM I.V INJECTION",
            "Registration_Number": "71-116-07",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MEGION 1GM I.V - I.M INJECTION",
            "Registration_Number": "72-116-07",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MEGION 2GM POW. FOR SOLU. FOR INJ OR INF",
            "Registration_Number": "76-116-08",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MESPORIN 1000 I.M.",
            "Registration_Number": "13-222-05",
            "Active_ingredient": "CEFTRIAXONE, LIDOCAINE",
            "ATC_Code": "J01DD54  ",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MESPORIN 1000 I.V.",
            "Registration_Number": "14-222-05",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MESPORIN 2000 I.V.",
            "Registration_Number": "12-222-05",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MESPORIN 500 I.M.",
            "Registration_Number": "16-222-05",
            "Active_ingredient": "CEFTRIAXONE, LIDOCAINE",
            "ATC_Code": "J01DD54  ",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "MESPORIN 500 I.V.",
            "Registration_Number": "15-222-05",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ROCEPHIN 1GM i.m. + 3.5 ML SOLVENT",
            "Registration_Number": "249-24-03",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "B",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ROCEPHIN 1GM i.v. + 10 ML SOLVENT",
            "Registration_Number": "248-24-03",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "B",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ROCEPHIN 500MG i.m. + 2 ML SOLVENT",
            "Registration_Number": "247-24-03",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ROXCEF 250MG I.M INJECTION",
            "Registration_Number": "97-119-00",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ROXCEF 250MG I.V INJECTION",
            "Registration_Number": "98-119-00",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "SAMIXON 1GM VIAL",
            "Registration_Number": "119-172-98",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "SAMIXON 1GM VIAL + SOLVENT",
            "Registration_Number": "122-172-99",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "SAMIXON 500MG VIAL",
            "Registration_Number": "120-172-98",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "SAMIXON 500MG VIAL + SOLVENT",
            "Registration_Number": "121-172-99",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "TRIAXONE 0.5G I.M VIAL+5ML SOLV.LIDOCAIN",
            "Registration_Number": "43-277-98",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "TRIAXONE 1GM VIAL I.M+5ML SOLV.LIDOCAINE",
            "Registration_Number": "45-277-98",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "TRIAXONE 500MG VIAL I.V+5MLWATER FOR INJ",
            "Registration_Number": "44-277-98",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "TRIAXONE1GM VIAL I.V +10ML WATER FOR INJ",
            "Registration_Number": "46-277-98",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PROTEDEX 500 mg powder for solution for injection",
            "Registration_Number": "31-432-15",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PROTEDEX 1 g powder for solution for injection",
            "Registration_Number": "32-432-15",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PROTEDEX 2 g powder for solution for injection",
            "Registration_Number": "33-432-15",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous",
            "Strength": "2",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAJECT 500 mg IV",
            "Registration_Number": "3-666-16",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAJECT 1 g IV",
            "Registration_Number": "4-666-16",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intravenous",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAJECT 500 mg IM",
            "Registration_Number": "5-666-16",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intramuscular",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CEFAJECT 1 g IM",
            "Registration_Number": "6-666-16",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Intramuscular",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ROXONE 1 gm Powder for Solution for Injection",
            "Registration_Number": "9-718-18",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder and solvent for solution for injection/infusion",
            "ROA": "Intramuscular,Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 0.25GM I.M. VIAL + SOLVENT",
            "Registration_Number": "132-186-01",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 0.25GM I.V. VIAL + SOLVENT",
            "Registration_Number": "131-186-01",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 0.25GM I.V. VIAL + SOLVENT",
            "Registration_Number": "196-186-03",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 1GM I.M. VIAL + SOLVENT",
            "Registration_Number": "130-186-01",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 1GM I.V. VIAL + SOLVENT",
            "Registration_Number": "129-186-01",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 1GM I.V. VIAL + SOLVENT",
            "Registration_Number": "197-186-03",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 500MG I.M. VIAL + SOLVENT",
            "Registration_Number": "187-186-02",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intramuscular",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 500MG I.V. VIAL + SOLVENT",
            "Registration_Number": "186-186-02",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "ENOXIRT 500MG I.V. VIAL + SOLVENT",
            "Registration_Number": "199-186-03",
            "Active_ingredient": "CEFTRIAXONE",
            "ATC_Code": "J01DD04",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "1-2 g daily for 7-14 days",
            "Quantity_Limit_Pediatrics": "1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)\r\n9 to 11 years (50 kg and above), 1 to 2 g once a day 12 to 17 years,1 to 2 g once a day",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "CLAFORAN 500 MG I.M.-I.V.VIALS",
            "Registration_Number": "7-37-84",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500mg",
            "G_or_B": "B",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "Recommended by The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FOXIME 1GM VIAL+5ML SOLVENT LIDOCAINE IM",
            "Registration_Number": "41-277-98",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD02",
            "Dosage_Form": "Injection*",
            "ROA": "Intramuscular",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "Recommended by The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FOXIME 1GM VIAL+5ML WATER FOR INJ IV USE",
            "Registration_Number": "40-277-98",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "Recommended by The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "FOXIME 500MG VIAL+AMP OF WATER IM-IV USE",
            "Registration_Number": "39-277-98",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "Recommended by The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "TOTAM 1GM IV\\IM INJECTION",
            "Registration_Number": "90-334-04",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "Recommended by The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PRIMOCEF 0.5 GM I.M- I.V VIAL",
            "Registration_Number": "151-186-01",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intramuscular,Intravenous (not otherwise specified)",
            "Strength": "500mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "Recommended by The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PRIMOCEF 1 g Powder for injection",
            "Registration_Number": "153-186-01",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intramuscular",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "Recommended by The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER BETA-LACTAM ANTIBACTERIALS",
            "Drug_Sub_Class": "Third-generation cephalosporins",
            "Trade_Name": "PRIMOCEF 1 GM I.V VIAL",
            "Registration_Number": "152-186-01",
            "Active_ingredient": "CEFOTAXIME",
            "ATC_Code": "J01DD01",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1g",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "Recommended by The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis",
            "Notes_1": "PA: Ceftriaxone-Cefotaxime\r\n If beta-lactamase-producing H. influenzae or M. catarrhalis is isolated or suspected, beta-lactamase inhibitors such as clavulanate should be concurrently administered with amoxicillin, Alternatively, a third-generation cephalosporin (ceftriaxone-cefotaxime) can be used, and this should be documented by the prescriber"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZIMAX 500MG F.C. TABLETS",
            "Registration_Number": "4-809-14",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Tablets",
            "ROA": "oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZIMAC 500 MG",
            "Registration_Number": "187-325-07",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Tablets",
            "ROA": "oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZEROX 500MG F.C. TABLETS",
            "Registration_Number": "162-172-08",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Tablets",
            "ROA": "oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZEROX 500MG F.C. TABLETS",
            "Registration_Number": "162-172-08",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Tablets",
            "ROA": "oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZYN 500 MG FILM COATED TABLET",
            "Registration_Number": "3-5088-18",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Tablets",
            "ROA": "oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZIFORTE 500MG F.C.TABLET",
            "Registration_Number": "183-368-18",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Tablets",
            "ROA": "oral",
            "Strength": "500 mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZOMYCIN 200MG\\5ML SUSP.",
            "Registration_Number": "191-186-03",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZETRON 200MG\\5ML POWDER FOR SUSP",
            "Registration_Number": "147-277-03",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZI-ONCE",
            "Registration_Number": "39-368-02",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZETRON 200MG\\5ML POWDER FOR SUSP",
            "Registration_Number": "147-277-03",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZIMAX 200MG\\5ML SUSP",
            "Registration_Number": "170-212-02",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZI-ONCE",
            "Registration_Number": "39-368-02",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZIMAX 200MG\\5ML SUSP",
            "Registration_Number": "170-212-02",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZI-ONCE",
            "Registration_Number": "39-368-02",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZOCIN 300MG/7.5ML SUSPENSION",
            "Registration_Number": "17-347-07",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZIMAX 200MG\\5ML SUSP",
            "Registration_Number": "170-212-02",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZITHROMAX 200MG-5ML SUSP.AFTER RECONSTIT",
            "Registration_Number": "11-892-13",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "B",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZOCIN 200MG-5ML POW. FOR ORAL SUSPENSION",
            "Registration_Number": "16-347-07",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZOMYNE 200MG\\5ML POWDER FOR ORAL SUSP",
            "Registration_Number": "21-371-11",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZEROX 200MG-5ML POWDER FOR ORAL SUSP.",
            "Registration_Number": "167-172-09",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Suspension",
            "ROA": "oral",
            "Strength": "200mg/5ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZIMAC 250 MG",
            "Registration_Number": "186-325-07",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Tablet",
            "ROA": "oral",
            "Strength": "250 mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZIMAX 250MG F.C. TABLETS",
            "Registration_Number": "3-809-14",
            "Active_ingredient": "Azithromycin",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Tablet",
            "ROA": "oral",
            "Strength": "251 mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZOMYCIN 200MG\\5ML SUSP.",
            "Registration_Number": "191-186-03",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZOMYCIN 200MG\\5ML SUSP.",
            "Registration_Number": "192-186-03",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "500 mg 3 times weekly  or 250 mg once daily. duration of treatment varied from 6 to 52 weeks. (off-label use)",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Oral: 18 to 35.9 kg: 250 mg three times weekly , ≥36 kg: 500 mg three times weekly, In children, the duration of therapy 12–24 months",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. ",
            "Notes_2": "Saudi guideline recommended for adults :Long term Oral Antibiotic Treatments the duration of treatment varied from 6 to 52 weeks; azithromycin 250–500 mg 2–3/times/week this is seem to be more accepted As adverse event frequency of azithromycin is likely to be dose related, 250mg 3 x/week is a pragmatic starting dose which can then be increased according to clinical response and adverse events."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYC 250MG CAPS",
            "Registration_Number": "2-217-93",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "400 mg once or twice daily for one year",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHRODAR",
            "Registration_Number": "16-124-85",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Gastro-resistant tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "400 mg once or twice daily for one year",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHRODAR 400MG FORT TAB",
            "Registration_Number": "17-124-96",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "400 mg once or twice daily for one year",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "OMATHROCIN 250 MG TABLET",
            "Registration_Number": "19-390-06",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "400 mg once or twice daily for one year",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "EROMYCIN 200MG-5ML SUSP",
            "Registration_Number": "101-186-99",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "400 mg once or twice daily for one year",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "OMATHROCIN ORAL DROPS 100 MG- 2.5 ML",
            "Registration_Number": "18-390-06",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "SOLUTION/ DROPS",
            "ROA": "ORAL",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "400 mg once or twice daily for one year",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHROMIL 200MG-5ML SUSP.",
            "Registration_Number": "61-119-89",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "SUSPENSION",
            "ROA": "ORAL",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "400 mg once or twice daily for one year",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHROMIL FORTE 400MG-5MLSUSP.",
            "Registration_Number": "62-119-89",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "SUSPENSION",
            "ROA": "ORAL",
            "Strength": "80mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "400 mg once or twice daily for one year",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "OMATHROCIN 200 ORAL SUSPENSION",
            "Registration_Number": "25-390-08",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "SUSPENSION",
            "ROA": "ORAL",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "400 mg once or twice daily for one year",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "RYTHINATE SUSP. 200MG-5ML",
            "Registration_Number": "25-172-88",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "SUSPENSION",
            "ROA": "ORAL",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "400 mg once or twice daily for one year",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "EROMYCIN 200MG-5ML SUSP",
            "Registration_Number": "101-186-99",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "400 mg once or twice daily for one year",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "EROMYCIN 250MG TABLET",
            "Registration_Number": "216-186-04",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250mg",
            "G_or_B": "G",
            "Prescribing_edits": "    PA  ",
            "Quantity_Limit_Adults": "400 mg once or twice daily for one year",
            "Notes_1": "PA:The prescriber should confirm the need for Long term Oral Antibiotic Treatments. Long term AB will be suitable for the following patients:\r\n•moderate to severe bronchiectasis with ≥3 exacerbations in the previous year \r\n•in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible, or in addition to or in place of an inhaled antibiotic, or \r\n•who have a high exacerbation frequency despite taking an inhaled antibiotic and not infected with P. aeruginosa \r\nthe prescriber should also check the following results before prescribing: \r\n•sputum culture should be obtained to exclude MAC\r\n•An ECG in adults to rule out prolonged QT prior to starting long term macrolides\r\n•electrolytes level checked (specifically calcium, potassium, and magnesium) for patient at high risk of electrolyte disturbance. "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment-Airway Clearance",
            "ICD_Code": "J47",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "BISOLVON 8MG TABLETS",
            "Registration_Number": "52-68-87",
            "Active_ingredient": "BROMHEXINE",
            "ATC_Code": "R05CB02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "8mg",
            "G_or_B": "B",
            "Prescribing_edits": " CU",
            "Quantity_Limit_Adults": "Inhalation: Solution for nebulization  8 mg twice daily\r\nOral: Initial: 8 to 16 mg 3 times daily as needed for the first 7 days, then 8 mg 3 times daily as needed ",
            "Quantity_Limit_Pediatrics": "oral: Children 2 to <6 years: (maximal 8mg/day)  .Children 6 to <12 years:  (maximum: 24 mg/day).Children ≥12 years and Adolescents: (maximum: 48 mg/day). Inhalation: Solution for nebulization (2 mg/mL):Children 2 to <6 years: 1.3 mg twice daily.  Children 6 to <12 years: 2 mg twice dailyChildren ≥12 years and Adolescents: 4 mg twice daily.",
            "Notes_1": "CU: Bromhexine\r\nBromhexine as mucolytics in bronchiectasis should be used with antibiotics, to help in sputum production and clearance, not to be used as monotherapy"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment-Airway Clearance",
            "ICD_Code": "J47",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "BISOLVON ELIXIR 4MG-5ML",
            "Registration_Number": "46-68-84",
            "Active_ingredient": "BROMHEXINE",
            "ATC_Code": "R05CB02",
            "Dosage_Form": "Oral solution",
            "ROA": "Oral",
            "Strength": "0.8mg/ml",
            "G_or_B": "B",
            "Prescribing_edits": " CU",
            "Quantity_Limit_Adults": "Inhalation: Solution for nebulization  8 mg twice daily\r\nOral: Initial: 8 to 16 mg 3 times daily as needed for the first 7 days, then 8 mg 3 times daily as needed ",
            "Quantity_Limit_Pediatrics": "oral: Children 2 to <6 years: (maximal 8mg/day)  .Children 6 to <12 years:  (maximum: 24 mg/day).Children ≥12 years and Adolescents: (maximum: 48 mg/day). Inhalation: Solution for nebulization (2 mg/mL):Children 2 to <6 years: 1.3 mg twice daily.  Children 6 to <12 years: 2 mg twice dailyChildren ≥12 years and Adolescents: 4 mg twice daily.",
            "Notes_1": "CU: Bromhexine\r\nBromhexine as mucolytics in bronchiectasis should be used with antibiotics, to help in sputum production and clearance, not to be used as monotherapy"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment-Airway Clearance",
            "ICD_Code": "J47",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "EZOLVIN 4MG\\5ML SYRUP",
            "Registration_Number": "26-352-02",
            "Active_ingredient": "BROMHEXINE",
            "ATC_Code": "R05CB02",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.8mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": " CU",
            "Quantity_Limit_Adults": "Inhalation: Solution for nebulization  8 mg twice daily\r\nOral: Initial: 8 to 16 mg 3 times daily as needed for the first 7 days, then 8 mg 3 times daily as needed ",
            "Quantity_Limit_Pediatrics": "oral: Children 2 to <6 years: (maximal 8mg/day)  .Children 6 to <12 years:  (maximum: 24 mg/day).Children ≥12 years and Adolescents: (maximum: 48 mg/day). Inhalation: Solution for nebulization (2 mg/mL):Children 2 to <6 years: 1.3 mg twice daily.  Children 6 to <12 years: 2 mg twice dailyChildren ≥12 years and Adolescents: 4 mg twice daily.",
            "Notes_1": "CU: Bromhexine\r\nBromhexine as mucolytics in bronchiectasis should be used with antibiotics, to help in sputum production and clearance, not to be used as monotherapy"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment-Airway Clearance",
            "ICD_Code": "J47",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "EZOLVIN 8MGTAB",
            "Registration_Number": "25-352-02",
            "Active_ingredient": "BROMHEXINE",
            "ATC_Code": "R05CB02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "8mg",
            "G_or_B": "G",
            "Prescribing_edits": " CU",
            "Quantity_Limit_Adults": "Inhalation: Solution for nebulization  8 mg twice daily\r\nOral: Initial: 8 to 16 mg 3 times daily as needed for the first 7 days, then 8 mg 3 times daily as needed ",
            "Quantity_Limit_Pediatrics": "oral: Children 2 to <6 years: (maximal 8mg/day)  .Children 6 to <12 years:  (maximum: 24 mg/day).Children ≥12 years and Adolescents: (maximum: 48 mg/day). Inhalation: Solution for nebulization (2 mg/mL):Children 2 to <6 years: 1.3 mg twice daily.  Children 6 to <12 years: 2 mg twice dailyChildren ≥12 years and Adolescents: 4 mg twice daily.",
            "Notes_1": "CU: Bromhexine\r\nBromhexine as mucolytics in bronchiectasis should be used with antibiotics, to help in sputum production and clearance, not to be used as monotherapy"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment-Airway Clearance",
            "ICD_Code": "J47",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "MUCOFREE 4MG-5ML SYRUP",
            "Registration_Number": "4-491-06",
            "Active_ingredient": "BROMHEXINE",
            "ATC_Code": "R05CB02",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.8mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": " CU",
            "Quantity_Limit_Adults": "Inhalation: Solution for nebulization  8 mg twice daily\r\nOral: Initial: 8 to 16 mg 3 times daily as needed for the first 7 days, then 8 mg 3 times daily as needed ",
            "Quantity_Limit_Pediatrics": "oral: Children 2 to <6 years: (maximal 8mg/day)  .Children 6 to <12 years:  (maximum: 24 mg/day).Children ≥12 years and Adolescents: (maximum: 48 mg/day). Inhalation: Solution for nebulization (2 mg/mL):Children 2 to <6 years: 1.3 mg twice daily.  Children 6 to <12 years: 2 mg twice dailyChildren ≥12 years and Adolescents: 4 mg twice daily.",
            "Notes_1": "CU: Bromhexine\r\nBromhexine as mucolytics in bronchiectasis should be used with antibiotics, to help in sputum production and clearance, not to be used as monotherapy"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment-Airway Clearance",
            "ICD_Code": "J47",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "PULMOTROPIC DROPS 2MG-ML",
            "Registration_Number": "5-58-87",
            "Active_ingredient": "BROMHEXINE",
            "ATC_Code": "R05CB02",
            "Dosage_Form": "Oral solution",
            "ROA": "Oral",
            "Strength": "2mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": " CU",
            "Quantity_Limit_Adults": "Inhalation: Solution for nebulization  8 mg twice daily\r\nOral: Initial: 8 to 16 mg 3 times daily as needed for the first 7 days, then 8 mg 3 times daily as needed ",
            "Quantity_Limit_Pediatrics": "oral: Children 2 to <6 years: (maximal 8mg/day)  .Children 6 to <12 years:  (maximum: 24 mg/day).Children ≥12 years and Adolescents: (maximum: 48 mg/day). Inhalation: Solution for nebulization (2 mg/mL):Children 2 to <6 years: 1.3 mg twice daily.  Children 6 to <12 years: 2 mg twice dailyChildren ≥12 years and Adolescents: 4 mg twice daily.",
            "Notes_1": "CU: Bromhexine\r\nBromhexine as mucolytics in bronchiectasis should be used with antibiotics, to help in sputum production and clearance, not to be used as monotherapy"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment-Airway Clearance",
            "ICD_Code": "J47",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "PULMOTROPIC ELIXIR 4MG-5ML",
            "Registration_Number": "4-58-87",
            "Active_ingredient": "BROMHEXINE",
            "ATC_Code": "R05CB02",
            "Dosage_Form": "Oral solution",
            "ROA": "Oral",
            "Strength": "0.8mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": " CU",
            "Quantity_Limit_Adults": "Inhalation: Solution for nebulization  8 mg twice daily\r\nOral: Initial: 8 to 16 mg 3 times daily as needed for the first 7 days, then 8 mg 3 times daily as needed ",
            "Quantity_Limit_Pediatrics": "oral: Children 2 to <6 years: (maximal 8mg/day)  .Children 6 to <12 years:  (maximum: 24 mg/day).Children ≥12 years and Adolescents: (maximum: 48 mg/day). Inhalation: Solution for nebulization (2 mg/mL):Children 2 to <6 years: 1.3 mg twice daily.  Children 6 to <12 years: 2 mg twice dailyChildren ≥12 years and Adolescents: 4 mg twice daily.",
            "Notes_1": "CU: Bromhexine\r\nBromhexine as mucolytics in bronchiectasis should be used with antibiotics, to help in sputum production and clearance, not to be used as monotherapy"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment-Airway Clearance",
            "ICD_Code": "J47",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "RIAXINE",
            "Registration_Number": "1-325-99",
            "Active_ingredient": "BROMHEXINE",
            "ATC_Code": "R05CB02",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.8mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": " CU",
            "Quantity_Limit_Adults": "Inhalation: Solution for nebulization  8 mg twice daily\r\nOral: Initial: 8 to 16 mg 3 times daily as needed for the first 7 days, then 8 mg 3 times daily as needed ",
            "Quantity_Limit_Pediatrics": "oral: Children 2 to <6 years: (maximal 8mg/day)  .Children 6 to <12 years:  (maximum: 24 mg/day).Children ≥12 years and Adolescents: (maximum: 48 mg/day). Inhalation: Solution for nebulization (2 mg/mL):Children 2 to <6 years: 1.3 mg twice daily.  Children 6 to <12 years: 2 mg twice dailyChildren ≥12 years and Adolescents: 4 mg twice daily.",
            "Notes_1": "CU: Bromhexine\r\nBromhexine as mucolytics in bronchiectasis should be used with antibiotics, to help in sputum production and clearance, not to be used as monotherapy"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment-Airway Clearance",
            "ICD_Code": "J47",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "SOLVEX 4MG-5ML SYRUP",
            "Registration_Number": "40-334-00",
            "Active_ingredient": "BROMHEXINE",
            "ATC_Code": "R05CB02",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.8mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": " CU",
            "Quantity_Limit_Adults": "Inhalation: Solution for nebulization  8 mg twice daily\r\nOral: Initial: 8 to 16 mg 3 times daily as needed for the first 7 days, then 8 mg 3 times daily as needed ",
            "Quantity_Limit_Pediatrics": "oral: Children 2 to <6 years: (maximal 8mg/day)  .Children 6 to <12 years:  (maximum: 24 mg/day).Children ≥12 years and Adolescents: (maximum: 48 mg/day). Inhalation: Solution for nebulization (2 mg/mL):Children 2 to <6 years: 1.3 mg twice daily.  Children 6 to <12 years: 2 mg twice dailyChildren ≥12 years and Adolescents: 4 mg twice daily.",
            "Notes_1": "CU: Bromhexine\r\nBromhexine as mucolytics in bronchiectasis should be used with antibiotics, to help in sputum production and clearance, not to be used as monotherapy"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment-Airway Clearance",
            "ICD_Code": "J47",
            "Drug_Class": "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",
            "Drug_Sub_Class": "Mucolytics",
            "Trade_Name": "MUCOLYTE SYRUP",
            "Registration_Number": "53-186-91",
            "Active_ingredient": "BROMHEXINE",
            "ATC_Code": "R05CB02",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "0.8mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": " CU",
            "Quantity_Limit_Adults": "Inhalation: Solution for nebulization  8 mg twice daily\r\nOral: Initial: 8 to 16 mg 3 times daily as needed for the first 7 days, then 8 mg 3 times daily as needed ",
            "Quantity_Limit_Pediatrics": "oral: Children 2 to <6 years: (maximal 8mg/day)  .Children 6 to <12 years:  (maximum: 24 mg/day).Children ≥12 years and Adolescents: (maximum: 48 mg/day). Inhalation: Solution for nebulization (2 mg/mL):Children 2 to <6 years: 1.3 mg twice daily.  Children 6 to <12 years: 2 mg twice dailyChildren ≥12 years and Adolescents: 4 mg twice daily.",
            "Notes_1": "CU: Bromhexine\r\nBromhexine as mucolytics in bronchiectasis should be used with antibiotics, to help in sputum production and clearance, not to be used as monotherapy"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORID 5% I.V SOLUTION",
            "Registration_Number": "215-149-00",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "5",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Inhalation: 7% hypertonic saline: 4 mL two times daily (Castellani 2018; Elkins 2006; Elkins 2016). Note: If patients cannot tolerate 7% hypertonic saline, 3% inhaled solution may be used;",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Inhalation: 7% solution: 4 mL inhaled twice daily. ",
            "Notes_1": "Note: Clinically, some CF centers use 3% or 3.5% inhaled solutions if patients cannot tolerate 7%; pretreatment with a bronchodilator is recommended to prevent potential bronchospasm",
            "Notes_2": "the use of nebulised saline immediately before respiratory physiotherapy  yielded significantly more sputum than physiotherapy alone.Larger studies should be considered in the future to investigate optimal treatment, dosages, durations and combinations"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORID 5% I.V SOLUTION",
            "Registration_Number": "214-149-00",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "5",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Inhalation: 7% hypertonic saline: 4 mL two times daily (Castellani 2018; Elkins 2006; Elkins 2016). Note: If patients cannot tolerate 7% hypertonic saline, 3% inhaled solution may be used;",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Inhalation: 7% solution: 4 mL inhaled twice daily. ",
            "Notes_1": "Note: Clinically, some CF centers use 3% or 3.5% inhaled solutions if patients cannot tolerate 7%; pretreatment with a bronchodilator is recommended to prevent potential bronchospasm",
            "Notes_2": "the use of nebulised saline immediately before respiratory physiotherapy  yielded significantly more sputum than physiotherapy alone.Larger studies should be considered in the future to investigate optimal treatment, dosages, durations and combinations"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 5.85% AMP",
            "Registration_Number": "143-149-98",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "5.85",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Inhalation: 7% hypertonic saline: 4 mL two times daily (Castellani 2018; Elkins 2006; Elkins 2016). Note: If patients cannot tolerate 7% hypertonic saline, 3% inhaled solution may be used;",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Inhalation: 7% solution: 4 mL inhaled twice daily. ",
            "Notes_1": "Note: Clinically, some CF centers use 3% or 3.5% inhaled solutions if patients cannot tolerate 7%; pretreatment with a bronchodilator is recommended to prevent potential bronchospasm",
            "Notes_2": "the use of nebulised saline immediately before respiratory physiotherapy  yielded significantly more sputum than physiotherapy alone.Larger studies should be considered in the future to investigate optimal treatment, dosages, durations and combinations"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 5.85% AMP",
            "Registration_Number": "144-149-98",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "5.85",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Inhalation: 7% hypertonic saline: 4 mL two times daily (Castellani 2018; Elkins 2006; Elkins 2016). Note: If patients cannot tolerate 7% hypertonic saline, 3% inhaled solution may be used;",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Inhalation: 7% solution: 4 mL inhaled twice daily. ",
            "Notes_1": "Note: Clinically, some CF centers use 3% or 3.5% inhaled solutions if patients cannot tolerate 7%; pretreatment with a bronchodilator is recommended to prevent potential bronchospasm",
            "Notes_2": "the use of nebulised saline immediately before respiratory physiotherapy  yielded significantly more sputum than physiotherapy alone.Larger studies should be considered in the future to investigate optimal treatment, dosages, durations and combinations"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 5.85% AMP",
            "Registration_Number": "142-149-98",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "5.85",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Inhalation: 7% hypertonic saline: 4 mL two times daily (Castellani 2018; Elkins 2006; Elkins 2016). Note: If patients cannot tolerate 7% hypertonic saline, 3% inhaled solution may be used;",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Inhalation: 7% solution: 4 mL inhaled twice daily. ",
            "Notes_1": "Note: Clinically, some CF centers use 3% or 3.5% inhaled solutions if patients cannot tolerate 7%; pretreatment with a bronchodilator is recommended to prevent potential bronchospasm",
            "Notes_2": "the use of nebulised saline immediately before respiratory physiotherapy  yielded significantly more sputum than physiotherapy alone.Larger studies should be considered in the future to investigate optimal treatment, dosages, durations and combinations"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIED 7.5 % W- V SOLUTION",
            "Registration_Number": "262-149-02",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "7.5",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Inhalation: 7% hypertonic saline: 4 mL two times daily (Castellani 2018; Elkins 2006; Elkins 2016). Note: If patients cannot tolerate 7% hypertonic saline, 3% inhaled solution may be used;",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Inhalation: 7% solution: 4 mL inhaled twice daily. ",
            "Notes_1": "Note: Clinically, some CF centers use 3% or 3.5% inhaled solutions if patients cannot tolerate 7%; pretreatment with a bronchodilator is recommended to prevent potential bronchospasm",
            "Notes_2": "the use of nebulised saline immediately before respiratory physiotherapy  yielded significantly more sputum than physiotherapy alone.Larger studies should be considered in the future to investigate optimal treatment, dosages, durations and combinations"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIED 7.5 % W- V SOLUTION",
            "Registration_Number": "263-149-02",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "7.5",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Inhalation: 7% hypertonic saline: 4 mL two times daily (Castellani 2018; Elkins 2006; Elkins 2016). Note: If patients cannot tolerate 7% hypertonic saline, 3% inhaled solution may be used;",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Inhalation: 7% solution: 4 mL inhaled twice daily. ",
            "Notes_1": "Note: Clinically, some CF centers use 3% or 3.5% inhaled solutions if patients cannot tolerate 7%; pretreatment with a bronchodilator is recommended to prevent potential bronchospasm",
            "Notes_2": "the use of nebulised saline immediately before respiratory physiotherapy  yielded significantly more sputum than physiotherapy alone.Larger studies should be considered in the future to investigate optimal treatment, dosages, durations and combinations"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIED 7.5 % W- V SOLUTION",
            "Registration_Number": "264-149-02",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for injection",
            "ROA": "Parenteral",
            "Strength": "7.5",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Inhalation: 7% hypertonic saline: 4 mL two times daily (Castellani 2018; Elkins 2006; Elkins 2016). Note: If patients cannot tolerate 7% hypertonic saline, 3% inhaled solution may be used;",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Inhalation: 7% solution: 4 mL inhaled twice daily. ",
            "Notes_1": "Note: Clinically, some CF centers use 3% or 3.5% inhaled solutions if patients cannot tolerate 7%; pretreatment with a bronchodilator is recommended to prevent potential bronchospasm",
            "Notes_2": "the use of nebulised saline immediately before respiratory physiotherapy  yielded significantly more sputum than physiotherapy alone.Larger studies should be considered in the future to investigate optimal treatment, dosages, durations and combinations"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 5% I.V INFUSION",
            "Registration_Number": "79-803-16",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Intravenous",
            "Strength": "5",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Inhalation: 7% hypertonic saline: 4 mL two times daily (Castellani 2018; Elkins 2006; Elkins 2016). Note: If patients cannot tolerate 7% hypertonic saline, 3% inhaled solution may be used;",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Inhalation: 7% solution: 4 mL inhaled twice daily. ",
            "Notes_1": "Note: Clinically, some CF centers use 3% or 3.5% inhaled solutions if patients cannot tolerate 7%; pretreatment with a bronchodilator is recommended to prevent potential bronchospasm",
            "Notes_2": "the use of nebulised saline immediately before respiratory physiotherapy  yielded significantly more sputum than physiotherapy alone.Larger studies should be considered in the future to investigate optimal treatment, dosages, durations and combinations"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIED 7.5 % W- V SOLUTION",
            "Registration_Number": "13-5023-19",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "7.5%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "Inhalation: 7% hypertonic saline: 4 mL two times daily (Castellani 2018; Elkins 2006; Elkins 2016). Note: If patients cannot tolerate 7% hypertonic saline, 3% inhaled solution may be used;",
            "Quantity_Limit_Pediatrics": "Children ≥6 years and Adolescents: Inhalation: 7% solution: 4 mL inhaled twice daily. ",
            "Notes_1": "Note: Clinically, some CF centers use 3% or 3.5% inhaled solutions if patients cannot tolerate 7%; pretreatment with a bronchodilator is recommended to prevent potential bronchospasm",
            "Notes_2": "the use of nebulised saline immediately before respiratory physiotherapy  yielded significantly more sputum than physiotherapy alone.Larger studies should be considered in the future to investigate optimal treatment, dosages, durations and combinations"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "AMINOGLYCOSIDE ANTIBACTERIALS",
            "Drug_Sub_Class": "Other aminoglycosides",
            "Trade_Name": "GENTAM 20MG-2ML AMP",
            "Registration_Number": "14-212-93",
            "Active_ingredient": "GENTAMICIN",
            "ATC_Code": "J01GB03",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "10",
            "G_or_B": "G",
            "Prescribing_edits": "PA-CU",
            "Quantity_Limit_Adults": "The recommended doses for Long term prophylaxis for patients with chronic lung infection are:\r\n- 80mg nebulised twice daily\r\n- 160mg nebulised once or twice daily ",
            "Notes_1": "PA-CU: Tobramycin-Gentamycin-Colistin\r\nThe use of inhaled antibiotics (tobramycin, gentamicin, or colistin) is not recommended except in very selected cases with chronic Pseudomonas colonization and frequent exacerbation and hospitalization, and this should be confirmed by the prescriber, inhaled antibiotic should not be used as monotherapy, Use in addition to systemic antibiotics .   PA: Inhaled Colistin-Tobramycin-Gentamycin\r\nOffering Long-term treatment with an inhaled antibiotic for adults with bronchiectasis who have three or more exacerbations per year and chronic P. aeruginosa infection, or for adults with bronchiectasis not infected with P. aeruginosa in whom oral antibiotic prophylaxis is contraindicated, not tolerated or ineffective and this should be confirmed by the prescriber.",
            "Notes_2": "Nebulised gentamicin is indicated in patients with chronic lung infection in non CF  bronchiectasis. This is an unlicensed use.\r\nGentamicin is used 2nd line after the patient has failed to respond to (or failed to tolerate) appropriate oral antibiotic prophylaxis. there is limited scientific evidence in patients with non-CF bronchiectasis (there is more for patients with CF)"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "AMINOGLYCOSIDE ANTIBACTERIALS",
            "Drug_Sub_Class": "Other aminoglycosides",
            "Trade_Name": "GENTAM 80MG-2ML AMP",
            "Registration_Number": "15-212-93",
            "Active_ingredient": "GENTAMICIN",
            "ATC_Code": "J01GB03",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "40",
            "G_or_B": "G",
            "Prescribing_edits": "PA-CU",
            "Quantity_Limit_Adults": "The recommended doses for Long term prophylaxis for patients with chronic lung infection are:\r\n- 80mg nebulised twice daily\r\n- 160mg nebulised once or twice daily ",
            "Notes_1": "PA-CU: Tobramycin-Gentamycin-Colistin\r\nThe use of inhaled antibiotics (tobramycin, gentamicin, or colistin) is not recommended except in very selected cases with chronic Pseudomonas colonization and frequent exacerbation and hospitalization, and this should be confirmed by the prescriber, inhaled antibiotic should not be used as monotherapy, Use in addition to systemic antibiotics .   PA: Inhaled Colistin-Tobramycin-Gentamycin\r\nOffering Long-term treatment with an inhaled antibiotic for adults with bronchiectasis who have three or more exacerbations per year and chronic P. aeruginosa infection, or for adults with bronchiectasis not infected with P. aeruginosa in whom oral antibiotic prophylaxis is contraindicated, not tolerated or ineffective and this should be confirmed by the prescriber.",
            "Notes_2": "Nebulised gentamicin is indicated in patients with chronic lung infection in non CF  bronchiectasis. This is an unlicensed use.\r\nGentamicin is used 2nd line after the patient has failed to respond to (or failed to tolerate) appropriate oral antibiotic prophylaxis. there is limited scientific evidence in patients with non-CF bronchiectasis (there is more for patients with CF)"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "AMINOGLYCOSIDE ANTIBACTERIALS",
            "Drug_Sub_Class": "Other aminoglycosides",
            "Trade_Name": "TOBI PODHALER 28MG",
            "Registration_Number": "260-11-13",
            "Active_ingredient": "TOBRAMYCIN",
            "ATC_Code": "J01GB01",
            "Dosage_Form": "Inhalation powder, hard capsule",
            "ROA": "Inhalation",
            "Strength": "28 mg",
            "G_or_B": "B",
            "Prescribing_edits": "PA-CU",
            "Quantity_Limit_Adults": "Acute exacerbation: 80 mg twice daily . Suppression: 160 mg or 300 mg twice daily [Inhalation: Doses should be administered as close to a 12-hour schedule as possible; do not administer less than 6 hours apart]",
            "Quantity_Limit_Pediatrics": "Children and Adolescents: 80 mg/dose 2 to 3 times daily [Inhalation: Doses should be administered as close to a 12-hour schedule as possible; do not administer less than 6 hours apart]",
            "Notes_1": "PA-CU: Tobramycin-Gentamycin-Colistin\r\nThe use of inhaled antibiotics (tobramycin, gentamicin, or colistin) is not recommended except in very selected cases with chronic Pseudomonas colonization and frequent exacerbation and hospitalization, and this should be confirmed by the prescriber, inhaled antibiotic should not be used as monotherapy, Use in addition to systemic antibiotics .   PA: Inhaled Colistin-Tobramycin-Gentamycin\r\nOffering Long-term treatment with an inhaled antibiotic for adults with bronchiectasis who have three or more exacerbations per year and chronic P. aeruginosa infection, or for adults with bronchiectasis not infected with P. aeruginosa in whom oral antibiotic prophylaxis is contraindicated, not tolerated or ineffective and this should be confirmed by the prescriber.",
            "Notes_2": "Non-cystic fibrosis bronchiectasis (off-label use): Note: Use may be considered in patients who have ≥3 exacerbations requiring antibiotic therapy per year; generally given in addition to oral or IV antimicrobials. Note: Dose prepared from preservative-free tobramycin injection solution (Le 2010)."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "AMINOGLYCOSIDE ANTIBACTERIALS",
            "Drug_Sub_Class": "Other aminoglycosides",
            "Trade_Name": "TOBRAMYCIN 20MG-2ML VIAL",
            "Registration_Number": "31-237-97",
            "Active_ingredient": "TOBRAMYCIN",
            "ATC_Code": "J01GB01",
            "Dosage_Form": "Injection*",
            "ROA": "Parenteral",
            "Strength": "10mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA-CU",
            "Quantity_Limit_Adults": "Acute exacerbation: 80 mg twice daily . Suppression: 160 mg or 300 mg twice daily [Inhalation: Doses should be administered as close to a 12-hour schedule as possible; do not administer less than 6 hours apart]",
            "Quantity_Limit_Pediatrics": "Children and Adolescents: 80 mg/dose 2 to 3 times daily [Inhalation: Doses should be administered as close to a 12-hour schedule as possible; do not administer less than 6 hours apart]",
            "Notes_1": "PA-CU: Tobramycin-Gentamycin-Colistin\r\nThe use of inhaled antibiotics (tobramycin, gentamicin, or colistin) is not recommended except in very selected cases with chronic Pseudomonas colonization and frequent exacerbation and hospitalization, and this should be confirmed by the prescriber, inhaled antibiotic should not be used as monotherapy, Use in addition to systemic antibiotics .   PA: Inhaled Colistin-Tobramycin-Gentamycin\r\nOffering Long-term treatment with an inhaled antibiotic for adults with bronchiectasis who have three or more exacerbations per year and chronic P. aeruginosa infection, or for adults with bronchiectasis not infected with P. aeruginosa in whom oral antibiotic prophylaxis is contraindicated, not tolerated or ineffective and this should be confirmed by the prescriber.",
            "Notes_2": "Non-cystic fibrosis bronchiectasis (off-label use): Note: Use may be considered in patients who have ≥3 exacerbations requiring antibiotic therapy per year; generally given in addition to oral or IV antimicrobials. Note: Dose prepared from preservative-free tobramycin injection solution (Le 2010)."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER ANTIBACTERIALS",
            "Drug_Sub_Class": "Polymyxins",
            "Trade_Name": "COLISTIN JPI Powder For Solution For Injection/Infusion",
            "Registration_Number": "263-334-17",
            "Active_ingredient": "COLISTIMETHATE SODIUM",
            "ATC_Code": "J01XB01 ",
            "Dosage_Form": "Powder for solution for injection or infusion",
            "ROA": "Intravenous",
            "Strength": "1000000IU",
            "G_or_B": "B",
            "Prescribing_edits": "PA-CU",
            "Quantity_Limit_Adults": "Inhalation: 30 to 150 mg CBA via nebulizer 1 to 2 times daily (maximum dose: 150 mg CBA 2 times daily) (off-label use/route): ",
            "Quantity_Limit_Pediatrics": "For pediatric patients : limited data available about the use of colisin in pediatric patient with  non- cystic fibrosis ",
            "Notes_1": "PA-CU: Tobramycin-Gentamycin-Colistin\r\nThe use of inhaled antibiotics (tobramycin, gentamicin, or colistin) is not recommended except in very selected cases with chronic Pseudomonas colonization and frequent exacerbation and hospitalization, and this should be confirmed by the prescriber, inhaled antibiotic should not be used as monotherapy, Use in addition to systemic antibiotics .   PA: Inhaled Colistin-Tobramycin-Gentamycin\r\nOffering Long-term treatment with an inhaled antibiotic for adults with bronchiectasis who have three or more exacerbations per year and chronic P. aeruginosa infection, or for adults with bronchiectasis not infected with P. aeruginosa in whom oral antibiotic prophylaxis is contraindicated, not tolerated or ineffective and this should be confirmed by the prescriber.",
            "Notes_2": "Colistin for inhalation should be administered promptly after being mixed with sterile water. This recommendation  was made by the US Food and Drug Administration (FDA) after a report that a cystic fibrosis patient died after being treated with a premixed colistin formulation. Polymyxins are generally reserved for the treatment of serious infections caused by P. aeruginosa isolates resistant to other agents. In such cases, they are often administered in combination with other antimicrobial agents and with a loading dose preceding the standing dose."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "VIRAL VACCINES",
            "Drug_Sub_Class": "Influenza vaccines",
            "Trade_Name": "ARAFLU 0.5/ML SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE",
            "Registration_Number": "4-800-13",
            "Active_ingredient": "INFLUENZA VACCINE",
            "ATC_Code": "J07BB",
            "Dosage_Form": "SUSPENSION FOR INJECTION",
            "ROA": "SC",
            "Strength": "0.5ML",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose, should be used as per Saudi protocol of vaccinations",
            "Notes_1": "Guidelines recommend following the Saudi Guideline for Influenza and Pneumococcal Vaccination, and recommended for routine use in chronic pulmonary illnesses such as bronchiectasis."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "VIRAL VACCINES",
            "Drug_Sub_Class": "Influenza vaccines",
            "Trade_Name": "AGRIPPAL S1 45MG\\0.5ML PRE-FILLED SYRING",
            "Registration_Number": "3-286-01",
            "Active_ingredient": "INFLUENZA VACCINE",
            "ATC_Code": "J07BB",
            "Dosage_Form": "SUSPENSION FOR INJECTION",
            "ROA": "SC",
            "Strength": "0.5ML",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose, should be used as per Saudi protocol of vaccinations",
            "Notes_1": "Guidelines recommend following the Saudi Guideline for Influenza and Pneumococcal Vaccination, and recommended for routine use in chronic pulmonary illnesses such as bronchiectasis."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "VIRAL VACCINES",
            "Drug_Sub_Class": "Influenza vaccines",
            "Trade_Name": "FLUARIX 15MCGOF ECH INFUENZA STR.5MLSRYG",
            "Registration_Number": "2-197-97",
            "Active_ingredient": "INFLUENZA VACCINE TYPE A &B",
            "ATC_Code": "J07BB",
            "Dosage_Form": "SUSPENSION FOR INJECTION",
            "ROA": "IM",
            "Strength": "0.5ML",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose, should be used as per Saudi protocol of vaccinations",
            "Notes_1": "Guidelines recommend following the Saudi Guideline for Influenza and Pneumococcal Vaccination, and recommended for routine use in chronic pulmonary illnesses such as bronchiectasis."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "VIRAL VACCINES",
            "Drug_Sub_Class": "Influenza vaccines",
            "Trade_Name": "INFLUVAC S.INJ. 15 MCG-0.5ML",
            "Registration_Number": "1-728-96",
            "Active_ingredient": "INFLUENZA VACCINE TYPE A &B",
            "ATC_Code": "J07BB",
            "Dosage_Form": "SUSPENSION FOR INJECTION",
            "ROA": "SC",
            "Strength": "0.5ML",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose, should be used as per Saudi protocol of vaccinations",
            "Notes_1": "Guidelines recommend following the Saudi Guideline for Influenza and Pneumococcal Vaccination, and recommended for routine use in chronic pulmonary illnesses such as bronchiectasis."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "VIRAL VACCINES",
            "Drug_Sub_Class": "Influenza vaccines",
            "Trade_Name": "VAXIGRIP SINGLE DOSE SYRINGE 0.5ML",
            "Registration_Number": "5-164-94",
            "Active_ingredient": "INFLUENZA VACCINE TYPE A &B",
            "ATC_Code": "J07BB",
            "Dosage_Form": "SUSPENSION FOR INJECTION",
            "ROA": "SC",
            "Strength": "0.5ML",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose, should be used as per Saudi protocol of vaccinations",
            "Notes_1": "Guidelines recommend following the Saudi Guideline for Influenza and Pneumococcal Vaccination, and recommended for routine use in chronic pulmonary illnesses such as bronchiectasis."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "BACTERIAL VACCINES",
            "Drug_Sub_Class": "Pneumococcal vaccines",
            "Trade_Name": "PNEUMOVAX 23 Solution for injection vaccine",
            "Registration_Number": "1-020-14",
            "Active_ingredient": "PNEUMOCOCCAL VACCINE",
            "ATC_Code": "J07AL01",
            "Dosage_Form": "Solution for injection",
            "ROA": "Subcutaneous",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose, should be used as per Saudi protocol of vaccinations",
            "Notes_1": "Guidelines recommend following the Saudi Guideline for Influenza and Pneumococcal Vaccination, and recommended for routine use in chronic pulmonary illnesses such as bronchiectasis."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "BACTERIAL VACCINES",
            "Drug_Sub_Class": "Pneumococcal vaccines",
            "Trade_Name": "PREVENAR 13 PRE-FILLED SYRINGE VACCINE",
            "Registration_Number": "16-110-16",
            "Active_ingredient": "PNEUMOCOCCAL POLYSACHARIDE CONJUGATED",
            "ATC_Code": "J07AL01  ",
            "Dosage_Form": "Injection*",
            "ROA": "Subcutaneous",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose, should be used as per Saudi protocol of vaccinations",
            "Notes_1": "Guidelines recommend following the Saudi Guideline for Influenza and Pneumococcal Vaccination, and recommended for routine use in chronic pulmonary illnesses such as bronchiectasis."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "BACTERIAL VACCINES",
            "Drug_Sub_Class": "Pneumococcal vaccines",
            "Trade_Name": "Pneumovax 23 Pneumococcal Vaccine Polyvalent",
            "Registration_Number": "4-20-19",
            "Active_ingredient": "Pneumococcal Polysaccharide Danish Type 1,2,3,4,5,6B,7F,8,9N,9V,10A,11A,12F,14,15B,17B,17F,18C,19A,19F,20,22F,23F,33F",
            "ATC_Code": "J07AL01  ",
            "Dosage_Form": "Solution for injection in pre-filled syringe ",
            "ROA": "Subcutaneous , Intravenous",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose, should be used as per Saudi protocol of vaccinations",
            "Notes_1": "Guidelines recommend following the Saudi Guideline for Influenza and Pneumococcal Vaccination, and recommended for routine use in chronic pulmonary illnesses such as bronchiectasis."
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics",
            "Trade_Name": "COMBIVENT UNIT DOSE VIAL NEBULISER SOLN.",
            "Registration_Number": "9-243-98",
            "Active_ingredient": "SALBUTAMOL, IPRATROPIUM BROMID ANHYDROUS",
            "ATC_Code": "R03AK04",
            "Dosage_Form": "Nebuliser solution",
            "ROA": "Inhalation",
            "Strength": "3.01, 0.5",
            "G_or_B": "B",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "Nebulization solution: Initial: 1 vial (3 mL) (ipratropium bromide 0.5 mg/albuterol 2.5 mg) every 6 hours (maximum: 6 vials [18 mL]/day)",
            "Quantity_Limit_Pediatrics": "Only indicated for severe exacerbations during initial management in an acute care setting,  Infants and Children: Nebulization solution (ipratropium bromide 0.5 mg/albuterol 2.5 mg): Oral inhalation: 1.5 to 3 mL every 20 minutes for 3 doses, then as needed for up to 3 hours.Adolescents: Nebulization solution (ipratropium bromide 0.5 mg/albuterol 2.5 mg): Oral inhalation: 3 mL every 20 minutes for 3 doses, then as needed for up to 3 hours.",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics ",
            "Notes_2": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are likely to respond to bronchodilators and the use should be according the thier guidelines protocols,   bronchodilators should be used before physiotherapy, including inhaled mucoactive drugs, as well as before inhaled antibiotics .being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Selective beta-2-adrenoreceptor agonists",
            "Trade_Name": "SALAMOL CFC-FREE 100MCG INHALER",
            "Registration_Number": "7-314-06",
            "Active_ingredient": "SALBUTAMOL",
            "ATC_Code": "R03AC02",
            "Dosage_Form": "Pressurised inhalation, solution",
            "ROA": "Inhalation",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "8 inhalations daily",
            "Quantity_Limit_Pediatrics": "8 inhalations daily",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics ",
            "Notes_2": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are likely to respond to bronchodilators and the use should be according the thier guidelines protocols,   bronchodilators should be used before physiotherapy, including inhaled mucoactive drugs, as well as before inhaled antibiotics .being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Selective beta-2-adrenoreceptor agonists",
            "Trade_Name": "SALAMOL EASI-BREATH CFC-FREE 100MCG",
            "Registration_Number": "8-314-06",
            "Active_ingredient": "SALBUTAMOL",
            "ATC_Code": "R03AC02",
            "Dosage_Form": "Pressurised inhalation, solution",
            "ROA": "Inhalation",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "8 inhalations daily",
            "Quantity_Limit_Pediatrics": "9 inhalations daily",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics ",
            "Notes_2": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are likely to respond to bronchodilators and the use should be according the thier guidelines protocols,   bronchodilators should be used before physiotherapy, including inhaled mucoactive drugs, as well as before inhaled antibiotics .being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Selective beta-2-adrenoreceptor agonists",
            "Trade_Name": "VENTOLIN 200MCG ROTACAP",
            "Registration_Number": "4-425-03",
            "Active_ingredient": "SALBUTAMOL",
            "ATC_Code": "R03AC02",
            "Dosage_Form": "Inhalation powder, hard capsule",
            "ROA": "Inhalation",
            "Strength": "200",
            "G_or_B": "B",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "2,400 mcg (12 capsules)/day",
            "Quantity_Limit_Pediatrics": "2,400 mcg (12 capsules)/day",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics ",
            "Notes_2": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are likely to respond to bronchodilators and the use should be according the thier guidelines protocols,   bronchodilators should be used before physiotherapy, including inhaled mucoactive drugs, as well as before inhaled antibiotics .being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Selective beta-2-adrenoreceptor agonists",
            "Trade_Name": "VENTOLIN DISKUS 200MCG",
            "Registration_Number": "6-413-04",
            "Active_ingredient": "SALBUTAMOL",
            "ATC_Code": "R03AC02",
            "Dosage_Form": "Inhalation powder, pre-dispensed",
            "ROA": "Inhalation",
            "Strength": "200",
            "G_or_B": "B",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "maximum: 4 inhalations (800 mcg)/day",
            "Quantity_Limit_Pediatrics": "maximum: 4 inhalations (800 mcg)/day",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics ",
            "Notes_2": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are likely to respond to bronchodilators and the use should be according the thier guidelines protocols,   bronchodilators should be used before physiotherapy, including inhaled mucoactive drugs, as well as before inhaled antibiotics .being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Selective beta-2-adrenoreceptor agonists",
            "Trade_Name": "VENTOLIN INHALER",
            "Registration_Number": "32-276-97",
            "Active_ingredient": "SALBUTAMOL",
            "ATC_Code": "R03AC02",
            "Dosage_Form": "Pressurised inhalation, solution",
            "ROA": "Inhalation",
            "Strength": "100",
            "G_or_B": "B",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "8 inhalations daily",
            "Quantity_Limit_Pediatrics": "8 inhalations daily",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics ",
            "Notes_2": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are likely to respond to bronchodilators and the use should be according the thier guidelines protocols,   bronchodilators should be used before physiotherapy, including inhaled mucoactive drugs, as well as before inhaled antibiotics .being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Selective beta-2-adrenoreceptor agonists",
            "Trade_Name": "VENTOLIN RESPIRATORY SOLUTIN",
            "Registration_Number": "34-276-97",
            "Active_ingredient": "SALBUTAMOL",
            "ATC_Code": "R03AC02",
            "Dosage_Form": "Inhalation solution",
            "ROA": "Inhalation",
            "Strength": "0.5",
            "G_or_B": "B",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "Up to 40 mg per day can be given under strict medical supervision in hospital.",
            "Quantity_Limit_Pediatrics": "Children aged 12 years and over: Dose as per adult population.\r\nChildren aged 4-11 years: 2.5 mg to 5 mg up to four times a day.",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics ",
            "Notes_2": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are likely to respond to bronchodilators and the use should be according the thier guidelines protocols,   bronchodilators should be used before physiotherapy, including inhaled mucoactive drugs, as well as before inhaled antibiotics .being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Selective beta-2-adrenoreceptor agonists",
            "Trade_Name": "BRONCHOVENT 5mg/ml nebuliser solution",
            "Registration_Number": "419-149-15",
            "Active_ingredient": "SALBUTAMOL",
            "ATC_Code": "R03AC02",
            "Dosage_Form": "Nebuliser solution",
            "ROA": "Inhalation",
            "Strength": "0.5",
            "G_or_B": "G",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "Up to 40 mg per day can be given under strict medical supervision in hospital.",
            "Quantity_Limit_Pediatrics": "Children aged 12 years and over: Dose as per adult population.\r\nChildren aged 4-11 years: 2.5 mg to 5 mg up to four times a day.",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics ",
            "Notes_2": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are likely to respond to bronchodilators and the use should be according the thier guidelines protocols,   bronchodilators should be used before physiotherapy, including inhaled mucoactive drugs, as well as before inhaled antibiotics .being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Selective beta-2-adrenoreceptor agonists",
            "Trade_Name": "BRONCHOVENT 5mg/ml nebuliser solution",
            "Registration_Number": "231-186-05",
            "Active_ingredient": "SALBUTAMOL",
            "ATC_Code": "R03AC02",
            "Dosage_Form": "SOLUTION",
            "ROA": "INHALATION",
            "Strength": "0.5%",
            "G_or_B": "G",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "Up to 40 mg per day can be given under strict medical supervision in hospital.",
            "Quantity_Limit_Pediatrics": "Children aged 12 years and over: Dose as per adult population.\r\nChildren aged 4-11 years: 2.5 mg to 5 mg up to four times a day.",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Selective beta-2-adrenoreceptor agonists",
            "Trade_Name": "BUTALIN 0.5% SOLUTION FOR NEBULISER",
            "Registration_Number": "239-186-06",
            "Active_ingredient": "SALBUTAMOL",
            "ATC_Code": "R03AC02",
            "Dosage_Form": "Inhalation solution",
            "ROA": "Inhalation",
            "Strength": "0.5%",
            "G_or_B": "G",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "Up to 40 mg per day can be given under strict medical supervision in hospital.",
            "Quantity_Limit_Pediatrics": "Children aged 12 years and over: Dose as per adult population.\r\nChildren aged 4-11 years: 2.5 mg to 5 mg up to four times a day.",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Selective beta-2-adrenoreceptor agonists",
            "Trade_Name": "BUTALIN 100MCG-DOSE INHALER",
            "Registration_Number": "48-186-91",
            "Active_ingredient": "SALBUTAMOL",
            "ATC_Code": "R03AC02",
            "Dosage_Form": "Pressurised inhalation, solution",
            "ROA": "Inhalation",
            "Strength": "100µg",
            "G_or_B": "G",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "Up to 40 mg per day can be given under strict medical supervision in hospital.",
            "Quantity_Limit_Pediatrics": "Children aged 12 years and over: Dose as per adult population.\r\nChildren aged 4-11 years: 2.5 mg to 5 mg up to four times a day.",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics "
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Selective beta-2-adrenoreceptor agonists",
            "Trade_Name": "BRICANYL 2.5MG-ML SOLN.FOR NEBULISATION",
            "Registration_Number": "59-15-98",
            "Active_ingredient": "TERBUTALINE SULPHATE",
            "ATC_Code": "R03AC03",
            "Dosage_Form": "Nebuliser solution",
            "ROA": "Inhalation",
            "Strength": "2.5",
            "G_or_B": "B",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "Adult: 5 to 10 mg given 2-4 times daily ",
            "Quantity_Limit_Pediatrics": "Children >25 kg: 5 mg  ,,Children <25 kg: based on age and weight : 10 kg 2.0mg  ,15kg 3mg  ,,20kg 4mg   ,,25+kg 5mg",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics ",
            "Notes_2": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are likely to respond to bronchodilators and the use should be according the thier guidelines protocols,   bronchodilators should be used before physiotherapy, including inhaled mucoactive drugs, as well as before inhaled antibiotics .being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Selective beta-2-adrenoreceptor agonists",
            "Trade_Name": "BRICANYL TURBUHALER 0.5MG-DOSE",
            "Registration_Number": "50-15-96",
            "Active_ingredient": "TERBUTALINE SULPHATE",
            "ATC_Code": "R03AC03",
            "Dosage_Form": "Inhalation powder",
            "ROA": "Inhalation",
            "Strength": "0.5",
            "G_or_B": "B",
            "Prescribing_edits": "CU ",
            "Quantity_Limit_Adults": "4 inhalations",
            "Quantity_Limit_Pediatrics": "4 inhalations",
            "Notes_1": "CU: to be used prior inhaled Antibiotics to prevent bronchospasm induced by inhaled antibiotics ",
            "Notes_2": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are likely to respond to bronchodilators and the use should be according the thier guidelines protocols,   bronchodilators should be used before physiotherapy, including inhaled mucoactive drugs, as well as before inhaled antibiotics .being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",
            "Drug_Sub_Class": "Anticholinergics",
            "Trade_Name": "ATROVENT 0.02MG-METERED DOSE INHALER",
            "Registration_Number": "51-68-87",
            "Active_ingredient": "IPRATROPIUM BROMIDE",
            "ATC_Code": "R03BB01",
            "Dosage_Form": "Pressurised inhalation*",
            "ROA": "Inhalation",
            "Strength": "0.02",
            "G_or_B": "B",
            "Prescribing_edits": " PA",
            "Quantity_Limit_Adults": "8 -12 puffs ",
            "Notes_1": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are likely to respond to bronchodilators and the use should be according the thier guidelines protocols,   bronchodilators should be used before physiotherapy, including inhaled mucoactive drugs, as well as before inhaled antibiotics .",
            "Notes_2": "being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "ADRENERGICS, INHALANTS",
            "Drug_Sub_Class": "Adrenergics in combinations with anticholinergics incl. triple combinations with corticosteroids",
            "Trade_Name": "COMBIVENT UNIT DOSE VIAL NEBULISER SOLN.",
            "Registration_Number": "9-243-98",
            "Active_ingredient": "SALBUTAMOL, IPRATROPIUM BROMID ANHYDROUS",
            "ATC_Code": "R03AL02  ",
            "Dosage_Form": "Nebuliser solution",
            "ROA": "Inhalation",
            "Strength": "3.01, 0.5",
            "G_or_B": "B",
            "Prescribing_edits": " PA",
            "Quantity_Limit_Adults": "Nebulization solution: Initial: 1 vial (3 mL) (ipratropium bromide 0.5 mg/albuterol 2.5 mg) every 6 hours (maximum: 6 vials [18 mL]/day)",
            "Quantity_Limit_Pediatrics": "Only indicated for severe exacerbations during initial management in an acute care setting,  Infants and Children: Nebulization solution (ipratropium bromide 0.5 mg/albuterol 2.5 mg): Oral inhalation: 1.5 to 3 mL every 20 minutes for 3 doses, then as needed for up to 3 hours.Adolescents: Nebulization solution (ipratropium bromide 0.5 mg/albuterol 2.5 mg): Oral inhalation: 3 mL every 20 minutes for 3 doses, then as needed for up to 3 hours.",
            "Notes_1": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are likely to respond to bronchodilators and the use should be according the thier guidelines protocols,   bronchodilators should be used before physiotherapy, including inhaled mucoactive drugs, as well as before inhaled antibiotics .",
            "Notes_2": "being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",
            "Drug_Sub_Class": "Anticholinergics",
            "Trade_Name": "ATROSOL 250 mcg/ml nebuliser solution",
            "Registration_Number": "418-149-15",
            "Active_ingredient": "IPRATROPIUM BROMIDE",
            "ATC_Code": "R03BB01",
            "Dosage_Form": "Nebuliser solution",
            "ROA": "Inhalation",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": " PA",
            "Quantity_Limit_Adults": "Adults (including the elderly) and adolescents > 12 years of age: 2000 mcg/ day ",
            "Quantity_Limit_Pediatrics": "children< 12 years: 1000 mcg/ day ",
            "Notes_1": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are\r\nlikely to respond to bronchodilators and the use should be according the thier guidelines protocols",
            "Notes_2": "being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",
            "Drug_Sub_Class": "Anticholinergics",
            "Trade_Name": "ATROVENT 250MCG-2ML UDV (SOLUTION FOR INHALATION)",
            "Registration_Number": "105-68-16",
            "Active_ingredient": "IPRATROPIUM BROMIDE",
            "ATC_Code": "R03BB01",
            "Dosage_Form": "Inhalation solution",
            "ROA": "Inhalation",
            "Strength": "0.125",
            "G_or_B": "B",
            "Prescribing_edits": " PA",
            "Quantity_Limit_Adults": "Adults (including the elderly) and adolescents > 12 years of age: 2000 mcg/ day ",
            "Quantity_Limit_Pediatrics": "children< 12 years: 1000 mcg/ day ",
            "Notes_1": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are\r\nlikely to respond to bronchodilators and the use should be according the thier guidelines protocols",
            "Notes_2": "being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",
            "Drug_Sub_Class": "Anticholinergics",
            "Trade_Name": "ATROVENT 500MCG-2ML UDV (SOLUTION FOR INHALATION)",
            "Registration_Number": "106-68-16",
            "Active_ingredient": "IPRATROPIUM BROMIDE",
            "ATC_Code": "R03BB01",
            "Dosage_Form": "Inhalation solution",
            "ROA": "Inhalation",
            "Strength": "0.25",
            "G_or_B": "B",
            "Prescribing_edits": " PA",
            "Quantity_Limit_Adults": "Adults (including the elderly) and adolescents > 12 years of age: 2000 mcg/ day ",
            "Quantity_Limit_Pediatrics": "children< 12 years: 1000 mcg/ day ",
            "Notes_1": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are\r\nlikely to respond to bronchodilators and the use should be according the thier guidelines protocols",
            "Notes_2": "being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",
            "Drug_Sub_Class": "Anticholinergics",
            "Trade_Name": "ATROSOL 250 mcg/2 ml nebuliser solution",
            "Registration_Number": "465-149-18",
            "Active_ingredient": "IPRATROPIUM BROMIDE",
            "ATC_Code": "R03BB01",
            "Dosage_Form": "Nebuliser solution",
            "ROA": "Inhalation",
            "Strength": "125",
            "G_or_B": "G",
            "Prescribing_edits": " PA",
            "Quantity_Limit_Adults": "Adults (including the elderly) and adolescents > 12 years of age: 2000 mcg/ day ",
            "Quantity_Limit_Pediatrics": "children< 12 years  1000 mcg/ day ",
            "Notes_1": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are\r\nlikely to respond to bronchodilators and the use should be according the thier guidelines protocols",
            "Notes_2": "being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",
            "Drug_Sub_Class": "Anticholinergics",
            "Trade_Name": "ATROPULM 250MCG-ML SOLUTION FOR INHALATION",
            "Registration_Number": "249-186-07",
            "Active_ingredient": "IPRATROPIUM BROMIDE",
            "ATC_Code": "R03BB01",
            "Dosage_Form": "Inhalation solution",
            "ROA": "Inhalation",
            "Strength": "0.25mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": " PA",
            "Quantity_Limit_Adults": "Adults (including the elderly) and adolescents > 12 years of age: 2000 mcg/ day ",
            "Quantity_Limit_Pediatrics": "children< 12 years  1000 mcg/ day ",
            "Notes_1": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are\r\nlikely to respond to bronchodilators and the use should be according the thier guidelines protocols",
            "Notes_2": "being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute Exacerbation of Bronchiectasis (Non-Cystic Fibrosis)-Long-Term Oral Antibiotic Treatment",
            "ICD_Code": "J47",
            "Drug_Class": "OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",
            "Drug_Sub_Class": "Anticholinergics",
            "Trade_Name": "ATROPULM 500MCG-2ML SOLUTION FOR INHALATION",
            "Registration_Number": "257-186-08",
            "Active_ingredient": "IPRATROPIUM BROMIDE",
            "ATC_Code": "R03BB01",
            "Dosage_Form": "Inhalation solution",
            "ROA": "Inhalation",
            "Strength": "0.5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": " PA",
            "Quantity_Limit_Adults": "Adults (including the elderly) and adolescents > 12 years of age: 2000 mcg/ day ",
            "Quantity_Limit_Pediatrics": "children< 12 years  1000 mcg/ day ",
            "Notes_1": "the use of bronchodilators in patients with acute bronchiectasis non-cystiv fibrosis is not routinely  , should be for supset patients only who exhibit hyper‑responsiveness or recurrent bronchospasm due to  concurrent asthma or COPD or because the bronchiectasis is secondary to ABPA or post‑TB: these conditions are\r\nlikely to respond to bronchodilators and the use should be according the thier guidelines protocols",
            "Notes_2": "being diagnosed  with bronchiectasis should not affect the use of inhaled corticosteroids with comorbid asthma or chronic obstructive pulmonary disease"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZIMAC 250 mg",
            "Registration_Number": "186-325-07",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid ).",
            "Notes_2": "Choice of antibiotics should be always based on local antibiogram results and resistance patterns. "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZIMAC 500 mg",
            "Registration_Number": "187-325-07",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZI-ONCE",
            "Registration_Number": "39-368-02",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZI-ONCE",
            "Registration_Number": "83-368-06",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZI-ONCE",
            "Registration_Number": "85-368-06",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZI-ONCE",
            "Registration_Number": "84-368-06",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZOMYNE 200MG\\5ML POWDER FOR ORAL SUSP",
            "Registration_Number": "21-371-11",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZOMYNE 200MG\\5ML POWDER FOR ORAL SUSP",
            "Registration_Number": "22-371-11",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZEROX 200MG-5ML POWDER FOR ORAL SUSP.",
            "Registration_Number": "167-172-09",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZEROX 200MG-5ML POWDER FOR ORAL SUSP.",
            "Registration_Number": "168-172-09",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZEROX 500MG F.C. TABLETS",
            "Registration_Number": "162-172-08",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZEROX 500MG F.C. TABLETS",
            "Registration_Number": "163-172-08",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZETRON 200MG\\5ML POWDER FOR SUSP",
            "Registration_Number": "147-277-03",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZETRON 200MG\\5ML POWDER FOR SUSP",
            "Registration_Number": "148-277-03",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZETRON 250 MG CAPSULE",
            "Registration_Number": "146-277-03",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZIMAX 200MG\\5ML SUSP",
            "Registration_Number": "169-212-02",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZIMAX 200MG\\5ML SUSP",
            "Registration_Number": "170-212-02",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZIMAX 200MG\\5ML SUSP",
            "Registration_Number": "212-212-06",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZIMAX 250MG CAP.",
            "Registration_Number": "162-212-02",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZIMAX 250MG CAP.",
            "Registration_Number": "163-212-02",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZOLID 250MG F.C. TABLETS",
            "Registration_Number": "3-809-14",
            "Active_ingredient": "AZITHROMYCIN DIHYDRATE",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZOLID 500MG F.C. TABLETS",
            "Registration_Number": "4-809-14",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZITHROMAX 200MG-5ML SUSP.AFTER RECONSTIT",
            "Registration_Number": "9-892-13",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZITHROMAX 200MG-5ML SUSP.AFTER RECONSTIT",
            "Registration_Number": "11-892-13",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZITHROMAX 200MG-5ML SUSP.AFTER RECONSTIT",
            "Registration_Number": "10-892-13",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZITHROMAX 250MG CAPS",
            "Registration_Number": "8-892-13",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZITHROMAX 250MG CAPS",
            "Registration_Number": "7-892-13",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZITHROMAX 500 MG POWDER FOR IV INFUSION",
            "Registration_Number": "1-799-11",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Parenteral",
            "Strength": "500",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZOCIN 200MG-5ML POW. FOR ORAL SUSPENSION",
            "Registration_Number": "16-347-07",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZOCIN 300 mg/7.5 ml suspension",
            "Registration_Number": "17-347-07",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ZOCIN 250MG CAPSULE",
            "Registration_Number": "2-347-03",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZYN 500 mg Film Coated Tablet",
            "Registration_Number": "3-5088-18",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZIFORTE 500MG F.C.TABLET",
            "Registration_Number": "183-368-18",
            "Active_ingredient": "AZITHROMYCIN DIHYDRATE",
            "ATC_Code": "J01FA10  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZOMYCIN 200MG\\5ML SUSP.",
            "Registration_Number": "191-186-03",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "AZOMYCIN 200MG\\5ML SUSP.",
            "Registration_Number": "192-186-03",
            "Active_ingredient": "AZITHROMYCIN",
            "ATC_Code": "J01FA10",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:250mg,exacerbations:500mg",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIDAR",
            "Registration_Number": "73-124-06",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIDAR 500 mg film-coated tablet",
            "Registration_Number": "72-124-06",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIDAR",
            "Registration_Number": "81-124-08",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIMAC 500 mg film-coated tablet",
            "Registration_Number": "170-325-05",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT 125 MG - 5 ML SUSPENSION",
            "Registration_Number": "149-277-03",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT 250 MG - 5 ML SUSPENSION",
            "Registration_Number": "150-277-03",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT 250 MG FILM COATED",
            "Registration_Number": "131-277-02",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT 500 MG FILM COATED TAB",
            "Registration_Number": "132-277-02",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT XL 500 MG EXTENDED RELEASE TAB.",
            "Registration_Number": "164-277-05",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Modified-release tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARITT XL 500MG EXTENDED RELEASE TABLETS",
            "Registration_Number": "216-277-11",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIVA 250 MG TABLET",
            "Registration_Number": "32-498-11",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "EMIMYCIN 500 MG TABLETS",
            "Registration_Number": "30-444-08",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERACID 250MG TABLET",
            "Registration_Number": "45-171-04",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERACID 500MG FILM COATED TABLETS",
            "Registration_Number": "69-171-10",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID 125MG-5ML SUSP",
            "Registration_Number": "2-139-94",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID 250MG TAB",
            "Registration_Number": "1-139-93",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID 500MG COATED TAB",
            "Registration_Number": "9-138-99",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID XL 500MG TAB",
            "Registration_Number": "10-138-01",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLACID XL 500MG TAB",
            "Registration_Number": "13-138-04",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLARIMID 250MG F.C. TABLETS",
            "Registration_Number": "26-346-09",
            "Active_ingredient": "CLARITHROMYCIN ",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLARIMID 250MG-5ML SUSPENSION",
            "Registration_Number": "25-346-08",
            "Active_ingredient": "CLARITHROMYCIN ",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLARIMID 500MG F.C. TABLETS",
            "Registration_Number": "27-346-09",
            "Active_ingredient": "CLARITHROMYCIN ",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "RESCLAR 500MG TABLETS",
            "Registration_Number": "12-584-10",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "KLARE 500 mg film-coated tablet",
            "Registration_Number": "45-437-16",
            "Active_ingredient": "CLARITHROMYCIN ",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLARIDAR XL 500 mg Tablet",
            "Registration_Number": "109-124-18",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09  ",
            "Dosage_Form": "Sustain release Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "CLAMYCIN 250 MG TABLET",
            "Registration_Number": "168-186-02",
            "Active_ingredient": "CLARITHROMYCIN",
            "ATC_Code": "J01FA09",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "exacerbations:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYC 250MG CAPS",
            "Registration_Number": "2-217-93",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01  ",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYSOL 2% TOPICAL LOTION",
            "Registration_Number": "7-609-09",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01  ",
            "Dosage_Form": "Cutaneous solution",
            "ROA": "Topical",
            "Strength": "2",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHRODAR",
            "Registration_Number": "16-124-85",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01  ",
            "Dosage_Form": "Gastro-resistant tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHRODAR 400MG FORT TAB",
            "Registration_Number": "17-124-96",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHROMIL 200MG-5ML SUSP.",
            "Registration_Number": "61-119-89",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHROMIL FORTE 400MG-5MLSUSP.",
            "Registration_Number": "62-119-89",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "80",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "ERYTHROMYCIN LACTOBIONATE 1G IV VIAL",
            "Registration_Number": "17-237-97",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01  ",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "1",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "OMATHROCIN ORAL DROPS 100 MG- 2.5 ML",
            "Registration_Number": "18-390-06",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01  ",
            "Dosage_Form": "Oral drops*",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "OMATHROCIN 200 ORAL SUSPENSION",
            "Registration_Number": "25-390-08",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "OMATHROCIN 250 MG TABLET",
            "Registration_Number": "19-390-06",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "RYTHINATE SUSP. 200MG-5ML",
            "Registration_Number": "25-172-88",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01  ",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "EROMYCIN 200MG-5ML SUSP",
            "Registration_Number": "101-186-99",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",
            "Drug_Sub_Class": "Macrolides",
            "Trade_Name": "EROMYCIN 250MG TABLET",
            "Registration_Number": "216-186-04",
            "Active_ingredient": "ERYTHROMYCIN",
            "ATC_Code": "J01FA01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "prophylaxis:1g orally",
            "Notes_1": "For prophylaxis in stable COPD patients, azithromycin and erythromycin are recommended for up to 1 year. For management of acute exacerbations, macrolides are considered first line options (other first line options are doxycycline, amoxicillin and amoxicillin with clavulanic acid )."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "AMOXIL 250MG CAP.",
            "Registration_Number": "5-212-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "AMOXIL 500MG CAP.",
            "Registration_Number": "6-212-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "AMOXIL POWDER FOR ORAL SUSPENSION 125MG-5ML",
            "Registration_Number": "7-212-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "AMOXIL POWDER FOR ORAL SUSPENSION FORTE 250MG-5ML",
            "Registration_Number": "8-212-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "MOXIDAD CAPSULES 250MG",
            "Registration_Number": "5-124-92",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "MOXIDAD FORTE",
            "Registration_Number": "6-124-92",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "E-MOX 125MG DRY MIX.",
            "Registration_Number": "21-201-96",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "E-MOX 250MG DRY MIX.",
            "Registration_Number": "22-201-96",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "E-MOX 500MG CAPS",
            "Registration_Number": "23-201-96",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "GLOMOX 500MG CAP",
            "Registration_Number": "2-444-03",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 125MG-5ML POWDER FOR ORAL SUSPENSION",
            "Registration_Number": "88-212-98",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 200MG-5ML POWDER FOR SUSPENSION",
            "Registration_Number": "230-212-08",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 250MG CAPS",
            "Registration_Number": "78-212-98",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 250MG-5ML POWDER FOR ORAL SUSPENSION",
            "Registration_Number": "89-212-98",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 400MG-5ML POWDER FOR SUSPENSION",
            "Registration_Number": "231-212-08",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 500MG CAPS",
            "Registration_Number": "79-212-98",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "HYMOX 875 mg film-coated tablet",
            "Registration_Number": "255-212-09",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "875",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "NEOMOX 125MG-5ML SUSPENSION",
            "Registration_Number": "3-584-08",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "NEOMOX 250MG-5ML SUSPENSION",
            "Registration_Number": "2-584-08",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OMACILLIN 100MG-ML ORAL DROPS",
            "Registration_Number": "15-390-06",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral drops*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OMACILLIN 125MG-5ML POWDER FOR ORAL SUSP",
            "Registration_Number": "20-390-06",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OMACILLIN 250MG CAP",
            "Registration_Number": "2-390-03",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OMACILLIN 500MG CAPSULES",
            "Registration_Number": "14-390-06",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 125MG-5ML SUSP",
            "Registration_Number": "47-116-93",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 250MG CAPS",
            "Registration_Number": "49-116-93",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 250MG-5ML SUSP.",
            "Registration_Number": "48-116-93",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 500MG TAB",
            "Registration_Number": "50-116-93",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "OSPAMOX 500MG-5ML POWDER FOR ORAL SUSP.",
            "Registration_Number": "66-116-06",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "PENAMOX 250MG-5ML SUSP.",
            "Registration_Number": "17-172-92",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "PENAMOX CAPS 500 MG",
            "Registration_Number": "19-172-92",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "REMOX 125MG-5ML SUSPENSION",
            "Registration_Number": "15-334-99",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "REMOX 250 MG CAPSULES",
            "Registration_Number": "17-334-99",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "REMOX 250MG -5ML SUSPENSION",
            "Registration_Number": "16-334-99",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "REMOX 500 MG CAPSULES",
            "Registration_Number": "18-334-99",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "ULTRAMOX FORTE 250MG-5ML SUSP.",
            "Registration_Number": "64-119-89",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "ULTRAMOX FORTE CAPS 500MG",
            "Registration_Number": "72-119-90",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "JULPHAMOX 250MG CAPSULE",
            "Registration_Number": "114-186-00",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "250mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "JULPHAMOX 250MG SUSP.",
            "Registration_Number": "136-186-01",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "50mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Penicillins with extended spectrum",
            "Trade_Name": "JULPHAMOX 500MG CAPSULES",
            "Registration_Number": "115-186-00",
            "Active_ingredient": "AMOXICILLIN",
            "ATC_Code": "J01CA04",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "500mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3g orally",
            "Notes_1": "For management of acute exacerbations, amoxicillin is considered a first line option (other first line options are doxycycline, macrolides and co-amoxiclav). For patients unable to take oral antibiotics or severely unwell, amoxicillin is considered a first-line intravenous option. (other first-line intravenous options include clarithromycin, co-amoxiclav, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 1 GM TAB",
            "Registration_Number": "134-172-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875,125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 1.2 GM VIAL",
            "Registration_Number": "136-172-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1000, 200",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3600mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 156MG-5ML SUSP",
            "Registration_Number": "108-172-97",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25, 6.2",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 228MG\\5ML SUSP",
            "Registration_Number": "132-172-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40, 5.6",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 375 MG TAB.",
            "Registration_Number": "115-172-98",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250, 125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 457MG\\5ML SUSP",
            "Registration_Number": "133-172-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80, 11.4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN 600MG VIAL",
            "Registration_Number": "135-172-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500, 100",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3600mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN FORTE 312MG-5ML SUSP",
            "Registration_Number": "109-172-97",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOCLAN FORTE 625MG TAB",
            "Registration_Number": "116-172-98",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500, 125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AMOXIPLUS 1.2GM Powder for injection",
            "Registration_Number": "1-724-11",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for solution for injection",
            "ROA": "Parenteral",
            "Strength": "1, 0.2",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "3600mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN (ES) SUSPENSION",
            "Registration_Number": "116-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "120, 8.55",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 1 G TAB",
            "Registration_Number": "118-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875,125",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 1.2GM VIAL",
            "Registration_Number": "114-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1000, 200",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3600mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 156 Mg-5 ML SUSPENSION",
            "Registration_Number": "121-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25, 6.2",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 228 MG-5ML SUSPENSION",
            "Registration_Number": "115-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40, 5.6",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 312 MG-5ML SUSPENSION",
            "Registration_Number": "120-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.4",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 457MG-5ML SUSPENSION",
            "Registration_Number": "112-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80, 11.4",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 600MG VIAL",
            "Registration_Number": "113-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500,100",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3600mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN 625 MG TAB",
            "Registration_Number": "119-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500,125",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN INFANT DROP",
            "Registration_Number": "117-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "50, 12.5",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3600mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN SR TABLET",
            "Registration_Number": "111-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "1000, 62.5",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "AUGMENTIN TAB 375 MG",
            "Registration_Number": "122-276-13",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250, 125",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CLAVODAR 1GM F.C. TABLETS",
            "Registration_Number": "91-124-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875,125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CLAVODAR 457MG/5ML SUSPENSION",
            "Registration_Number": "93-124-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "457, 5",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CLAVODAR 625GM FILM COATED TABLET",
            "Registration_Number": "94-124-11",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500,125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CO AMOX - MEPHA 1000MG F.C. TABLETS",
            "Registration_Number": "28-222-09",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875, 125",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 1.2GM POW. FOR SOLN. FOR INJECTION- INFUSION",
            "Registration_Number": "80-116-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1000, 200",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3600mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 156.25MG-5ML POWDER FOR SUSP",
            "Registration_Number": "52-116-99",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25, 6.2",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 2.2GM POW. FOR SOLN. FOR INJECTION- INFUSION",
            "Registration_Number": "81-116-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "2000, 200",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3600mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 312.5 MG-5ML POWDER FOR SUSP",
            "Registration_Number": "53-116-99",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.4",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 457MG-5ML POW. FOR ORAL SUSPENSION",
            "Registration_Number": "78-116-09",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80, 11.4",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 600MG POW. FOR SOLN. FOR INJECTION- INFUSION",
            "Registration_Number": "79-116-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500, 100",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "3600mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "CURAM 625 MG F.C TAB",
            "Registration_Number": "51-116-99",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500,125",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "GLOCLAV 1GM FILM COATED TABLETS",
            "Registration_Number": "32-444-09",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875, 125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "GLOCLAV 375MG TAB",
            "Registration_Number": "3-444-04",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250, 125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "GLOCLAV 625MG TABLET",
            "Registration_Number": "4-444-04",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500, 125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 1GM TAB",
            "Registration_Number": "150-212-01",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875, 125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 228MG\\5ML SUSPENSION",
            "Registration_Number": "174-212-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40, 5.6",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 312.5 MG-5ML SUSPENSION",
            "Registration_Number": "77-212-98",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.5",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 375MG F.C.TAB",
            "Registration_Number": "74-212-98",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250, 125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 457MG\\5ML SUSPENSION",
            "Registration_Number": "175-212-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80, 11.4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 62.5MG DROPS",
            "Registration_Number": "191-212-03",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.5",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "KLAVOX 625MG F.C.TAB",
            "Registration_Number": "75-212-98",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500, 125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 156 MG SUSP",
            "Registration_Number": "28-334-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25, 6.2",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 1GM TAB",
            "Registration_Number": "45-334-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875,125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 228 MG SUSP",
            "Registration_Number": "30-334-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "40, 5.6",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 312MG SUSP",
            "Registration_Number": "29-334-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 375 MG TAB",
            "Registration_Number": "43-334-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250, 125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 457MG SUSP",
            "Registration_Number": "54-334-01",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80, 11.4",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 625 MG TAB",
            "Registration_Number": "74-334-02",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500, 125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX 625 MG TAB",
            "Registration_Number": "44-334-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500,125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "OXICLAV 625MG F.C.TABLETS",
            "Registration_Number": "23-539-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500, 125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "RAMOCLAV",
            "Registration_Number": "25-295-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "125, 31.25",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "RAMOCLAV",
            "Registration_Number": "26-295-10",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Oral suspension",
            "ROA": "Oral",
            "Strength": "250, 62.50",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MEGAMOX ES 600 mg powder for oral suspension",
            "Registration_Number": "228-334-16",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "120, 8.6",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "MOXICLAV 1 gm Film Coted Tablet",
            "Registration_Number": "8-718-18",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875, 125",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 1.2GM INJ.",
            "Registration_Number": "226-186-04",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1000, 200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 1.2GM INJ.",
            "Registration_Number": "225-186-04",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "1000, 200mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 156.25 MG POWDER FOR SUSP",
            "Registration_Number": "118-186-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "25, 6.2mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 2X. 1000MG TABLETS",
            "Registration_Number": "240-186-06",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "875, 125mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 2X. 457MG-5ML ORAL SUSPENSION",
            "Registration_Number": "241-186-06",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "80, 11.4mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 375 MG TAB",
            "Registration_Number": "116-186-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "250, 125mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 600MG INJ.",
            "Registration_Number": "223-186-04",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500, 100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 600MG INJ.",
            "Registration_Number": "224-186-04",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for injection",
            "ROA": "Parenteral",
            "Strength": "500, 100mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN 625 MG TAB",
            "Registration_Number": "117-186-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500, 125mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN ES SUSPENSION",
            "Registration_Number": "296-186-17",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "120, 8.58mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "JULMENTIN FORTE 312.5MG POWDER FOR SUSP",
            "Registration_Number": "119-186-00",
            "Active_ingredient": "AMOXICILLIN, CLAVULANIC ACID",
            "ATC_Code": "J01CR02",
            "Dosage_Form": "Powder for oral suspension",
            "ROA": "Oral",
            "Strength": "50, 12.5mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "1875mg",
            "Notes_1": "Use oral amox-clav in case of treatment failure with 2 of the following agents; amoxicillin, clarithromycin or doxycycline.OR for patients with high risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications). For patients unable to take oral antibiotics or severely unwell, co-amoxiclav is considered a first-line intravenous option. (other first-line intravenous options include (macrolides, co-trimoxazole and piperacillin with tazobactam.)"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PIPERACILLIN - TAZOPACTAM SANDOZ 2.25GM VIAL",
            "Registration_Number": "85-116-12",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2, 0.25",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "18g",
            "Notes_1": "ST: Piperacillin and tazobactam is recommended only for patients unable to take oral drugs or severely unwell"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PIPERACILLIN - TAZOPACTAM SANDOZ 4.5GM VIAL",
            "Registration_Number": "86-116-12",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "18g",
            "Notes_1": "ST: Piperacillin and tazobactam is recommended only for patients unable to take oral drugs or severely unwell"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PRIZMA 2GM/0.25GM POWDER FOR I.V. INFUSION",
            "Registration_Number": "138-334-11",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2000, 250",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "18g",
            "Notes_1": "ST: Piperacillin and tazobactam is recommended only for patients unable to take oral drugs or severely unwell"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PRIZMA 4GM-0.5GM POWDER FOR I.V INFUSION",
            "Registration_Number": "124-334-09",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "18g",
            "Notes_1": "ST: Piperacillin and tazobactam is recommended only for patients unable to take oral drugs or severely unwell"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "TAZOCIN 2.25G VIAL",
            "Registration_Number": "24-47-94",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2000, 250",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "18g",
            "Notes_1": "ST: Piperacillin and tazobactam is recommended only for patients unable to take oral drugs or severely unwell"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "TAZOCIN 4.5GM VIAL + EDTA",
            "Registration_Number": "1-497-05",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "18g",
            "Notes_1": "ST: Piperacillin and tazobactam is recommended only for patients unable to take oral drugs or severely unwell"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "TAZORAX 2.25 GM Powder for injection",
            "Registration_Number": "270-277-13",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "2, 0.25",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "18g",
            "Notes_1": "ST: Piperacillin and tazobactam is recommended only for patients unable to take oral drugs or severely unwell"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "TAZORAX 4.5 GM Powder for injection",
            "Registration_Number": "271-277-13",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "18g",
            "Notes_1": "ST: Piperacillin and tazobactam is recommended only for patients unable to take oral drugs or severely unwell"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BETA-LACTAM ANTIBACTERIALS, PENICILLINS",
            "Drug_Sub_Class": "Combinations of penicillins, incl. beta-lactamase inhibitors",
            "Trade_Name": "PIPERACILLIN - TAZOPACTAM SANDOZ 4.5GM VIAL",
            "Registration_Number": "103-116-17",
            "Active_ingredient": "PIPERACILLIN, TAZOBACTAM",
            "ATC_Code": "J01CR05",
            "Dosage_Form": "Powder for solution for infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "4, 0.5",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "18g",
            "Notes_1": "ST: Piperacillin and tazobactam is recommended only for patients unable to take oral drugs or severely unwell"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "APO-DOXY 100MG CAPS",
            "Registration_Number": "1-249-97",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "Age",
            "Quantity_Limit_Adults": "200mg",
            "Notes_1": "For management of acute exacerbations, doxycycline is an essential first line option (other first line options are amoxicillin and macrolides) .Age: The use of doxycycline for the treatment of acute infections in children aged 8 years to less than 12 years should be carefully justified in situations where other drugs are not available, are not likely to be effective or are contraindicated. Doxycycline should not be used in children aged younger than 8 years due to the risk of teeth discolouration. "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DORYX CAPS 100MG",
            "Registration_Number": "1-217-92",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "Age",
            "Quantity_Limit_Adults": "200mg",
            "Notes_1": "For management of acute exacerbations, doxycycline is an essential first line option (other first line options are amoxicillin and macrolides) .Age: The use of doxycycline for the treatment of acute infections in children aged 8 years to less than 12 years should be carefully justified in situations where other drugs are not available, are not likely to be effective or are contraindicated. Doxycycline should not be used in children aged younger than 8 years due to the risk of teeth discolouration. "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DOXYCIN",
            "Registration_Number": "122-325-04",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "Age",
            "Quantity_Limit_Adults": "200mg",
            "Notes_1": "For management of acute exacerbations, doxycycline is an essential first line option (other first line options are amoxicillin and macrolides) .Age: The use of doxycycline for the treatment of acute infections in children aged 8 years to less than 12 years should be carefully justified in situations where other drugs are not available, are not likely to be effective or are contraindicated. Doxycycline should not be used in children aged younger than 8 years due to the risk of teeth discolouration. "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DOXYDAR",
            "Registration_Number": "19-124-96",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "Age",
            "Quantity_Limit_Adults": "200mg",
            "Notes_1": "For management of acute exacerbations, doxycycline is an essential first line option (other first line options are amoxicillin and macrolides) .Age: The use of doxycycline for the treatment of acute infections in children aged 8 years to less than 12 years should be carefully justified in situations where other drugs are not available, are not likely to be effective or are contraindicated. Doxycycline should not be used in children aged younger than 8 years due to the risk of teeth discolouration. "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DUMOXIN SYRUP 10MG-ML",
            "Registration_Number": "50-49-81",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "10",
            "G_or_B": "G",
            "Prescribing_edits": "Age",
            "Quantity_Limit_Adults": "200mg",
            "Notes_1": "For management of acute exacerbations, doxycycline is an essential first line option (other first line options are amoxicillin and macrolides) .Age: The use of doxycycline for the treatment of acute infections in children aged 8 years to less than 12 years should be carefully justified in situations where other drugs are not available, are not likely to be effective or are contraindicated. Doxycycline should not be used in children aged younger than 8 years due to the risk of teeth discolouration. "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DUMOXIN TAB 100 MG",
            "Registration_Number": "49-49-81",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "Age",
            "Quantity_Limit_Adults": "200mg",
            "Notes_1": "For management of acute exacerbations, doxycycline is an essential first line option (other first line options are amoxicillin and macrolides) .Age: The use of doxycycline for the treatment of acute infections in children aged 8 years to less than 12 years should be carefully justified in situations where other drugs are not available, are not likely to be effective or are contraindicated. Doxycycline should not be used in children aged younger than 8 years due to the risk of teeth discolouration. "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "TABOCINE 100",
            "Registration_Number": "14-277-97",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule, hard",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "G",
            "Prescribing_edits": "Age",
            "Quantity_Limit_Adults": "200mg",
            "Notes_1": "For management of acute exacerbations, doxycycline is an essential first line option (other first line options are amoxicillin and macrolides) .Age: The use of doxycycline for the treatment of acute infections in children aged 8 years to less than 12 years should be carefully justified in situations where other drugs are not available, are not likely to be effective or are contraindicated. Doxycycline should not be used in children aged younger than 8 years due to the risk of teeth discolouration. "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "VIBRAMYCIN 100MG TABLET",
            "Registration_Number": "1-5029-18",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100",
            "G_or_B": "B",
            "Prescribing_edits": "Age",
            "Quantity_Limit_Adults": "200mg",
            "Notes_1": "For management of acute exacerbations, doxycycline is an essential first line option (other first line options are amoxicillin and macrolides) .Age: The use of doxycycline for the treatment of acute infections in children aged 8 years to less than 12 years should be carefully justified in situations where other drugs are not available, are not likely to be effective or are contraindicated. Doxycycline should not be used in children aged younger than 8 years due to the risk of teeth discolouration. "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "TETRACYCLINES",
            "Drug_Sub_Class": "Tetracyclines",
            "Trade_Name": "DURADOX 100 MG CAPS",
            "Registration_Number": "109-186-99",
            "Active_ingredient": "DOXYCYCLINE",
            "ATC_Code": "J01AA02",
            "Dosage_Form": "Capsule*",
            "ROA": "Oral",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "Age",
            "Quantity_Limit_Adults": "200mg",
            "Notes_1": "For management of acute exacerbations, doxycycline is an essential first line option (other first line options are amoxicillin and macrolides) .Age: The use of doxycycline for the treatment of acute infections in children aged 8 years to less than 12 years should be carefully justified in situations where other drugs are not available, are not likely to be effective or are contraindicated. Doxycycline should not be used in children aged younger than 8 years due to the risk of teeth discolouration. "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BACTRIM AMP 5ML I.V",
            "Registration_Number": "26-24-80",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "80, 16",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "2.88g",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BACTRIM FORTE TAB",
            "Registration_Number": "82-212-98",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "800, 160",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BACTRIM PED SYRUP (200+40mg-5ML)",
            "Registration_Number": "24-24-80",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BACTRIM SUSP(200+40MG-5ML)",
            "Registration_Number": "72-212-97",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8",
            "G_or_B": "B",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BALKATRIN SUSP( 200+40MG-5ML)",
            "Registration_Number": "41-119-82",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BALKATRIN SUSP( 200+40MG-5ML)",
            "Registration_Number": "42-119-82",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "BALKATRIN TAB",
            "Registration_Number": "40-119-82",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "400, 80",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "SEPTRIN I.M INJ 3ML",
            "Registration_Number": "50-8-84",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Solution for injection",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "266.7, 53.3",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "2.88g",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "SEPTRIN PAED TAB",
            "Registration_Number": "36-8-82",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "100, 20",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "ZOTRIM FORTE TAB.",
            "Registration_Number": "61-334-01",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "800, 160",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "ZOTRIM SUSP.",
            "Registration_Number": "60-334-01",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "SEPTRIN 240MG SUSP",
            "Registration_Number": "15-887-17",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01  ",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "SEPTRIN PAED TAB",
            "Registration_Number": "21-186-86",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "100, 20mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "TRIMOL SUSP.",
            "Registration_Number": "22-186-86",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "SULFONAMIDES AND TRIMETHOPRIM",
            "Drug_Sub_Class": "Combinations of sulfonamides and trimethoprim, incl. derivatives",
            "Trade_Name": "TRIMOL SUSP.",
            "Registration_Number": "30-186-87",
            "Active_ingredient": "SULFAMETHOXAZOLE, TRIMETHOPRIM",
            "ATC_Code": "J01EE01",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "40, 8mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "1920mg",
            "Notes_1": "ST: Combination of sulfamethoxazole and trimethoprim is a second line agent given in the following conditions:\r\n1.\tFailure of first line agents and contraindication to amox-clav (preferred second line agent)\r\n2.\tPatients with high risk of treatment failure who cannot take amox-clav\r\n3.\tPatients unable to take oral drugs or severely unwell,ONLY if other IV options are not available.                                                                                                                                                                                          "
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOFLOX 500MG F.C. TABLET",
            "Registration_Number": "37-390-12",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 500MG FILM COATED TABLETS",
            "Registration_Number": "162-334-12",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOX 500MG FILM COATED TABLET",
            "Registration_Number": "273-212-11",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOX 750MG FILM COATED TABLET",
            "Registration_Number": "274-212-11",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVANIC 250MG F.C TAB",
            "Registration_Number": "43-23-02",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "B",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVANIC 500MG F.C TAB",
            "Registration_Number": "44-23-02",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "B",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOFLOXACIN Sandoz 500 mg film-coated tablet",
            "Registration_Number": "96-116-15",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVACIN 500 mg film-coated tablet",
            "Registration_Number": "78-539-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVACIN 750 mg film-coated tablet",
            "Registration_Number": "79-539-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVAQUIN 250 mg film-coated tablet",
            "Registration_Number": "67-370-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVAQUIN 500 mg film-coated tablet",
            "Registration_Number": "68-370-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVON 500 mg film-coated tablet",
            "Registration_Number": "18-968-16",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVON 750 mg film-coated tablet",
            "Registration_Number": "19-968-16",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 250 mg film-coated tablet",
            "Registration_Number": "238-334-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 750 mg film-coated tablet",
            "Registration_Number": "239-334-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "PRINCEOXIN 500 mg film-coated tablet",
            "Registration_Number": "32-249-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "PRINCEOXIN 250 mg film-coated tablet",
            "Registration_Number": "31-249-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVFLOX 500 mg film-coated tablet",
            "Registration_Number": "48-437-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVANIX 500 mg film-coated tablet",
            "Registration_Number": "13-584-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVANIX 500 mg film-coated tablet",
            "Registration_Number": "14-584-17",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EVOX 250MG FILM COATED TABLET",
            "Registration_Number": "18-535-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EVOX 500MG FILM COATED TABLET",
            "Registration_Number": "19-535-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EVOX 750MG FILM COATED TABLET",
            "Registration_Number": "20-535-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LIVADOR 750MG F.C.TABLET",
            "Registration_Number": "117-124-18",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet  ",
            "ROA": "Oral",
            "Strength": "750",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LIVADOR 250 MG FILM COATED TABLET",
            "Registration_Number": "121-124-19",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "250",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LIVADOR 500 MG FILM COATED TABLET",
            "Registration_Number": "120-124-19",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "MD, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVOBAT 500 MG FILM COATED TABLET",
            "Registration_Number": "30-590-19",
            "Active_ingredient": "LEVOFLOXACIN HEMIHYDRATE",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "FLOXMED 500MG F.C.TABLET",
            "Registration_Number": "16-631-19",
            "Active_ingredient": "LEVOFLOXACIN (AS HEMIHYDRATE)",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "FILM COATED TABLET",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "EMIFLOC 500 mg Film-coated Tablet",
            "Registration_Number": "42-444-19",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "Film-coated tablet ",
            "ROA": "Oral",
            "Strength": "500",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LAVOXIN 500 mg solution for infusion",
            "Registration_Number": "20-535-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVODIS 5 mg/ml Solution For Injection",
            "Registration_Number": "68-370-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "B",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 5 mg/ml Infusion",
            "Registration_Number": "238-334-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 5 mg/ml Infusion",
            "Registration_Number": "249-334-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 500MG-100ML SOLUTION FOR I.V. INFUSION",
            "Registration_Number": "162-334-12",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LOXAMOX 250MG/50ML SOL. FOR IV INFUSION",
            "Registration_Number": "117-124-18",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12 ",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LOXAMOX 500MG/100ML SOL. FOR INFUSION",
            "Registration_Number": "17-5286-19",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12 ",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVANIC 5 MG -1 ML SOLUTION I.V INFUSION",
            "Registration_Number": "43-23-02",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LAVOXIN 500 mg solution for infusion",
            "Registration_Number": "20-535-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVODIS 5 mg/ml Solution For Injection",
            "Registration_Number": "68-370-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 5 mg/ml Infusion",
            "Registration_Number": "238-334-16",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 5 mg/ml Infusion",
            "Registration_Number": "249-334-17",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LEVONIC 500MG-100ML SOLUTION FOR I.V. INFUSION",
            "Registration_Number": "162-334-12",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LOXAMOX 250MG/50ML SOL. FOR IV INFUSION",
            "Registration_Number": "117-124-18",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12 ",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "LOXAMOX 500MG/100ML SOL. FOR INFUSION",
            "Registration_Number": "17-5286-19",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12 ",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "TAVANIC 5 MG -1 ML SOLUTION I.V INFUSION",
            "Registration_Number": "43-23-02",
            "Active_ingredient": "LEVOFLOXACIN",
            "ATC_Code": "J01MA12",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5mg/ml",
            "G_or_B": "B",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "500mg",
            "Notes_1": "MD: Levofloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Levofloxacin can be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialistAge: contraindicated in children (<18years) or growing adolescents."
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "AVALOX 400MG SOLUTION FOR I.V. INFUSION",
            "Registration_Number": "49-4-06",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "SOLUTION",
            "ROA": "Intravenous",
            "Strength": "400mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "AVALOX 400MG TAB",
            "Registration_Number": "43-4-01",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "AVALOX 400MG TAB",
            "Registration_Number": "42-4-01",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "AVORES 400 Film Coated Tablets",
            "Registration_Number": "81-171-19",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "AVORES 400 Film Coated Tablets",
            "Registration_Number": "80-171-19",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "FLOMOCIN 400 mg film-coated tablet",
            "Registration_Number": "3-5015-17",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "FLOMOCIN 400 mg film-coated tablet",
            "Registration_Number": "4-5015-17",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "FLOMOXIN 400 mg Solution for Infusion",
            "Registration_Number": "275-334-18",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "1.6mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "MAXIM 400MG FILM COATED TABLETS",
            "Registration_Number": "119-368-09",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "MAXIM 400MG FILM COATED TABLETS",
            "Registration_Number": "120-368-09",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "MOXICAN 400 mg film-coated tablet",
            "Registration_Number": "78-370-17",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "MOXIFLOX 400 mg film-coated tablet",
            "Registration_Number": "11-968-15",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "MOXIFLOX 400 mg film-coated tablet",
            "Registration_Number": "12-968-15",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "MOXIVE 400 mg film-coated tablet",
            "Registration_Number": "326-212-15",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "MOXIVE 400 mg film-coated tablet",
            "Registration_Number": "327-212-15",
            "Active_ingredient": "MOXIFLOXACIN",
            "ATC_Code": "J01MA14",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "QUINOLONE ANTIBACTERIALS",
            "Drug_Sub_Class": "Fluoroquinolones",
            "Trade_Name": "MOXIQUIN 400MG TABLET",
            "Registration_Number": "48-498-19",
            "Active_ingredient": "MOXIFLOXACIN HYDROCHLORIDE",
            "ATC_Code": "J01MA14 ",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST, Age",
            "Quantity_Limit_Adults": "400mg",
            "Notes_1": "AGE: Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established. MD: Moxifloxacin is essential for management of patients at higher risk of treatment failure (repeated courses of antibiotics, resistant bacteria in sputum culture or high risk of developing complications) Only if co-amoxiclav or co-trimoxazole cannot be used. Quinolones may be used as first line for severe COPD FEV1 < 50%, more than 3 exacerbations/year, antibiotic use in past 3 months. The specialist should review each case and decide the place in therapy. The safety concerns of levofloxacin should be reviewed and monitored by the specialist"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "VIRAL VACCINES",
            "Drug_Sub_Class": "Influenza vaccines",
            "Trade_Name": "ARAFLU 0.5/ML SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE",
            "Registration_Number": "4-800-13",
            "Active_ingredient": "INFLUENZA VACCINE",
            "ATC_Code": "J07BB",
            "Dosage_Form": "SUSPENSION FOR INJECTION",
            "ROA": "SC",
            "Strength": "0.5ML",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose",
            "Notes_2": "it should be part of  stable COPD management not COPD exacerbation"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "VIRAL VACCINES",
            "Drug_Sub_Class": "Influenza vaccines",
            "Trade_Name": "AGRIPPAL S1 45MG\\0.5ML PRE-FILLED SYRING",
            "Registration_Number": "3-286-01",
            "Active_ingredient": "INFLUENZA VACCINE",
            "ATC_Code": "J07BB",
            "Dosage_Form": "SUSPENSION FOR INJECTION",
            "ROA": "SC",
            "Strength": "0.5ML",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose",
            "Notes_2": "it should be part of  stable COPD management not COPD exacerbation"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "VIRAL VACCINES",
            "Drug_Sub_Class": "Influenza vaccines",
            "Trade_Name": "FLUARIX 15MCGOF ECH INFUENZA STR.5MLSRYG",
            "Registration_Number": "2-197-97",
            "Active_ingredient": "INFLUENZA VACCINE TYPE A &B",
            "ATC_Code": "J07BB",
            "Dosage_Form": "SUSPENSION FOR INJECTION",
            "ROA": "IM",
            "Strength": "0.5ML",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose",
            "Notes_2": "it should be part of  stable COPD management not COPD exacerbation"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "VIRAL VACCINES",
            "Drug_Sub_Class": "Influenza vaccines",
            "Trade_Name": "INFLUVAC S.INJ. 15 MCG-0.5ML",
            "Registration_Number": "1-728-96",
            "Active_ingredient": "INFLUENZA VACCINE TYPE A &B",
            "ATC_Code": "J07BB",
            "Dosage_Form": "SUSPENSION FOR INJECTION",
            "ROA": "SC",
            "Strength": "0.5ML",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose",
            "Notes_2": "it should be part of  stable COPD management not COPD exacerbation"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "VIRAL VACCINES",
            "Drug_Sub_Class": "Influenza vaccines",
            "Trade_Name": "VAXIGRIP SINGLE DOSE SYRINGE 0.5ML",
            "Registration_Number": "5-164-94",
            "Active_ingredient": "INFLUENZA VACCINE TYPE A &B",
            "ATC_Code": "J07BB",
            "Dosage_Form": "SUSPENSION FOR INJECTION",
            "ROA": "SC",
            "Strength": "0.5ML",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose",
            "Notes_2": "it should be part of  stable COPD management not COPD exacerbation"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BACTERIAL VACCINES",
            "Drug_Sub_Class": "Pneumococcal vaccines",
            "Trade_Name": "PNEUMOVAX 23 Solution for injection vaccine",
            "Registration_Number": "1-020-14",
            "Active_ingredient": "PNEUMOCOCCAL VACCINE",
            "ATC_Code": "J07AL01",
            "Dosage_Form": "Solution for injection",
            "ROA": "Subcutaneous",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "No Maximum daily dose",
            "Notes_2": "it should be part of  stable COPD management not COPD exacerbation"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BACTERIAL VACCINES",
            "Drug_Sub_Class": "Pneumococcal vaccines",
            "Trade_Name": "PREVENAR 13 PRE-FILLED SYRINGE VACCINE",
            "Registration_Number": "16-110-16",
            "Active_ingredient": "PNEUMOCOCCAL POLYSACHARIDE CONJUGATED",
            "ATC_Code": "J07AL01  ",
            "Dosage_Form": "Injection*",
            "ROA": "Subcutaneous",
            "G_or_B": "B",
            "Notes_2": "it should be part of  stable COPD management not COPD exacerbation"
        },
        {
            "Indication": "Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
            "ICD_Code": "J44.1",
            "Drug_Class": "BACTERIAL VACCINES",
            "Drug_Sub_Class": "Pneumococcal vaccines",
            "Trade_Name": "Pneumovax 23 Pneumococcal Vaccine Polyvalent",
            "Registration_Number": "4-20-19",
            "Active_ingredient": "Pneumococcal Polysaccharide Danish Type 1,2,3,4,5,6B,7F,8,9N,9V,10A,11A,12F,14,15B,17B,17F,18C,19A,19F,20,22F,23F,33F",
            "ATC_Code": "J07AL01  ",
            "Dosage_Form": "Solution for injection in pre-filled syringe ",
            "ROA": "Subcutaneous , Intravenous",
            "G_or_B": "B",
            "Notes_2": "it should be part of  stable COPD management not COPD exacerbation"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "0.9% W/V SODIUM CHLORIDE INJECTION B.P",
            "Registration_Number": "91-149-95",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "0.9% W/V SODIUM CHLORIDE INJECTION B.P",
            "Registration_Number": "92-149-95",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "0.9% W/V SODIUM CHLORIDE INJECTION B.P",
            "Registration_Number": "46-803-12",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "NORMAL SALINE (0.9% W/V SODIUM CHLORIDE) INJECTION",
            "Registration_Number": "11-5023-19",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05XA03",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "NORMAL SALINE (0.9% W/V SODIUM CHLORIDE) INJECTION",
            "Registration_Number": "12-5023-19",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05XA03",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "NORMAL SALINE (0.9% W/V SODIUM CHLORIDE) INJECTION",
            "Registration_Number": "14-5023-19",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05XA03",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "NORMAL SALINE (0.9% W/V SODIUM CHLORIDE) INJECTION",
            "Registration_Number": "11-149-91",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05XA03",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "NORMAL SALINE I.V. INFUSION",
            "Registration_Number": "67-149-93",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "NORMAL SALINE I.V. INFUSION",
            "Registration_Number": "10-149-91",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "NORMAL SALINE I.V. INFUSION",
            "Registration_Number": "66-149-93",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "NORMAL SALINE I.V. INFUSION",
            "Registration_Number": "9-149-91",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "NORMAL SALINE I.V. INFUSION",
            "Registration_Number": "9-407-03",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9%",
            "Registration_Number": "26-188-87",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9%",
            "Registration_Number": "129-149-96",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "79-549-99",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "36-549-90",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "81-549-99",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "82-549-99",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "27-549-90",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "32-253-98",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "31-253-98",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "33-253-98",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "29-253-98",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "30-253-98",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "28-253-98",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "9-158-86",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "8-158-86",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "8-168-89",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "32-168-93",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "5-168-89",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "6-168-89",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "33-168-93",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "38-168-96",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "36-168-96",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SOD.CHLORIDE 0.9% INJ",
            "Registration_Number": "83-549-99",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% BP INFUSION",
            "Registration_Number": "2-803-11",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Parenteral",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% BP INFUSION",
            "Registration_Number": "3-803-11",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Parenteral",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% BP INFUSION",
            "Registration_Number": "4-803-11",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Parenteral",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% BP INFUSION",
            "Registration_Number": "6-803-11",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Parenteral",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% BP INFUSION",
            "Registration_Number": "7-803-11",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Parenteral",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% BP INFUSION",
            "Registration_Number": "5-803-11",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Parenteral",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% BP INFUSION",
            "Registration_Number": "3-352-00",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "Solution for infusion",
            "ROA": "Parenteral",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% I.V INFUSION",
            "Registration_Number": "376-149-09",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION",
            "Registration_Number": "156-149-98",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION",
            "Registration_Number": "157-149-98",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION",
            "Registration_Number": "294-149-04",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION",
            "Registration_Number": "375-149-09",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION",
            "Registration_Number": "377-149-09",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION",
            "Registration_Number": "379-149-09",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION",
            "Registration_Number": "387-149-09",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION",
            "Registration_Number": "378-149-09",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION",
            "Registration_Number": "295-149-04",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION",
            "Registration_Number": "293-149-04",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION",
            "Registration_Number": "52-149-92",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION",
            "Registration_Number": "1-303-99",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INFUSION SOLN",
            "Registration_Number": "27-430-19",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INJECTION",
            "Registration_Number": "28-430-19",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01 ",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "IRRIGATING SOLUTIONS",
            "Drug_Sub_Class": "Salt solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% INJECTION",
            "Registration_Number": "20-762-12",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05CB01 ",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "PARENTERAL",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% SOLU. FOR I.V. INFU. IN VIAFLEX",
            "Registration_Number": "21-762-12",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05XA03",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% SOLU. FOR I.V. INFU. IN VIAFLEX",
            "Registration_Number": "22-762-12",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05XA03",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% SOLU. FOR I.V. INFU. IN VIAFLEX",
            "Registration_Number": "18-762-12",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05XA03",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% SOLU. FOR I.V. INFU. IN VIAFLEX",
            "Registration_Number": "19-762-12",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05XA03",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% SOLU. FOR I.V. INFU. IN VIAFLEX",
            "Registration_Number": "63-762-17",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05XA03",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% SOLU. FOR I.V. INFU. IN VIAFLEX",
            "Registration_Number": "62-762-17",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05XA03",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM CHLORIDE 0.9% SOLU. FOR I.V. INFU. IN VIAFLEX",
            "Registration_Number": "273-149-03",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05XA03",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "NORMAL SALINE (0.9% W/V SODIUM CHLORIDE) INJECTION",
            "Registration_Number": "6-353-00",
            "Active_ingredient": "SODIUM CHLORIDE",
            "ATC_Code": "B05XA03",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "0.9%",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "COMPOUND SODIUM LACTATE INF.",
            "Registration_Number": "55-149-93",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "COMPOUND SODIUM LACTATE INF.",
            "Registration_Number": "12-149-91",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "COMPOUND SODIUM LACTATE INF.",
            "Registration_Number": "13-149-91",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "COMPOUND SODIUM LACTATE INF.",
            "Registration_Number": "402-149-10",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "COMPOUND SODIUM LACTATE INFUSION",
            "Registration_Number": "46-168-96",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05XA31 ",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "LACTATED RINGERS",
            "Registration_Number": "30-168-91",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "LACTATED RINGERS",
            "Registration_Number": "71-549-99",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "LACTATED RINGERS INJ",
            "Registration_Number": "46-549-91",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "LACTATED RINGERS INJ",
            "Registration_Number": "45-549-91",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "LACTATED RINGERS INJ",
            "Registration_Number": "40-253-98",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "LACTATED RINGER'S INJ",
            "Registration_Number": "42-253-98",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "LACTATED RINGER'S INJ",
            "Registration_Number": "41-253-98",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "LACTATED RINGER'S INJ",
            "Registration_Number": "12-352-02",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "LACTATED RINGERS INJECTION USP 500 ML",
            "Registration_Number": "7-158-86",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGER LACTATE 500ML",
            "Registration_Number": "60-4-18",
            "Active_ingredient": "RINGER'S-LACTATE SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGERS INJECTION",
            "Registration_Number": "9-303-00",
            "Active_ingredient": "RINGERS SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGER SOLUTION I.V INFUSION",
            "Registration_Number": "18-352-02",
            "Active_ingredient": "RINGER'S SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGERS INJECATION 500 ML SOLUTION",
            "Registration_Number": "37-253-98",
            "Active_ingredient": "RINGER'S SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGER'S INJECTION",
            "Registration_Number": "36-253-98",
            "Active_ingredient": "RINGER'S SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGER'S INJECTION",
            "Registration_Number": "34-803-11",
            "Active_ingredient": "RINGER'S SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGER'S INJECTION",
            "Registration_Number": "35-803-11",
            "Active_ingredient": "RINGER'S SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "Solution for injection/infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGER'S INJECTION",
            "Registration_Number": "404-149-10",
            "Active_ingredient": "RINGER'S SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "Solution for injection/infusion",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGERS SOLUTION",
            "Registration_Number": "69-149-93",
            "Active_ingredient": "RINGER'S SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGERS SOLUTION",
            "Registration_Number": "73-149-93",
            "Active_ingredient": "RINGER'S SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGERS SOLUTION",
            "Registration_Number": "26-149-91",
            "Active_ingredient": "RINGER'S SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGERS SOLUTION",
            "Registration_Number": "165-149-98",
            "Active_ingredient": "RINGER'S SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGERS SOLUTION",
            "Registration_Number": "46-149-92",
            "Active_ingredient": "RINGER'S SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "I.V. SOLUTIONS",
            "Drug_Sub_Class": "Solutions affecting the electrolyte balance",
            "Trade_Name": "RINGERS SOLUTION",
            "Registration_Number": "38-253-98",
            "Active_ingredient": "RINGER'S SOLUTION",
            "ATC_Code": "B05BB01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "NA",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "30 mL/kg ",
            "Quantity_Limit_Pediatrics": "20ml/kg ",
            "Notes_1": "isotonic crystalloids are essential as initial management for expansion of intravascular volume in patients at risk for AKI or with AKI. Regular fluid assessment is required by physician till resolution of AKI. "
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "BLOOD AND RELATED PRODUCTS",
            "Drug_Sub_Class": "Blood substitutes and plasma protein fractions",
            "Trade_Name": "BUMINATE 5% BOTTLE FOR I.V ADMINISTRATIO",
            "Registration_Number": "73-253-07",
            "Active_ingredient": "ALBUMIN (HUMAN ALBUMIN SOLUTION)",
            "ATC_Code": "B05AA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "Intravenous",
            "Strength": "5%",
            "G_or_B": "G",
            "Prescribing_edits": "ST,PA",
            "Quantity_Limit_Adults": "12.5 g (250 mL) repeat as needed",
            "Quantity_Limit_Pediatrics": "1 g/kg/dose May repeat if response is not adequate ",
            "Notes_1": "Albumin is essential in case of resuscitation (septic shock)\r\nST: should be considered after inadequate response to crystalloid therapy.\r\nPA: used cautiously in patients with risk of volume overload assessed by specialist"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "BLOOD AND RELATED PRODUCTS",
            "Drug_Sub_Class": "Blood substitutes and plasma protein fractions",
            "Trade_Name": "BUMINATE 5% BOTTLE FOR I.V ADMINISTRATIO",
            "Registration_Number": "74-253-07",
            "Active_ingredient": "ALBUMIN (HUMAN ALBUMIN SOLUTION)",
            "ATC_Code": "B05AA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "Intravenous",
            "Strength": "5%",
            "G_or_B": "G",
            "Prescribing_edits": "ST,PA",
            "Quantity_Limit_Adults": "12.5 g (250 mL) repeat as needed",
            "Quantity_Limit_Pediatrics": "1 g/kg/dose May repeat if response is not adequate ",
            "Notes_1": "Albumin is essential in case of resuscitation (septic shock)\r\nST: should be considered after inadequate response to crystalloid therapy.\r\nPA: used cautiously in patients with risk of volume overload assessed by specialist"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "BLOOD AND RELATED PRODUCTS",
            "Drug_Sub_Class": "Blood substitutes and plasma protein fractions",
            "Trade_Name": "HUMAN ALBUMIN 5%",
            "Registration_Number": "5-163-00",
            "Active_ingredient": "ALBUMIN (HUMAN ALBUMIN SOLUTION)",
            "ATC_Code": "B05AA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5%",
            "G_or_B": "G",
            "Prescribing_edits": "ST,PA",
            "Quantity_Limit_Adults": "12.5 g (250 mL) repeat as needed",
            "Quantity_Limit_Pediatrics": "1 g/kg/dose May repeat if response is not adequate ",
            "Notes_1": "Albumin is essential in case of resuscitation (septic shock)\r\nST: should be considered after inadequate response to crystalloid therapy.\r\nPA: used cautiously in patients with risk of volume overload assessed by specialist"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "BLOOD AND RELATED PRODUCTS",
            "Drug_Sub_Class": "Blood substitutes and plasma protein fractions",
            "Trade_Name": "HUMAN ALBUMIN 5%",
            "Registration_Number": "6-163-00",
            "Active_ingredient": "ALBUMIN (HUMAN ALBUMIN SOLUTION)",
            "ATC_Code": "B05AA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5%",
            "G_or_B": "G",
            "Prescribing_edits": "ST,PA",
            "Quantity_Limit_Adults": "12.5 g (250 mL) repeat as needed",
            "Quantity_Limit_Pediatrics": "1 g/kg/dose May repeat if response is not adequate ",
            "Notes_1": "Albumin is essential in case of resuscitation (septic shock)\r\nST: should be considered after inadequate response to crystalloid therapy.\r\nPA: used cautiously in patients with risk of volume overload assessed by specialist"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "BLOOD AND RELATED PRODUCTS",
            "Drug_Sub_Class": "Blood substitutes and plasma protein fractions",
            "Trade_Name": "HUMAN ALBUMIN 5%",
            "Registration_Number": "9-160-85",
            "Active_ingredient": "ALBUMIN (HUMAN ALBUMIN SOLUTION)",
            "ATC_Code": "B05AA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5%",
            "G_or_B": "G",
            "Prescribing_edits": "ST,PA",
            "Quantity_Limit_Adults": "12.5 g (250 mL) repeat as needed",
            "Quantity_Limit_Pediatrics": "1 g/kg/dose May repeat if response is not adequate ",
            "Notes_1": "Albumin is essential in case of resuscitation (septic shock)\r\nST: should be considered after inadequate response to crystalloid therapy.\r\nPA: used cautiously in patients with risk of volume overload assessed by specialist"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "BLOOD AND RELATED PRODUCTS",
            "Drug_Sub_Class": "Blood substitutes and plasma protein fractions",
            "Trade_Name": "HUMAN ALBUMIN 5%",
            "Registration_Number": "8-160-85",
            "Active_ingredient": "ALBUMIN (HUMAN ALBUMIN SOLUTION)",
            "ATC_Code": "B05AA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5%",
            "G_or_B": "G",
            "Prescribing_edits": "ST,PA",
            "Quantity_Limit_Adults": "12.5 g (250 mL) repeat as needed",
            "Quantity_Limit_Pediatrics": "1 g/kg/dose May repeat if response is not adequate ",
            "Notes_1": "Albumin is essential in case of resuscitation (septic shock)\r\nST: should be considered after inadequate response to crystalloid therapy.\r\nPA: used cautiously in patients with risk of volume overload assessed by specialist"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "BLOOD AND RELATED PRODUCTS",
            "Drug_Sub_Class": "Blood substitutes and plasma protein fractions",
            "Trade_Name": "HUMAN ALBUMIN 50G-I BAXTER 250ML",
            "Registration_Number": "1-187-89",
            "Active_ingredient": "ALBUMIN (HUMAN ALBUMIN SOLUTION)",
            "ATC_Code": "B05AA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "5%",
            "G_or_B": "G",
            "Prescribing_edits": "ST,PA",
            "Quantity_Limit_Adults": "12.5 g (250 mL) repeat as needed",
            "Quantity_Limit_Pediatrics": "1 g/kg/dose May repeat if response is not adequate ",
            "Notes_1": "Albumin is essential in case of resuscitation (septic shock)\r\nST: should be considered after inadequate response to crystalloid therapy.\r\nPA: used cautiously in patients with risk of volume overload assessed by specialist"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "LEVOPHED 4MG-4ML AMP(I.V)",
            "Registration_Number": "53-549-02",
            "Active_ingredient": "NOREPINEPHRINE (NORADRENALINE) ACID TARTRATE",
            "ATC_Code": "C01CA03",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "1mg/ml",
            "G_or_B": "B",
            "Prescribing_edits": "PA,EU",
            "Quantity_Limit_Adults": "3.3mcg/kg/minute",
            "Quantity_Limit_Pediatrics": "2mcg/kg/minute",
            "Notes_1": "Norepinephrine is essential for treatment of shock in patients with, or at risk for, AKI.                                                                                                                                                    EU: should be used in emergency setting.                                                                                                                                                                                                                                                    PA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "EPINOR 1 mg/ml Injection",
            "Registration_Number": "14-430-18",
            "Active_ingredient": "NOREPINEPHRINE (NORADRENALINE) BITARTRATE",
            "ATC_Code": "C01CA03",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "1mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA,EU",
            "Quantity_Limit_Adults": "3.3mcg/kg/minute",
            "Quantity_Limit_Pediatrics": "2mcg/kg/minute",
            "Notes_1": "Norepinephrine is essential for treatment of shock in patients with, or at risk for, AKI.                                                                                                                                                    EU: should be used in emergency setting.                                                                                                                                                                                                                                                    PA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "NEVOLEEN 1 mg/ml Ampoule",
            "Registration_Number": "273-334-18",
            "Active_ingredient": "NOREPINEPHRINE (NORADRENALINE) BITARTRATE",
            "ATC_Code": "C01CA03",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "1mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA,EU",
            "Quantity_Limit_Adults": "3.3mcg/kg/minute",
            "Quantity_Limit_Pediatrics": "2mcg/kg/minute",
            "Notes_1": "Norepinephrine is essential for treatment of shock in patients with, or at risk for, AKI.                                                                                                                                                    EU: should be used in emergency setting.                                                                                                                                                                                                                                                    PA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "NOREPIRIN 2 mg/ml Injection",
            "Registration_Number": "1-5160-18",
            "Active_ingredient": "NOREPINEPHRINE (NORADRENALINE) BITARTRATE",
            "ATC_Code": "C01CA03",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "2mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA,EU",
            "Quantity_Limit_Adults": "3.3mcg/kg/minute",
            "Quantity_Limit_Pediatrics": "2mcg/kg/minute",
            "Notes_1": "Norepinephrine is essential for treatment of shock in patients with, or at risk for, AKI.                                                                                                                                                    EU: should be used in emergency setting.                                                                                                                                                                                                                                                    PA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "DOMINE 40 mg/ml concentrate for solution for infusion",
            "Registration_Number": "234-334-16",
            "Active_ingredient": "DOPAMINE HYDROCHLORIDE",
            "ATC_Code": "C01CA04",
            "Dosage_Form": "INJECTION, SOLUTION, CONCENTRATE",
            "ROA": "INTRAVENOUS",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, EU, ST",
            "Quantity_Limit_Adults": "50 mcg/kg/minute",
            "Quantity_Limit_Pediatrics": "based on response ",
            "Notes_1": "dopamine is essential for treatment of shock in patients with, or at risk for, AKI\r\nEU: should be used in emergency setting. \r\nPA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock.\r\nST: should be used after norepinephrine."
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "DOPAMIN HCL 40MG-ML INJ VIAL",
            "Registration_Number": "7-549-89",
            "Active_ingredient": "DOPAMINE HYDROCHLORIDE",
            "ATC_Code": "C01CA04",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, EU, ST",
            "Quantity_Limit_Adults": "50 mcg/kg/minute",
            "Quantity_Limit_Pediatrics": "based on response ",
            "Notes_1": "dopamine is essential for treatment of shock in patients with, or at risk for, AKI\r\nEU: should be used in emergency setting. \r\nPA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock.\r\nST: should be used after norepinephrine."
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "DOPAMIN HCL INJ 40MG-ML SYRING",
            "Registration_Number": "9-549-89",
            "Active_ingredient": "DOPAMINE HYDROCHLORIDE",
            "ATC_Code": "C01CA04",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "40mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, EU, ST",
            "Quantity_Limit_Adults": "50 mcg/kg/minute",
            "Quantity_Limit_Pediatrics": "based on response ",
            "Notes_1": "dopamine is essential for treatment of shock in patients with, or at risk for, AKI\r\nEU: should be used in emergency setting. \r\nPA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock.\r\nST: should be used after norepinephrine."
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "ADRENALINE 0.1MG/ML INJECTION",
            "Registration_Number": "2-5077-19",
            "Active_ingredient": "ADRENALINE/EPINEPHRINE",
            "ATC_Code": "C01CA24",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRATHECAL, INTRAVENOUS ,INTRAMUSCULAR",
            "Strength": "0.1mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, EU,(CU, ST adults)",
            "Quantity_Limit_Adults": "0.7 mcg/kg/minute",
            "Quantity_Limit_Pediatrics": "0.5 mg every 20 minutes for 3 doses",
            "Notes_1": "epinephrine is essential for treatment of shock in patients with, or at risk for, AKI\r\nEU: should be used in emergency setting. CU(adults): epinephrine is used as add on therapy to norepinephrine \r\nPA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock.\r\nST(adults): should be used after norepinephrine. epinephrine is first line in pediatrics"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "ADRENALINE 1:1000 INJ",
            "Registration_Number": "1-239-86",
            "Active_ingredient": "EPINEPHRINE (ADRENALINE)",
            "ATC_Code": "C01CA24",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "Intravenous",
            "Strength": "1mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, EU,(CU, ST adults)",
            "Quantity_Limit_Adults": "0.7 mcg/kg/minute",
            "Quantity_Limit_Pediatrics": "0.5 mg every 20 minutes for 3 doses",
            "Notes_1": "epinephrine is essential for treatment of shock in patients with, or at risk for, AKI\r\nEU: should be used in emergency setting. CU(adults): epinephrine is used as add on therapy to norepinephrine \r\nPA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock.\r\nST(adults): should be used after norepinephrine. epinephrine is first line in pediatrics"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "ADRENALINE HCL 1MG-ML AMP",
            "Registration_Number": "1-526-84",
            "Active_ingredient": "EPINEPHRINE (ADRENALINE)",
            "ATC_Code": "C01CA24",
            "Dosage_Form": "SOLUTION",
            "ROA": "Intravenous",
            "Strength": "1mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, EU,(CU, ST adults)",
            "Quantity_Limit_Adults": "0.7 mcg/kg/minute",
            "Quantity_Limit_Pediatrics": "0.5 mg every 20 minutes for 3 doses",
            "Notes_1": "epinephrine is essential for treatment of shock in patients with, or at risk for, AKI\r\nEU: should be used in emergency setting. CU(adults): epinephrine is used as add on therapy to norepinephrine \r\nPA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock.\r\nST(adults): should be used after norepinephrine. epinephrine is first line in pediatrics"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "EPINEPHRINE INJ 1:10000 ABBOJECT GLASS SYRINGE (18 G x 3 1/2\")",
            "Registration_Number": "5-549-89",
            "Active_ingredient": "EPINEPHRINE (ADRENALINE)",
            "ATC_Code": "C01CA24",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "100µg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, EU,(CU, ST adults)",
            "Quantity_Limit_Adults": "0.7 mcg/kg/minute",
            "Quantity_Limit_Pediatrics": "0.5 mg every 20 minutes for 3 doses",
            "Notes_1": "epinephrine is essential for treatment of shock in patients with, or at risk for, AKI\r\nEU: should be used in emergency setting. CU(adults): epinephrine is used as add on therapy to norepinephrine \r\nPA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock.\r\nST(adults): should be used after norepinephrine. epinephrine is first line in pediatrics"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "EPINEPHRINE INJ 1:10000 ABBOJECT GLASS SYRINGE (20 G x 1 1/2\")",
            "Registration_Number": "6-549-89",
            "Active_ingredient": "EPINEPHRINE (ADRENALINE)",
            "ATC_Code": "C01CA24",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "100µg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, EU,(CU, ST adults)",
            "Quantity_Limit_Adults": "0.7 mcg/kg/minute",
            "Quantity_Limit_Pediatrics": "0.5 mg every 20 minutes for 3 doses",
            "Notes_1": "epinephrine is essential for treatment of shock in patients with, or at risk for, AKI\r\nEU: should be used in emergency setting. CU(adults): epinephrine is used as add on therapy to norepinephrine \r\nPA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock.\r\nST(adults): should be used after norepinephrine. epinephrine is first line in pediatrics"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "DOBUJECT 50MG-ML(250MG-5ML) AMPOULE",
            "Registration_Number": "1-881-13",
            "Active_ingredient": "DOBUTAMINE",
            "ATC_Code": "C01CA07",
            "Dosage_Form": "SOLUTION, CONCENTRATE",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "50mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, EU, ST",
            "Quantity_Limit_Adults": "no available dose in shock",
            "Notes_1": "dobutamine is essential for treatment of shock in patients with, or at risk for, AKI.\r\nEU: should be used in emergency setting. \r\nPA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock.\r\nST: should be used after norepinephrine."
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "DOBUTAMINE HCL 250MG-20ML VIAL",
            "Registration_Number": "39-237-98",
            "Active_ingredient": "DOBUTAMINE",
            "ATC_Code": "C01CA07",
            "Dosage_Form": "SOLUTION, CONCENTRATE",
            "ROA": "INTRAVENOUS",
            "Strength": "12.5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, EU, ST",
            "Quantity_Limit_Adults": "no available dose in shock",
            "Notes_1": "dobutamine is essential for treatment of shock in patients with, or at risk for, AKI.\r\nEU: should be used in emergency setting. \r\nPA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock.\r\nST: should be used after norepinephrine."
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "DOBUTAMINE JPI 250 mg/20 ml solution for IV infusion",
            "Registration_Number": "232-334-16",
            "Active_ingredient": "DOBUTAMINE",
            "ATC_Code": "C01CA07",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "12.5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, EU, ST",
            "Quantity_Limit_Adults": "no available dose in shock",
            "Notes_1": "dobutamine is essential for treatment of shock in patients with, or at risk for, AKI.\r\nEU: should be used in emergency setting. \r\nPA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock.\r\nST: should be used after norepinephrine."
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES",
            "Drug_Sub_Class": "Adrenergic and dopaminergic agents",
            "Trade_Name": "DOBUTAMINE JPI 250 mg/20 ml solution for IV infusion",
            "Registration_Number": "241-334-17",
            "Active_ingredient": "DOBUTAMINE",
            "ATC_Code": "C01CA07",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "12.5mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "PA, EU, ST",
            "Quantity_Limit_Adults": "no available dose in shock",
            "Notes_1": "dobutamine is essential for treatment of shock in patients with, or at risk for, AKI.\r\nEU: should be used in emergency setting. \r\nPA: should be used in persistent hypotension despite aggressive fluid resuscitation or after optimization of intravascular volume in patients with shock.\r\nST: should be used after norepinephrine."
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "DIUSEMIDE 20MG-2ML AMP",
            "Registration_Number": "81-119-96",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "10mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "200 mg/dose",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "DIUSEMIDE 40 MG TAB",
            "Registration_Number": "10-119-82",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "40mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "600 mg/day",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "IMPUGAN 10MG-ML INJ 2ML AMP",
            "Registration_Number": "34-49-81",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "10mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "200 mg/dose",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "IMPUGAN TABLETS 40 MG",
            "Registration_Number": "35-49-81",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "40mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "600 mg/day",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "LASIX AMP 20MG-2ML",
            "Registration_Number": "9-23-80",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "10mg/ml",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "200 mg/dose",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "LASIX AMP 20MG-2ML",
            "Registration_Number": "13-883-16",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "10mg/ml",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "200 mg/dose",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "LASIX INFUSION SOLN 250 MG.",
            "Registration_Number": "34-23-87",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "250mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "200 mg/dose",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "LASIX INFUSION SOLN 250 MG.",
            "Registration_Number": "14-883-17",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "250mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "200 mg/dose",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "LASIX PAED. LIQUID",
            "Registration_Number": "1-544-92",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "SOLUTION",
            "ROA": "ORAL",
            "Strength": "1mg/ml",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "600 mg/day",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "LASIX TAB 40 MG",
            "Registration_Number": "8/23/80",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "40mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "600 mg/day",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "OEDEMAX",
            "Registration_Number": "4-152-87",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "40mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "600 mg/day",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "OEDEMAX",
            "Registration_Number": "3-152-87",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "40mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "600 mg/day",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "SALURIN 20MG-2ML AMPOULES",
            "Registration_Number": "252-186-08",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "Injection*",
            "ROA": "Intravenous (not otherwise specified)",
            "Strength": "10mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "200 mg/dose",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "SALURIN 40 MG TABLETS",
            "Registration_Number": "205-186-03",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "40mg",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "600 mg/day",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "SALURIN 5MG-5ML SYRUP",
            "Registration_Number": "183-186-02",
            "Active_ingredient": "FUROSEMIDE",
            "ATC_Code": "C03CA01",
            "Dosage_Form": "Syrup",
            "ROA": "Oral",
            "Strength": "1mg/ml",
            "G_or_B": "G",
            "Quantity_Limit_Adults": "600 mg/day",
            "Quantity_Limit_Pediatrics": "600 mg/day",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (AKI)",
            "ICD_Code": "N17",
            "Drug_Class": "HIGH-CEILING DIURETICS",
            "Drug_Sub_Class": "Sulfonamides, plain",
            "Trade_Name": "BURINEX TABLETS 1 MG",
            "Registration_Number": "2-19-82",
            "Active_ingredient": "BUMETANIDE",
            "ATC_Code": "C03CA02",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "1mg",
            "G_or_B": "B",
            "Quantity_Limit_Adults": "10mg",
            "Notes_1": "Loop diuretics are essential for treatment of volume overload"
        },
        {
            "Indication": "Acute Kidney Injury (CI-AKI)-Contrast Induced",
            "ICD_Code": "N14.1, N14.2, N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "BASIC BICARBONATE CONCENTRATE 8.4% INFUS",
            "Registration_Number": "12-353-00",
            "Active_ingredient": "SODIUM BICARBONATE",
            "ATC_Code": "B05XA02",
            "Dosage_Form": "SOLUTION",
            "ROA": "Intravenous",
            "Strength": "8.4%",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "Not applicable",
            "Notes_1": "Sodium bicarbonate is essential for I.V. volume expansion, in patients at increased risk for contrast induced acute kidney injury although not FDA approved for this indication but is recommended by guidelines with high level of evidence(1A).\r\n"
        },
        {
            "Indication": "Acute Kidney Injury (CI-AKI)-Contrast Induced",
            "ICD_Code": "N14.1, N14.2, N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM BICARB. SOLUTION CAT.NO 3F-005",
            "Registration_Number": "43-149-92",
            "Active_ingredient": "SODIUM BICARBONATE",
            "ATC_Code": "B05XA02",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "8.4%",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "Not applicable",
            "Notes_1": "Sodium bicarbonate is essential for I.V. volume expansion, in patients at increased risk for contrast induced acute kidney injury although not FDA approved for this indication but is recommended by guidelines with high level of evidence(1A).\r\n"
        },
        {
            "Indication": "Acute Kidney Injury (CI-AKI)-Contrast Induced",
            "ICD_Code": "N14.1, N14.2, N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM BICARBONATE 8.4% INF.",
            "Registration_Number": "27-149-91",
            "Active_ingredient": "SODIUM BICARBONATE",
            "ATC_Code": "B05XA02",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "8.4%",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "Not applicable",
            "Notes_1": "Sodium bicarbonate is essential for I.V. volume expansion, in patients at increased risk for contrast induced acute kidney injury although not FDA approved for this indication but is recommended by guidelines with high level of evidence(1A).\r\n"
        },
        {
            "Indication": "Acute Kidney Injury (CI-AKI)-Contrast Induced",
            "ICD_Code": "N14.1, N14.2, N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM BICARBONATE 8.4% INF.",
            "Registration_Number": "47-149-92",
            "Active_ingredient": "SODIUM BICARBONATE",
            "ATC_Code": "B05XA02",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "8.4%",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "Not applicable",
            "Notes_1": "Sodium bicarbonate is essential for I.V. volume expansion, in patients at increased risk for contrast induced acute kidney injury although not FDA approved for this indication but is recommended by guidelines with high level of evidence(1A).\r\n"
        },
        {
            "Indication": "Acute Kidney Injury (CI-AKI)-Contrast Induced",
            "ICD_Code": "N14.1, N14.2, N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM BICARBONATE 8.4% INF.",
            "Registration_Number": "65-549-95",
            "Active_ingredient": "SODIUM BICARBONATE",
            "ATC_Code": "B05XA02",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "8.4%",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "Not applicable",
            "Notes_1": "Sodium bicarbonate is essential for I.V. volume expansion, in patients at increased risk for contrast induced acute kidney injury although not FDA approved for this indication but is recommended by guidelines with high level of evidence(1A).\r\n"
        },
        {
            "Indication": "Acute Kidney Injury (CI-AKI)-Contrast Induced",
            "ICD_Code": "N14.1, N14.2, N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM BICARBONATE 8.4% INJ. ",
            "Registration_Number": "35-549-90",
            "Active_ingredient": "SODIUM BICARBONATE",
            "ATC_Code": "B05XA02",
            "Dosage_Form": "INJECTION, SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "8.4%",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "Not applicable",
            "Notes_1": "Sodium bicarbonate is essential for I.V. volume expansion, in patients at increased risk for contrast induced acute kidney injury although not FDA approved for this indication but is recommended by guidelines with high level of evidence(1A).\r\n"
        },
        {
            "Indication": "Acute Kidney Injury (CI-AKI)-Contrast Induced",
            "ICD_Code": "N14.1, N14.2, N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM BICARBONATE 8.4% INJ. VIAL",
            "Registration_Number": "222-149-01",
            "Active_ingredient": "SODIUM BICARBONATE",
            "ATC_Code": "B05XA02",
            "Dosage_Form": "SOLUTION",
            "ROA": "INTRAVENOUS",
            "Strength": "8.4%",
            "G_or_B": "G",
            "Prescribing_edits": "ST",
            "Quantity_Limit_Adults": "Not applicable",
            "Notes_1": "Sodium bicarbonate is essential for I.V. volume expansion, in patients at increased risk for contrast induced acute kidney injury although not FDA approved for this indication but is recommended by guidelines with high level of evidence(1A).\r\n"
        },
        {
            "Indication": "Acute Kidney Injury (CI-AKI)-Contrast Induced",
            "ICD_Code": "N14.1, N14.2, N17",
            "Drug_Class": "I.V. SOLUTION ADDITIVES",
            "Drug_Sub_Class": "Electrolyte solutions",
            "Trade_Name": "SODIUM BICARBONATE 325 mg Tablet",
            "Active_ingredient": "SODIUM BICARBONATE",
            "ATC_Code": "B05XA02  ",
            "Dosage_Form": "Tablet",
            "ROA": "Oral",
            "Strength": "325 mg",
            "Quantity_Limit_Adults": "5850 mg/day",
            "Notes_1": "Sodium Bicarbonate is essential for treatment of metabolic acidosis associated with chronic kidney .\r\n"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Lithium",
            "Trade_Name": "LITAREX. TAB 564MG",
            "Registration_Number": "46-49-81",
            "Active_ingredient": "LITHIUM CITRATE",
            "ATC_Code": "N05AN01",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "564 MG",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, PA",
            "Quantity_Limit_Adults": "based on serum level",
            "Quantity_Limit_Pediatrics": "based on serum level",
            "Notes_1": "lithium is essenial for treatment of acute mania episodes as first line treatmentin adults, elderly and pediatrics. AGE: it should be used in children > 12 years old.\r\nPA: Lithium therapy should not be initiated unless adequate facilities for routine monitoring of serum concentrations are available"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Lithium",
            "Trade_Name": "LITHIOFOR 660MG TAB",
            "Registration_Number": "1-157-85",
            "Active_ingredient": "LITHIUM SULPHATE",
            "ATC_Code": "N05AN01",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "660 MG",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, PA",
            "Quantity_Limit_Adults": "based on serum level",
            "Quantity_Limit_Pediatrics": "based on serum level",
            "Notes_1": "lithium is essenial for treatment of acute mania episodes as first line treatmentin adults, elderly and pediatrics. AGE: it should be used in children > 12 years old.\r\nPA: Lithium therapy should not be initiated unless adequate facilities for routine monitoring of serum concentrations are available"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Butyrophenone derivatives",
            "Trade_Name": "SYLADOR INJ 5MG-ML",
            "Registration_Number": "58-49-86",
            "Active_ingredient": "HALOPERIDOL",
            "ATC_Code": "N05AD01",
            "Dosage_Form": "SOLUTION FOR INJECTION",
            "ROA": "PARENTERAL",
            "Strength": "5 MG/ML",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, PA, ST",
            "Quantity_Limit_Adults": "acute mania: 15 mg, agitation: 20 mg according EMC , 15 mg according to guidelines",
            "Notes_1": "haloperidol is essential as monotherapy or adjunctive therapy for management of acute mania episodes and agitation in bipolar disorder patients.\r\nAGE: Treatment of moderate to severe manic episodes associated with bipolar I disorder in patients ≥ 18 years.\r\nPA: patients must be regularly monitored for response and tolerability.\r\nST: second line option as monotherapy or third line option as adjunctive therapy for acute mania and second line for agitation associated with mania"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Butyrophenone derivatives",
            "Trade_Name": "HALDOL 5MG-ML AMP",
            "Registration_Number": "20-6-81",
            "Active_ingredient": "HALOPERIDOL",
            "ATC_Code": "N05AD01",
            "Dosage_Form": "SOLUTION FOR INJECTION",
            "ROA": "PARENTERAL",
            "Strength": "5 MG/ML",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, PA, ST",
            "Quantity_Limit_Adults": "acute mania: 15 mg, agitation: 20 mg according EMC , 15 mg according to guidelines",
            "Notes_1": "haloperidol is essential as monotherapy or adjunctive therapy for management of acute mania episodes and agitation in bipolar disorder patients.\r\nAGE: Treatment of moderate to severe manic episodes associated with bipolar I disorder in patients ≥ 18 years.\r\nPA: patients must be regularly monitored for response and tolerability.\r\nST: second line option as monotherapy or third line option as adjunctive therapy for acute mania and second line for agitation associated with mania"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Butyrophenone derivatives",
            "Trade_Name": "HALDOL 2MG-ML DROPS",
            "Registration_Number": "19-6-81",
            "Active_ingredient": "HALOPERIDOL",
            "ATC_Code": "N05AD01",
            "Dosage_Form": "DROPS (SOLUTION)",
            "ROA": "ORAL",
            "Strength": "2 MG/ML",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, PA, ST",
            "Quantity_Limit_Adults": "acute mania: 15 mg, agitation: 20 mg according EMC , 15 mg according to guidelines",
            "Notes_1": "haloperidol is essential as monotherapy or adjunctive therapy for management of acute mania episodes and agitation in bipolar disorder patients.\r\nAGE: Treatment of moderate to severe manic episodes associated with bipolar I disorder in patients ≥ 18 years.\r\nPA: patients must be regularly monitored for response and tolerability.\r\nST: second line option as monotherapy or third line option as adjunctive therapy for acute mania and second line for agitation associated with mania"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Butyrophenone derivatives",
            "Trade_Name": "SYLADOR TAB. 5 MG.",
            "Registration_Number": "61-49-86",
            "Active_ingredient": "HALOPERIDOL",
            "ATC_Code": "N05AD01",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "5 MG_",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, PA, ST",
            "Quantity_Limit_Adults": "acute mania: 15 mg, agitation: 20 mg according EMC , 15 mg according to guidelines",
            "Notes_1": "haloperidol is essential as monotherapy or adjunctive therapy for management of acute mania episodes and agitation in bipolar disorder patients.\r\nAGE: Treatment of moderate to severe manic episodes associated with bipolar I disorder in patients ≥ 18 years.\r\nPA: patients must be regularly monitored for response and tolerability.\r\nST: second line option as monotherapy or third line option as adjunctive therapy for acute mania and second line for agitation associated with mania"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Butyrophenone derivatives",
            "Trade_Name": "HALDOL 5MG TABLET",
            "Registration_Number": "92-6-03",
            "Active_ingredient": "HALOPERIDOL",
            "ATC_Code": "N05AD01",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "5 MG_",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, PA, ST",
            "Quantity_Limit_Adults": "acute mania: 15 mg, agitation: 20 mg according EMC , 15 mg according to guidelines",
            "Notes_1": "haloperidol is essential as monotherapy or adjunctive therapy for management of acute mania episodes and agitation in bipolar disorder patients.\r\nAGE: Treatment of moderate to severe manic episodes associated with bipolar I disorder in patients ≥ 18 years.\r\nPA: patients must be regularly monitored for response and tolerability.\r\nST: second line option as monotherapy or third line option as adjunctive therapy for acute mania and second line for agitation associated with mania"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Butyrophenone derivatives",
            "Trade_Name": "SYLADOR 0.5MG TAB",
            "Registration_Number": "59-49-86",
            "Active_ingredient": "HALOPERIDOL",
            "ATC_Code": "N05AD01",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "0.5 MG",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, PA, ST",
            "Quantity_Limit_Adults": "acute mania: 15 mg, agitation: 20 mg according EMC , 15 mg according to guidelines",
            "Notes_1": "haloperidol is essential as monotherapy or adjunctive therapy for management of acute mania episodes and agitation in bipolar disorder patients.\r\nAGE: Treatment of moderate to severe manic episodes associated with bipolar I disorder in patients ≥ 18 years.\r\nPA: patients must be regularly monitored for response and tolerability.\r\nST: second line option as monotherapy or third line option as adjunctive therapy for acute mania and second line for agitation associated with mania"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Butyrophenone derivatives",
            "Trade_Name": "SYLADOR TAB 2 MG.",
            "Registration_Number": "60-49-86",
            "Active_ingredient": "HALOPERIDOL",
            "ATC_Code": "N05AD01",
            "Dosage_Form": "TABLETS",
            "ROA": "ORAL",
            "Strength": "2 MG",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, PA, ST",
            "Quantity_Limit_Adults": "acute mania: 15 mg, agitation: 20 mg according EMC , 15 mg according to guidelines",
            "Notes_1": "haloperidol is essential as monotherapy or adjunctive therapy for management of acute mania episodes and agitation in bipolar disorder patients.\r\nAGE: Treatment of moderate to severe manic episodes associated with bipolar I disorder in patients ≥ 18 years.\r\nPA: patients must be regularly monitored for response and tolerability.\r\nST: second line option as monotherapy or third line option as adjunctive therapy for acute mania and second line for agitation associated with mania"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ABILIFY MAINTENA 400 mg Powder And Solvent For Prolonged-Release",
            "Registration_Number": "39-136-17",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "POWDER, FOR SOLUTION",
            "ROA": "INTRAMUSCULAR",
            "Strength": "400mg",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "400 mg monthly",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.IM Dosage_Form is essential for managenent of agitation associated with mania, it is not approved by EMC but recommened by guidelines with stron level of evidence)\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARIPEX 10 mg tablet",
            "Registration_Number": "13-968-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARIPEX 15 mg tablet",
            "Registration_Number": "15-968-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARIPEX 5 mg tablet",
            "Registration_Number": "14-968-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARPENIA 1 mg/ml Oral Solution",
            "Registration_Number": "14-993-18",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "SOLUTION",
            "ROA": "ORAL",
            "Strength": "1mg/ml",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARPENIA 10 mg ORODISPERSIBLE TABLET",
            "Registration_Number": "351-277-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARPENIA 10 mg tablet",
            "Registration_Number": "324-277-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARPENIA 15 mg ORODISPERSIBLE TABLET",
            "Registration_Number": "352-277-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ARPENIA 15 mg tablet",
            "Registration_Number": "325-277-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ZOLINDA 10 mg tablet",
            "Registration_Number": "328-212-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ZOLINDA 15 mg tablet",
            "Registration_Number": "330-212-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ZOLINDA 5 mg tablet",
            "Registration_Number": "329-212-16",
            "Active_ingredient": "ARIPIPRAZOLE",
            "ATC_Code": "N05AX12",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ORYVA 10MG TABLET",
            "Registration_Number": "7-5173-19",
            "Active_ingredient": "ARIPIPRAZOLE ",
            "ATC_Code": "N05AX12 ",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazoleis essential for acute mania as first line in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ORYVA 15MG TABLET",
            "Registration_Number": "8-5173-19",
            "Active_ingredient": "ARIPIPRAZOLE ",
            "ATC_Code": "N05AX12 ",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazole: first line for acute mania in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Other antipsychotics",
            "Trade_Name": "ORYVA 5MG TABLET",
            "Registration_Number": "6-5173-19",
            "Active_ingredient": "ARIPIPRAZOLE ",
            "ATC_Code": "N05AX12 ",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, ST (elderly), QL",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "30 mg",
            "Notes_1": "Aripiprazoleis essential for acute mania as first line in adults and pediatrics.\r\nST (elderly):  third line option after lithium or divalproex or quetiapine.AGE, QL:Aripiprazoleshould be used for up to 12 weeks  in adolescents aged 12 years and older "
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "DINOBAX 10 mg Tablet",
            "Registration_Number": "58-249-17",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "29 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "DINOBAX 5 mg Tablet",
            "Registration_Number": "57-249-17",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "LAPRIX 10MG COATED TABLET",
            "Registration_Number": "274-277-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "LAPRIX 5MG COATED TABLET",
            "Registration_Number": "273-277-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLANA 10 mg orodispersible tablet",
            "Registration_Number": "76-539-15",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLANA 5 mg orodispersible tablet",
            "Registration_Number": "75-539-15",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 10MG FILM COATED TABLETS",
            "Registration_Number": "248-325-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 15MG FILM COATED TABLETS",
            "Registration_Number": "249-325-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 2.5MG FILM COATED TABLETS",
            "Registration_Number": "246-325-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "2.5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 20MG FILM COATED TABLETS",
            "Registration_Number": "250-325-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 5MG FILM COATED TABLETS",
            "Registration_Number": "245-325-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 7.5MG FILM COATED TABLETS",
            "Registration_Number": "247-325-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "7.5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLENZA 10 mg orally disintegrating tablet",
            "Registration_Number": "352-212-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, ORALLY DISINTEGRATING",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLENZA 15 mg orally disintegrating tablet",
            "Registration_Number": "353-212-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, ORALLY DISINTEGRATING",
            "ROA": "ORAL",
            "Strength": "15mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLENZA 20 mg orally disintegrating tablet",
            "Registration_Number": "354-212-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, ORALLY DISINTEGRATING",
            "ROA": "ORAL",
            "Strength": "20mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLENZA 5 mg orally disintegrating tablet",
            "Registration_Number": "351-212-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, ORALLY DISINTEGRATING",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OZAPIN 10 mg orally disintegrating tablet",
            "Registration_Number": "25-968-17",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OZAPIN 5 mg orally disintegrating tablet",
            "Registration_Number": "24-968-17",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "PRANZA 10 mg film-coated tablet",
            "Registration_Number": "215-334-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "PRANZA 5 mg film-coated tablet",
            "Registration_Number": "214-334-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "PRANZA ODT 10 mg",
            "Registration_Number": "213-334-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "PRANZA ODT 5 mg",
            "Registration_Number": "212-334-16",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "PREXAL 10MG FILM COATED TABLETS",
            "Registration_Number": "17-535-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "PREXAL 5MG FILM COATED TABLETS",
            "Registration_Number": "16-535-14",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ZOLAN 10 MG FILM-COATED  TABLET",
            "Registration_Number": "182-368-18",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03 ",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ZOLAN 5 MG FILM-COATED  TABLET",
            "Registration_Number": "181-368-18",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03 ",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ZYLANZA 10 mg Orodispersible Tablet",
            "Registration_Number": "4-5035-17",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ZYLANZA 5 mg Orodispersible Tablet",
            "Registration_Number": "3-5035-17",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ZYPREXA 10MG F.C.TAB",
            "Registration_Number": "13-5117-19",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "Film-coated tablet",
            "ROA": "Oral",
            "Strength": "10mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ZYPREXA 5MG COATED TABLETS",
            "Registration_Number": "12-5117-19",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "Coated tablet",
            "ROA": "Oral",
            "Strength": "5mg",
            "G_or_B": "B",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 5 mg Orodispersible Tablet",
            "Registration_Number": "292-325-18",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "Orodispersible tablet",
            "ROA": "Oral",
            "Strength": "5mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "OLAZINE 10 mg Orodispersible Tablet",
            "Registration_Number": "293-325-18",
            "Active_ingredient": "OLANZAPINE",
            "ATC_Code": "N05AH03",
            "Dosage_Form": "Orodispersible tablet",
            "ROA": "Oral",
            "Strength": "10mg",
            "G_or_B": "G",
            "Prescribing_edits": "ST,AGE",
            "Quantity_Limit_Adults": "30 mg",
            "Quantity_Limit_Pediatrics": "Children 4 to <6 years: 10 mg,  6yrs- adolescents: 20 mg",
            "Notes_1": "Olanzapine is essential for treatment of acute mania in adults and pediatrics  as second line agent and is essential for treatment agitation associated with manic episodes as first line (it is not appproved by EMC for pediatrics but recommended by giudelines with strong level of evidence) ST: second line in acute mania in adults and pediatrics, AGE: should be used  in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ESPERAL 100 mg Film Coated Tablet",
            "Registration_Number": "114-124-18",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ESPERAL 200 mg Film Coated Tablet",
            "Registration_Number": "115-124-18",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ESPERAL 25 mg Film Coated Tablet",
            "Registration_Number": "113-124-18",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ESPERAL 300 mg Film Coated Tablet",
            "Registration_Number": "116-124-18",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETAL 50 mg XR extended-release tablet",
            "Registration_Number": "243-334-17",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "50mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETAL XR 150 mg film-coated tablet",
            "Registration_Number": "191-334-15",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "150mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETAL XR 200 mg film-coated tablet",
            "Registration_Number": "190-334-15",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUETAL XR 300 mg film-coated tablet",
            "Registration_Number": "192-334-15",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL 100 MG TAB",
            "Registration_Number": "51-7-01",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL 200 MG TAB",
            "Registration_Number": "52-7-01",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL 25 MG TAB",
            "Registration_Number": "50-7-01",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL 300MG F-C TABS",
            "Registration_Number": "56-7-06",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL STARTER PACK 10 TABLETS",
            "Registration_Number": "53-7-02",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET",
            "ROA": "ORAL",
            "Strength": "25 , 100 , 200mg",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL XL 200MG FILM COATED TABLET",
            "Registration_Number": "58-7-12",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL XL 300MG FILM COATED TABLET",
            "Registration_Number": "59-7-12",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL XL 400MG FILM COATED TABLET",
            "Registration_Number": "60-7-12",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "SEROQUEL XL 50MG FILM COATED TABLET",
            "Registration_Number": "57-7-12",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "50mg",
            "G_or_B": "B",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN 100MG F.C.TABLET",
            "Registration_Number": "45-968-19",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04 ",
            "Dosage_Form": "tablet",
            "ROA": "Oral",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN 25MG F.C.TABLET",
            "Registration_Number": "44-968-19",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04 ",
            "Dosage_Form": "tablet",
            "ROA": "Oral",
            "Strength": "25mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN 150MG F.C.TABLET",
            "Registration_Number": "46-968-19",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04 ",
            "Dosage_Form": "tablet",
            "ROA": "Oral",
            "Strength": "150mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN 200MG F.C.TABLET",
            "Registration_Number": "47-968-19",
            "Active_ingredient": "QUETIAPINE",
            "ATC_Code": "N05AH04 ",
            "Dosage_Form": "tablet",
            "ROA": "Oral",
            "Strength": "200mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ADAZIO 100 mg film-coated tablet",
            "Registration_Number": "267-325-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ADAZIO 200 mg film-coated tablet",
            "Registration_Number": "268-325-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ADAZIO 25 mg film-coated tablet",
            "Registration_Number": "266-325-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ADAZIO 300 mg film-coated tablet",
            "Registration_Number": "269-325-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ATAPINA 100MG FILM COATED TABLET",
            "Registration_Number": "55-539-13",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ATAPINA 200MG FILM COATED TABLET",
            "Registration_Number": "56-539-13",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ATAPINA 25MG FILM COATED TABLET",
            "Registration_Number": "54-539-13",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "25mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "ATAPINA 300MG FILM COATED TABLET",
            "Registration_Number": "57-539-13",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN XR 150MG TABLETS",
            "Registration_Number": "39-968-18",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04 ",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "150mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN XR 200 mg tablet",
            "Registration_Number": "28-968-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN XR 300 mg tablet",
            "Registration_Number": "29-968-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QATPEN XR 400 mg tablet",
            "Registration_Number": "30-968-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "400mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUENTA XR 200MG PROLONGED-RELEASE TABLET",
            "Registration_Number": "28-892-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUENTA XR 300MG PROLONGED-RELEASE TABLET",
            "Registration_Number": "29-892-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "300mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUENTA XR 50MG PROLONGED-RELEASE TABLET",
            "Registration_Number": "27-892-15",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, EXTENDED RELEASE",
            "ROA": "ORAL",
            "Strength": "50mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUET 100 mg Film-coated Tablet",
            "Registration_Number": "2-976-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "100mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
        {
            "Indication": "Acute Mania",
            "ICD_Code": "F30",
            "Drug_Class": "ANTIPSYCHOTICS",
            "Drug_Sub_Class": "Diazepines, oxazepines, thiazepines and oxepines",
            "Trade_Name": "QUET 200 mg Film-coated Tablet",
            "Registration_Number": "3-976-17",
            "Active_ingredient": "QUETIAPINE FUMARATE",
            "ATC_Code": "N05AH04",
            "Dosage_Form": "TABLET, FILM COATED",
            "ROA": "ORAL",
            "Strength": "200mg",
            "G_or_B": "G",
            "Prescribing_edits": "AGE, \r\nST (elderly) ",
            "Quantity_Limit_Adults": "Acute manic episodes and maintenance: 800mg",
            "Quantity_Limit_Pediatrics": "600 mg",
            "Notes_1": "Quetiapine is essential for treatment  in acute mania as first line option in adults and pediatrics.\r\nST (elderly):  second line should be used after lithium or divalproex, AGE: should be used in children and Adolescents ≥10 years"
        },
